ANTISENSE OLIGONUCLEOTIDES FOR MODULATION OF LONG NONCODING RNAS

Abstract

The present invention relates to noncoding RNAs as novel disease targets, and methods of modulating the activity of such ncRNA targets in patients. In particular, the invention relates to modulation of long non-coding RNAs, such as circular RNAs (circRNAs) or large intergenic noncoding RNAs (lincRNAs) in cancer using antisense oligonucleotides.

Description

FIELD

The present invention relates to noncoding RNAs as novel disease targets, and methods of modulating the activity of such ncRNA targets in patients. In particular, the invention relates to modulation of long non-coding RNAs, such as circular RNAs (circRNAs) or large intergenic noncoding RNAs (lincRNAs) in cancer using antisense oligonucleotides.

SEQUENCE LISTING

The present application is being filed along with a sequence listing in electronic format, and is provided as a file named seqListing_ST25_win.txt created on June 8th 2016, which is 1.1 MB (1146832 bytes) in size. The disclosure in the electronic format of the sequence listing is incorporated herein by reference in its entirety.

BACKGROUND

One of the biggest surprises of the Human Genome Project was the finding that the human genome contains only about 21.000 protein-coding genes, comprising less than 2% of the total genomic sequence (Lander et al. 2001, Nature 409: 860-921; Venter et al. 2001, Science 291: 1304-51, Harrow et al. 2012, Genome Research 22: 1760-74). However, recent reports have shown that the human genome is pervasively transcribed, giving rise to tens of thousands of non-protein coding transcripts (ncRNAs) (Carninci et al. 2006, Science 309: 1559-1563; Djebali et al. 2012, Nature 489: 101-108; Derrien et al. 2012, Genome Research 22: 1775-1789). Indeed, the use of genetics, tiling arrays, RNA cloning and whole-transcriptome profiling by RNA sequencing (RNA-Seq) has uncovered multiple classes of ncRNAs, such as microRNAs (miRNAs), large intergenic noncoding RNAs (lincRNAs), and circular RNAs (circRNAs) (Ambros 2011, Curr Opin Genet Dev 21: 511-517; Bartel 2009, Cell 136: 215-233; Guttman and Rinn 2012, Nature 482: 339-346; Memczak, S, et al., Nature 495 (7441): 333-8; Mercer and Mattick 2013, Nat Struc Mol Biol 20: 300-307). Increasing evidence suggests that noncoding RNAs (ncRNAs) play key regulatory roles in many biological processes in the cell. Furthermore, ncRNA dysregulation is prevalent in human disease, suggesting that ncRNAs may represent a new class of targets for disease intervention (Ventura and Jacks 2009, Cell 136: 586-591.; Huarte and Rinn 2010, Human Mol Genet 19: R152-R161). Given that these findings can be translated from basic scientific discoveries to development of novel, ncRNA-targeted therapeutics, such therapies may provide life-changing treatments for a broad range of diseases.

The term long noncoding RNAs (IncRNAs) refers to an expanding inventory of ncRNAs whose defining characteristics are that they are longer than 200 nucleotides and that they lack a significant open reading frame. Recent technological advances in high-throughput sequencing have allowed rapid identification of IncRNAs. Various characteristics of IncRNAs are used to divide this growing list of molecules into subclasses, such as large intergenic ncRNAs (lincRNA), long intronic ncRNAs, antisense RNAs, pseudogene RNAs, circular RNAs (circRNA) and transcribed-ultraconserved regions.

While functional annotation of this class of RNAs is still limited, IncRNAs have emerged as important regulatory molecules in the pathogenesis of cancer. For example, the lincRNA HOX antisense intergenic RNA (HOTAIR) is part of the HOXC gene cluster on chromosome 12 and is an example of an IncRNA that functions as a scaffold and guides epigenetic regulators to genomic loci in trans. HOTAIR promotes silencing by acting as a scaffold to assemble the Polycomb Repressive Complex 2 (PRC2) and the Lysine-specific Demethylase 1 (LSD1) on the HOXD cluster, where these protein complexes specifically trimethylate histone H3 on lysine 27 and demethylate H3 on lysine 4, respectively, resulting in epigenetic silencing of HOXD genes (Rinn et al. 2007, Cell, 129:1311-1323; Tsai et al. Science 2010, 329:689-693). HOTAIR is highly expressed in primary as well as metastatic breast tumors and high level of expression in primary breast tumors is a powerful predictor of subsequent metastasis and death (Gupta et al. 2010, Nature, 464:1071-1076). CDKN2B-AS, also known as ANRIL (antisense non-coding RNA in the INK4 locus) exemplifies an antisense RNA transcript involved in cis regulation of the INK4b/ARF/INK4a tumor suppressor locus. The nascent ANRIL transcript directly interacts with PRC1 and PRC2 resulting in cis recruitment of gene silencing complexes to the INK4A-ARF-INK4B gene cluster and ANRIL has been shown to be up-regulated in prostate cancer cells (Yap et al. 2010, Mol Cell, 38:662-674, Kotake et al. 2011, Nature 448:943-946). The lincRNA Growth Arrest-Specific 5 (GAS5) is a negative regulator of gene expression exerting its function by acting as a decoy glucocorticoid response element (GRE) capable of binding the glucocorticoid receptor (GR) transcription factor. GAS5 transcripts can compete for binding to GR with GREs in promoter regions of GR target genes resulting in modulation of their expression (Kino et al. 2010, Sci Signal. 3:ra8). Reduced GAS5 transcript levels have been demonstrated in breast cancer relative to adjacent normal tissue; it hosts several snoRNAs in its introns, and plays an important role in controlling apoptosis and cell growth (Mourtada-Maarabouni et al. 2009, Oncogene, 28:195-208). The Malat1 lincRNA regulates alternative splicing (Tripathi et al. 2010, Mol Cell, 39:925-938). Malat1 is up-regulated in many solid tumors and associated with cancer metastasis and recurrence (Ji et al. 2003, Oncogene, 22:8031-8041; Yamada et al. 2006, Cancer Sci, 97:106-112; Lin et al. 2007, FEBS Lett, 585:671-676; Guffanti et al. 2009, BMC Genomics, 10:163; Lai et al., 2012, Med Oncol. 29:1810-1816). Taken together, IncRNAs comprise a class of RNAs that are highly interesting as biomarkers due to the fact that they often show tight spatio-temporal regulation, and as targets for novel anti-cancer therapeutic approaches due to their central role as regulators of many biological processes (Huarte and Rinn 2010, Human Mol Genet 19: R152-R161).

Recent studies combining RNA sequencing (RNAseq)-based transcriptome profiling with focused bioinformatic analyses have revealed large numbers of circRNAs that are stable and much more abundant than previously appreciated (Jeck et al., 2013, RNA 19: 141-57; Memczak et al., 2013, Nature 495: 333-8; Salzman et al., 2012, PLoS One 7: e30733). These molecules constitute the most recent addition to the continuously expanding list of long noncoding RNA (IncRNA) transcripts and tens of thousands have already been identified (Glažar et al., 2014, RNA 20: 1666-70). CircRNAs are formed by a backsplice event, in which a splice donor is joined to an upstream splice acceptor and the resulting RNA molecule can encompass exons (Hansen et al., 2013, Nature 495: 384-8; Memczak et al., 2013, Nature 495: 333-8), introns (Zhang et al., 2013, Mol. Cell 51: 792-806), or a combination of both (Li et al., 2015, Nat. Struct. Mol. Biol. 22: 256-64). Several pathways for biogenesis of circRNAs have been proposed, including circularization driven by inverted repeats in flanking introns (Zhang et al., 2014, Cell 159: 134-147), RNA binding proteins (Ashwal-Fluss et al., 2014, Mol. Cell 56: 55-66; Conn et al., 2015, Cell 160: 1125-34), and lariat formation following exon skipping (Jeck et al., 2013, RNA 19: 141-57). Recent data suggest that the canonical spliceosome machinery functions in the biogenesis of circular RNAs (Starke et al., 2015, Cell Rep. 10: 103-111), and circRNAs have been shown to exhibit cell type and developmental stage specific expression. Furthermore, the expression levels of circRNAs do not always correlate with the linear transcripts from which they are generated (Memczak et al., 2013, Nature 495: 333-8; Salzman et al., 2013, PLoS Genet. 9: e1003777), suggesting that the biogenesis of circRNAs is a regulated process.

Functional studies of specific circRNAs have shown that they can act as competitive endogenous RNAs (ceRNAs) (Salmena et al., 2011, Cell 146: 353-358), and they are involved in post-transcriptional regulation by functioning as miRNA sponges (Hansen et al., 2013, Nature 495: 384-8; Memczak et al., 2013, Nature 495: 333-8; Li et al., 2015, Oncotarget 6: 6001-6013), protein decoys (Ashwal-Fluss et al., 2014, Mol. Cell 56: 55-66), or modulators of transcription of their parent gene (Li et al., 2015, Nat. Struct. Mol. Biol. 22: 256-64). Four circRNAs shown to function as miRNA sponges include: (i) CDR1-AS/ciRS-7 acting as a decoy for the tumor suppressor miR-7 (Hansen et al., 2013, Nature 495: 384-8; Memczak et al., 2013, Nature 495: 333-8), (ii) the testis specific circRNA SRY capable of sequestering miR-138 (Hansen et al., 2013, Nature 495: 384-8), (iii) cir-ITCH, which acts as a sponge for miR-7, miR-17, and miR-214 (Li et al., 2015, Oncotarget 6: 6001-6013), and circHIPK3, which sponges multiple miRNAs, including miR-124 (Zheng et al., 2016, Nat. Commun. 7:11215). CircRNAs are well suited for their function as miRNA sponges, since they do not contain 5′ or 3′ ends and are therefore not subject to miRISC-mediated deadenylation and decapping, which in linear transcripts triggers target mRNA degradation. While ciRS-7 contains 74 miR-7 binding sites, genome-wide studies of circRNAs using a high-throughput sequencing technique called CircleSeq has shown that most exonic circRNAs only have a small number of putative miRNA binding sites (Jeck et al., 2014, Nat. Biotechnol. 32: 453-61). This implies that miRNA sponge activity might not be the prevalent mode of action for this class of molecules (Jeck et al., 2014, Nat. Biotechnol. 32: 453-61). Nonetheless, the identification of circular miRNA sponges, co-expressed with the cognate miRNA, as exemplified by miR-7/ciRS-7 (Hansen et al., 2013, Nature 495: 384-8; Memczak et al., 2013, Nature 495: 333-8), has revealed an increased complexity of miRNA regulatory networks (Salmena et al., 2011, Cell 146: 353-358).

A link between circRNAs and disease was first suggested by Burd et al., who showed that a circular variant of the IncRNA ANRIL correlates with increased risk of atherosclerosis (Burd et al., 2010, PLoS Genet. 6: e1001233). Furthermore, the effective ciRS-7 mediated regulation of miR-7 activity is highly interesting due to the role of miR-7 in suppressing cancer cell growth, proliferation, survival, migration and invasion, as well as increasing sensitivity of resistant tumor cells to therapeutics (Kalinowski et al., 2014, Int. J. Biochem. Cell Biol. 54: 312-7). Although the functions of most circRNAs in human disease are largely unknown, circRNAs are often found to be differentially expressed between cancer and normal tissues (Zheng et al., 2016, Nat. Commun. 7:11215), and many circRNAs are associated with human disease (Ghosal et al., 2013, Front Genet. 4:283), suggesting that circRNAs could represent a new class of targets for development of circRNA-based therapeutics for a wide range of human diseases.

SUMMARY

The present invention provides novel antisense oligonucleotides (ASOs) and methods of using such ASOs for modulation of lincRNAs and circular RNAs (circRNAs) in cells. The antisense oligonucleotides and methods may in some embodiments be used for treatment of human disease, such as cancer.

Targeting circRNAs

Specifically, an antisense oligonucleotide according to the invention is complementary to a circRNA, and is for use in knockdown of a circRNA. In one such embodiment, the antisense oligonucleotide is of 14-22 nucleotides in length, and is a gapmer comprising a stretch of DNA that varies in length from 6 to 16 nucleotides flanked at each end by wings comprising from 1 to 5 nucleotide analogues, and wherein the antisense oligonucleotide comprises from 1 to 21, such as from 6 to 21 phosphorothioate internucleotide linkages, and wherein all internucleotide linkages in the DNA stretch are phosphorothioate linkages. This allows the oligonucleotide to bind specifically to the target circRNA and cause degradation of the targeted circRNA, whereby the effect of the target circRNA in a disease is alleviated in whole or in part. In some embodiments, the nucleotide analogues in the antisense oligonucleotides of the invention are locked nucleic acids (LNA). In another embodiment, the antisense oligonucleotide is consisting of a sequence of 10-22 nucleobases in length that is a mixmer which does not comprise a region of more than anyone of 2, 3, 4 or 5 consecutive DNA nucleotides, and which comprises from 3 to 22 affinity-enhancing nucleotide analogues, and wherein the antisense oligonucleotide comprises 1 to 21 phosphorothioate internucleotide linkages, and wherein the oligonucleotide is complementary to an endogenous circRNA.

In some preferred embodiments, the antisense oligonucleotides of the invention are complementary to an endogenous circRNA. In some embodiments, the antisense oligonucleotide has a sequence, which is complementary to a circRNA back-splice junction. In a preferred embodiment, the antisense oligonucleotides of the invention are complementary to a circRNA sequence, which overlaps the back-splice junction by at least 3 nucleotides. This design provides the advantage of targeting the circRNA molecule and not its parental transcript. In some embodiments, the invention provides a siRNA that target a circRNA sequence which overlaps the back-splice juncion by at least 3 nuceotides.

In some embodiments, the antisense oligonucleotide of the invention is complementary to, and thereby targets a circRNA which is anyone of a circRNA selected from the list of ciRS-7, circPVT1, circHIPK3, circSRY, circSLC35E2B, circCDK11A, circUNKNOWN00000001, circARHGAP32, circSLC8A3, circHERC2, circZFAND6, circRP1-168P16.1, circAURKC, circAFTPH, circSCD, circSMC3, circSNORA23| IPO7.1, circZNF124.1, circSNX5 | OVOL2, circRALY, circTFPI, circAHSG.1, circAHSG.2, circAHSG.3, circUBXN7, circAFP, circHIST1H3A, circHIST1H3C.1, circANAPC2, circRMRPI RMRP, circCENPI, circFIRRE, circMBNL3, circGPC3.

In some embodiments, the antisense oligonucleotide of the invention is complementary to, and thereby targets a circRNA which is anyone of a circRNA selected from the list of ciRS-7, circPVT1, circHIPK3, circSRY, circSLC35E2B, circCDK11A, circUNKNOWN00000001, circARHGAP32, circSLC8A3, circHERC2, circZFAND6, circRP1-168P16.1, circAURKC, circAFTPH, circSCD, circSMC3, circSNORA23 | IPO7.1, circZNF124.1, circSNX5 | OVOL2, circRALY, circTFPI, circAHSG.1, circAHSG.2, circAHSG.3, circUBXN7, circAFP, circHIST1H3A, circHIST1H3C.1, circANAPC2, circRMRP | RMRP, circCENPI, circFIRRE, circMBNL3, circGPC3, circPROSER2, circMALRD1, circFAM208B, circMCU, circKIF20B, circABCC2, circEIF4G2|SNORD97.1, circEIF4G2|SNORD97.2, circEIF4G2|SNORD97.3, circEIF4G2|SNORD97.4, circEIF4G2|SNORD97.5, circEIF4G2|SNORD97.6, circEIF4G2|SNORD97.7, circEIF4G2|SNORD97.8, circEIF4G2|SNORD97.9, circEIF4G2|SNORD97.10, circlGF2, circQSER1, circUNKNOWN00000002, circCHD1L, circPRUNE, circSLC27A3, circGATAD2B, circKIAA0907, circCCT3, circPLEKHM2, circVWCE, circATF6, circMALAT1.1, circMALAT1.2, circMALAT1.3, circMALAT1.4, circMALAT1.5, circMALAT1.6, circMALAT1.7, circMALAT1.8, circMALAT1.9, circMALAT1.10, circMALAT1.11, circMALAT1.12, circMALAT1.13, circUNKNOWN00000003, circMALAT1.14, circMALAT1.15, circMALAT1.16, circMALAT1.17, circMALAT1.18, circMALAT1.19, circUCK2, circSUCO, circRAB6A, circRPS3|SNORD15B.1, circRPS3|SNORD15B.2, circRPS3|SNORD15B.3, circRSF1, circABL2, circGNB1, circRPLP2|SNORA52, circPICALM.1, circPICALM.2, circSNORA23|IPO7.2, circSNORA23|IPO7.3, circCFH, circSLC41A2.1, circSLC41A2.2, circCORO1C, circEIF4G3|RP11-487E1.2, circNAA25, circMED13L, circLPGAT1| RN7SL344P, circAACS, circTP53BP2, circSOX5, circDNAH14, circKDM1A|MIR3115, circTTC13, circEGLN1, circTCEA3, circTOMM20|SNORA14B, circSCCPDH, circZNF124.2, circGLS2, circR3HDM2, circDHDDS, circSNORA73AI RCC1| SNHG3.1, circSNORA73A|RCC1| SNHG3.2, circSNORA61|SNHG12, circCEP83|RBMS2P1, circFGD6, circPUM1, circTMCO3|RP11-230F18.6, circPTP4A2, circZMYM5, circN6AMT2, circRPL21|SNORA27, circGTF2F2, circZMYM4, circLINC00355, circUNKNOWN00000004, circFARP1, circDYNC1H1, circCDC42BPB, circCCNB1IP1|SNORA79|AL355075.1, circRPPH1|RPPH1.1, circRPPH1|RPPH1.2, circRPPH1|RPPH1.3, circRPPH1|RPPH1.4, circSNORD8|CHD8.1, circSNORD8|CHD8.2, circPPP1R3E, circCHMP4A|RP11-468E2.1|AL136419.6, circUNKNOWN00000005, circSEC23A, circSNORD46| RPS8, circSAMD4A, circPCNX, circPSEN1, circFCF1, circSCARNA13 |SNHG10.1, circSCARNA13|SNHG10.2, circSCARNA13|SNHG10.3, circUNKNOWN00000006, circTJP1, circRP11-632K20.7, circTTBK2, circPPIB, circUBE2Q2, circETFA, circSEC11A, circPDE8A, circDAB1|OMA1, circABHD2, circlQGAP1.1, circlQGAP1.2, circCHD2, circIGF1R, circNPRL3, circNDE1, circABCC1, circRPS2|SNORA64, circPOLR3E, circATXN2L, circMVP, circASPHD1, circITGAL, circRP5-857K21.6.1, circRP5-857K21.6.2, circRP5-857K21.6.3, circRP5-857K21.6.4, circZNF720, circLONP2, circCHD9, circSLC7A6, circCARHSP1, circFANCA, circRAD51D|RAD51L3-RFFL, circHDAC5, circUTP18, circSRSF1, circPPM1D, circBRIP1, circPRKCA.1, circPRKCA.2, circEIF4A1|SNORD10|RP11-186B7.4|SENP3-EIF4A1.1, circEIF4A1|SNORD10|RP11-186B7.4| SENP3-EIF4A1.2, circPGS1, circRPTOR, circRPL26|RP11-849F2.7, circRP11-206L10.8, circPIAS2, circTYMS, circPPP4R1, circZNF91, circWDR62, circADCK4, circARHGAP35, circNUCB1, circSNORD33| RPL13A.1, circSNORD33| RPL13A.2, circSNORD33| RPL13A.3, circMUC16, circLZIC, circSNX5|SNORD17|OVOL2.1, circSNX5|SNORD17 |OVOL2.2, circSNORA71A|SNHG17, circPLTP, circTMEM230, circCYP24A1, circZBTB46, circGART, circRAB3GAP1, circDYRK1A, circUNKNOWN00000007, circCOL18A1.1, circCOL18A1.2, circNBAS, circCH507-513H4.1.1, circCH507-513H4.1.2, circCH507-513H4.1.3, circANKAR, circGLS, circBMPR2, circRHBDD1, circATG16L1|SCARNA5, circDGKD, circPASK, circPPP6R2, circBIRC6, circPRKD3, circKIAA1841|RP11-493E12.3, circRTKN, circELMOD3, circREV1, circZBTB20, circTIMMDC1, circACAD9, circPLXND1, circHDAC11, circCEP70, circRNF13.1, circRNF13.2, circGOLIM4, circEIF4A2|SNORD2.1, circEIF4A2|SNORD2.2, circSDHAP1, circSETD2, circSCAP, circUSP4, circRPL29, circPHF7, circNEK4, circFLNB, circSLC25A26, circNFKB1, circFIP1L1|RP11-231C18.3, circTBC1D14, circALB.1, circALB.2, circALB.3, circNUP54, circAFF1, circSLC12A7|MIR4635, circMAN2A1.1, circMAN2A1.2, circAFF4, circUBE2D2, circANKHD1|ANKHD1-EIF4EBP3, circMAPK9, circGPBP1, circCEP72, circRP11-98J23.2, circFAM169A, circWDR41, circRASGRF2, circRHOBTB3, circCEP85L, circARID1B.1, circARID1B.2, circTULP4|RP11-732M18.4, circTULP4, circTMEM181, circHIST1H3B, circHIST1H3C.2, circUNKNOWN00000008, circC6orf136, circHLA-C|HLA-B|XXbac-BPG248L24.10|WASF5P|XXbac-BPG248L24.13.1, circHLA-C|HLA-B|XXbac-BPG248L24.10|WASF5P|XXbac-BPG248L24.13.2, circFKBP5, circCNPY3, circSRF, circRN7SK, circFARS2, circMLIP, circZNF292, circPNRC1, circUNKNOWN00000009, circNDUFB2, circKMT2C, circESYT2, circMPP6, circHERPUD2, circOGDH, circZNF680, circKDELR2|DAGLB, circZDHHC4, circCCZ1B, circPOM121, circBAZ1B, circGTF2I, circSNORA14A, circCDK14, circCCDC132, circTRRAP|MIR3609, circCYP3A7|CYP3A7-CYP3A51P, circCCAT1.1, circCCAT1.2, circCCAT1.3, circCCAT1.4, circCCAT1.5, circCCAT1.6, circCCAT1.7, circASAP1, circPTK2.1, circPTK2.2, circSLC45A4, circADGRB1, circRBPMS, circFGFR1, circHOOK3, circASPH, circTMEM245, circUNKNOWN00000010, circHSPA5, circGLE1, circFOCAD, circNFX1, circUBAP2, circKDM4C|RP11-146B14.1, circAGTPBP1, circFAM120A.1, circFAM120A.2, circHIATL1, circPPP2R3B, circATRX, or circTBL1X.

In some embodiments, the antisense oligonucleotide or the siRNA of the invention is complementary to, and thereby targets a circRNA selected from anyone of those listed in Table 1, such as targeting anyone of SEQ ID NOs: 1-359.

In some embodiments, the antisense oligonucleotides of the invention are complementary to a circRNA, which is expressed in cancer cells, or where its expression is upregulated in a cancer cell in comparison with normal liver cells. In some embodiments, the cancer cell is a hepatocellular carcinoma cell.

The oligonucleotides of the invention are for use as medicaments. In some embodiments, the antisense oligonucleotides of the invention are made for use in compositions for treatment of cancer, such as in non-limiting example, cancer that overexpresses a specific circRNA to which the antisense oligonucleotide is complemetary.

Targeting of Long Noncoding RNAs

In one aspect, the antisense oligonucleotides of the invention are designed to target and downregulate expression of IncRNAs. Specifically, in such an aspect, the antisense oligonucleotide according to the invention is complementary to an IncRNA, and is for use in knockdown of an IncRNA. In such an embodiment, the antisense oligonucleotide is 14-20 nucleotides in length, and is a gapmer comprising a stretch of DNA that varies in length from 6 to 16 nucleotides flanked at each end by wings comprising from 1 to 5 nucleotide analogues, and wherein the antisense oligonucleotide comprises from 1 to 19, such as from 6 to 19 phosphorothioate internucleotide linkages, and wherein all internucleotide linkages in the DNA stretch are phosphorothioate linkages. This allows the oligonucleotide to bind specifically to the target IncRNA and cause degradation of the targeted IncRNA, whereby the effect of the target IncRNA in a disease is alleviated in whole or in part. In some embodiments, the nucleotide analogues in the antisense oligonucleotides of the invention are locked nucleic acids (LNA).

In some preferred embodiments, the antisense oligonucleotides of the invention are complementary to an endogenous IncRNA. In some more preferred embodiments, the antisense oligonucleotides of the invention are fully complementary to the endogenous IncRNA. In some preferred embodiments, the antisense oligonucleotides of the invention contain no DNA -or LNA mismatches to the endogenous IncRNA.

The antisense oligonucleotides of the present invention that target IncRNAs are designed to provide highly specific and efficient targeting of the IncRNA molecule and a minimum of off-target effects.

In some embodiments, the antisense oligonucleotide of the invention is complementary to, and thereby targets anyone of the long noncoding RNAs (IncRNAs) selected from the list of DANCR, H19, HOTAIR, HOTTIP, HULC, LINC-ROR, MALAT1, MVIH, NEAT1, PCBP2-OT1, PVT1, TUG1, UCA1, UFC1 and LINC01215.

In certain embodiments, the antisense oligonucleotides are designed to target IncRNAs and are compounds of anyone of SEQ ID NOs: 2149 to 2259, that target IncRNAs selected from the list of DANCR, H19, HOTAIR, HOTTIP, HULC, LINC-ROR, MALAT1, MVIH, NEAT1, PCBP2-OT1, PVT1, TUG1, UCA1, UFC1 and LINC01215, and their uses as medicaments.

In some embodiments, the antisense oligonucleotides of the invention, selected from the list of anyone of SEQ ID NOs: 2149 to 2259 are for use in the treatment of cancer.

In some embodiments, the antisense oligonucleotides of the invention, selected from the list of anyone of SEQ ID NOs: 2149 to 2259 comprise LNA in the wings, such as in non-limiting example, beta-D-Oxy LNA.

FIGURE LEGENDS

FIG. 1. Knockdown of the PVT1 lincRNA in the lung cancer cell line A549 cells treated with antisense oligonucleotides (ASOs) targeting PVT1 at 25 nM, 5 nM, 1 nM concentration of the ASOs CRM0091 or CRM0092 (SEQ ID NOs 2233 and 2234 respectively) or mock. PVT1 expression was determined by quantitative real-time RT-PCR carried out on a Quantstudio 6 Flex Real-Time thermocycler (ABI) and results were normalized to GAPDH expression levels. PVT1 expression is shown as % of mock.

FIG. 2. Knockdown of the ciRS-7 circRNA in the lung cancer cell line A549 cells treated with antisense oligonucleotides targeting ciRS-7 RNA at 25 nM, 5 nM, 1 nM concentration of the antisense oligonucleotides CRM0106, CRM0107 or CRM0108 (SEQ ID NOs 360, 361 and 362 respectively) or mock. ciRS-7 expression was determined by quantitative real-time RT-PCR carried out on a Quantstudio 6 Flex Real-Time thermocycler (ABI) and results were normalized to GAPDH expression levels. ciRS-7 levels are shown as % of mock. Total amount of ciRS-7 transcript was measured using a Taqman assay designed with convergent PCR primers (conv or con) specific to the RNA, while the circularized form of ciRS-7 was measured using a Taqman assay designed with divergent PCR primers (div) specific to the ciRS-7 RNA.

FIG. 3. ciRS-7 levels in the lung cancer cell line A549 cells treated with antisense oligonucleotides targeting ciRS-7 RNA at 25 nM concentration of the oligonucleotides CRM0106, CRM0107 or CRM0108 (SEQ ID NOs 360, 361 and 362 respectively) or mock. ciRS-7 expression was determined after incubation for 24 hours, 48 hours or 72 hours by quantitative real-time RT-PCR carried out on a Quantstudio 6 Flex Real-Time thermocycler (ABI) and results were normalized to GAPDH expression levels. ciRS-7 expression is shown as % of mock.

FIG. 4. Knockdown of ciRS-7 in the human prostate cancer cell line PC3, after lipofectamine-assisted uptake of the antisense oligonucleotides CRM0106, or CRM0108 (SEQ ID NOs 360, and 362 respectively) at 1, 5 and 25 nM concentrations. The levels of ciRS-7 are marked “ciRS-7 div”.

FIG. 5. Knockdown of ciRS-7 in the multiple myeloma cell line MM.1S, after unassisted uptake of the antisense oligonucleotides CRM0106, CRM0107 or CRM0108 (SEQ ID NOs 360, 361 and 362 respectively) at 0.5 or 2.5 micromolar concentrations, respectively. The levels of ciRS-7 are marked “ciRS-7 div”.

FIG. 6. Effect of ciRS-7 knockdown on proliferation of A549 lung cancer cells after transfection at 1 nM, 5 nM or 25 nM concentrations of the ciRS-7 antisense oligonucleotides CRM0106, CRM0107 or CRM0108 (SEQ ID NOs 360, 361 and 362 respectively). Data are shown as cell density, measured as % of mock after 24 hours, 48 hours or 72 hours of incubation with the ciRS-7 antisense oligonucleotides.

FIG. 7. Knockdown of the MALAT1 lincRNA in the multiple myeloma cell line MM.1S after unassisted uptake of the antisense oligonucleotide (SEQ ID NO 2198) at 1 or 5 micromolar concentrations, respectively, for 72 hours, 96 hours or for 120 hours. MALAT1 levels were determined by quantitative real-time RT-PCR carried out on a Quantstudio 6 Flex RealTime thermocycler (ABI) and results were normalized to GAPDH expression levels. MALAT1 expression is shown as % of mock.

FIG. 8. Induction of apoptosis in A549 lung cancer cells by lipofectamine-mediated transfection of MALAT1 antisense oligonucleotide (SEQ ID NO: 2198). Antisense oligonucleotide concentration was 25 nM and incubation time 24 hours. Cells were harvested, stained and analyzed in a flow cytometer to detect apoptotic cells. Results were compared to mock. 8A shows mock-treated cells and 8B MALAT1 antisense oligonucleotide-treated cells, respectively.

FIG. 9. A) Knockdown of the ciRS-7 circRNA in the human liver adenocarcinoma cell line SK-Hep-1. Cells were treated with antisense oligonucleotides targeting ciRS-7 RNA at 25 nM or 5 nM concentration of the antisense oligonucleotides CRM0106, CRM0107 or CRM0108 (SEQ ID NOs 360, 361 and 362 respectively) or scrambled control (Scr. Control) or Mock. ciRS-7 expression was determined by quantitative real-time RT-PCR carried out on a Quantstudio 6 Flex Real-Time thermocycler (ABI) and results were normalized to GAPDH expression levels. ciRS-7 levels are shown as % of mock. B) Knockdown of the ciRS-7 circRNA in the human hepatoma cell line Hep3B. Same experimental setup as in 9A), using 25 nM or 5 nM concentration of the antisense oligonucleotides CRM0106, CRM0107 or CRM0108 (SEQ ID NOs 360, 361 and 362 respectively) or scrambled control (Scr. Control) or Mock. Results were normalized to GAPDH expression levels. ciRS-7 levels are shown as % of mock. Total amount of ciRS-7 transcript was measured using a Taqman assay designed with convergent PCR primers (conv or con) specific to the RNA, while the circularized form of ciRS-7 was measured using a Taqman assay designed with divergent PCR primers (div) specific to the ciRS-7 RNA.

FIG. 10. A549 Knockdown of the COROC1c circRNA in the human lung carcinoma cell line A549. Cells were treated with antisense oligonucleotides targeting COROC1c RNA at 25 nM or 5 nM concentration of the antisense oligonucleotides CRM00173, (SEQ ID NO 2266) or scrambled control (Scr. Control) or Mock. COROC1c expression was determined by quantitative real-time RT-PCR carried out on a Quantstudio 6 Flex Real-Time thermocycler (ABI) and results were normalized to GAPDH expression levels. COROC1c levels are shown as % of mock. B) Knockdown of the FAT1 circRNA in the human lung carcinoma cell line A549. Same experimental setup as in 10A), using 25 nM or 5 nM concentration of the antisense oligonucleotides CRM0168, (SEQ ID NO 2262) or scrambled control (Scr. Control) or Mock. Results were normalized to GAPDH expression levels. FAT1 levels are shown as % of mock. C) Knockdown of the HIPK3 circRNA in the human lung carcinoma cell line A549. Same experimental setup as in 10A), using 25 nM or 5 nM concentration of the antisense oligonucleotides CRM0171, (SEQ ID NO 374) or scrambled control (Scr. Control) or Mock. Results were normalized to GAPDH expression levels. HIPK3 levels are shown as % of mock. D) Knockdown of the PVT1 circRNA in the human lung carcinoma cell line A549. Same experimental setup as in 10A), using 25 nM or 5 nM concentration of the antisense oligonucleotides CRM0177, (SEQ ID NOs 2269) or scrambled control (Scr. Control) or Mock. Results were normalized to GAPDH expression levels. PVT1 levels are shown as % of mock. E) Knockdown of the FIRRE circRNA in the human lung carcinoma cell line A549. Same experimental setup as in 10A), using 25 nM or 5 nM concentration of the antisense oligonucleotides CRM0178, (SEQ ID NOs 2270) or scrambled control (Scr. Control) or Mock. Results were normalized to GAPDH expression levels. FIRRE levels are shown as % of mock. F) Knockdown of the CCT3 circRNA in the human lung carcinoma cell line A549. Same experimental setup as in 10A), using 25 nM or 5 nM concentration of the antisense oligonucleotides CRM0182, (SEQ ID NOs 2274 respectively) or scrambled control (Scr. Control) or Mock. Results were normalized to GAPDH expression levels. CCT3 levels are shown as % of mock. Total amount of circRNA transcript was measured using a Taqman assay designed with convergent PCR primers (conv or con) specific to the RNA, while the circularized form of the circRNA was measured using a Taqman assay designed with divergent PCR primers (div) specific to the circRNA.

FIG. 11. A) ) Knockdown of the CORO1C circRNA in the human liver adenocarcinoma cell line SK-Hep-1. Cells were treated with antisense oligonucleotides targeting COROC1c RNA at 25 nM or 5 nM concentration of the antisense oligonucleotides CRM00173, CRM0174 or CRM0175 (SEQ ID NOs 2269, 2270 and 2275 respectively) or scrambled control (Scr. Control) or Mock. COROC1c expression was determined by quantitative real-time RT-PCR carried out on a Quantstudio 6 Flex Real-Time thermocycler (ABI) and results were normalized to GAPDH expression levels. COROC1c levels are shown as % of mock. B) Knockdown of the FAT1 circRNA in the human liver adenocarcinoma cell line SK-Hep-1. Cells were treated with antisense oligonucleotides targeting FAT1 RNA at 25 nM or 5 nM concentration of the antisense oligonucleotides CRM00167, CRM0168 or CRM0169 (SEQ ID NOs 2285, 2286 and 2287 respectively) or scrambled control (Scr. Control) or Mock. FAT1 expression was determined by quantitative real-time RT-PCR carried out on a Quantstudio 6 Flex Real-Time thermocycler (ABI) and results were normalized to GAPDH expression levels. COROC1c levels are shown as % of mock. C) Knockdown of the HIPK3 circRNA in the human liver adenocarcinoma cell line SK-Hep-1. Cells were treated with antisense oligonucleotides targeting HIPK3 RNA at 25 nM or 5 nM concentration of the antisense oligonucleotides CRM0170, CRM0171 or CRM0172 (SEQ ID NOs 2264, 374 and 2265 respectively) or scrambled control (Scr. Control) or Mock. HIPK3 expression was determined by quantitative real-time RT-PCR carried out on a Quantstudio 6 Flex Real-Time thermocycler (ABI) and results were normalized to GAPDH expression levels. HIPK3 levels are shown as % of mock. D) Knockdown of the PVT1 circRNA in the human liver adenocarcinoma cell line SK-Hep-1. Cells were treated with antisense oligonucleotides targeting PVT1 RNA at 25 nM or 5 nM concentration of the antisense oligonucleotides CRM00176,or CRM0177 (SEQ ID NOs 2268 and 2269 respectively) or scrambled control (Scr. Control) or Mock. PVT1 expression was determined by quantitative real-time RT-PCR carried out on a Quantstudio 6 Flex Real-Time thermocycler (ABI) and results were normalized to GAPDH expression levels. PVT1 levels are shown as % of mock. E) Knockdown of the FIRRE circRNA in the human liver adenocarcinoma cell line SK-Hep-1. Cells were treated with antisense oligonucleotides targeting FIRRE RNA at 25 nM or 5 nM concentration of the antisense oligonucleotides CRM00178, CRM0179 or CRM0180 (SEQ ID NOs 2270, 2271 and 2272 respectively) or scrambled control (Scr. Control) or Mock. FIRRE expression was determined by quantitative real-time RT-PCR carried out on a Quantstudio 6 Flex Real-Time thermocycler (ABI) and results were normalized to GAPDH expression levels. FIRRE levels are shown as % of mock. F) Knockdown of the CCT3 circRNA in the human liver adenocarcinoma cell line SK-Hep-1. Cells were treated with antisense oligonucleotides targeting CCT3 RNA at 25 nM or 5 nM concentration of the antisense oligonucleotides CRM00181, or CRM0182 (SEQ ID NOs 2273 and 2274 respectively) or scrambled control (Scr. Control) or Mock. CCT3 expression was determined by quantitative real-time RT-PCR carried out on a Quantstudio 6 Flex Real-Time thermocycler (ABI) and results were normalized to GAPDH expression levels. CCT3 levels are shown as % of mock. Total amount of circRNA transcript was measured using a Taqman assay designed with convergent PCR primers (conv or con) specific to the RNA, while the circularized form of the circRNA was measured using a Taqman assay designed with divergent PCR primers (div) specific to the circRNA.

FIG. 12 A) Knockdown of the FAT1 circRNA in the human hepatoma cell line Hep3B. Same experimental setup as in 9A), using 25 nM or 5 nM concentration of the antisense oligonucleotides CRM0167, CRM0168 or CRM0169 (SEQ ID NOs 2285, 2286 and 2287 respectively) or scrambled control (Scr. Control) or Mock. Results were normalized to GAPDH expression levels. FAT1 levels are shown as % of mock. Total amount of FAT1 transcript was measured using a Taqman assay designed with convergent PCR primers (conv or con) specific to the RNA, while the circularized form of FAT1 was measured using a Taqman assay designed with divergent PCR primers (div) specific to the FAT1 RNA. B) Knockdown of the HIPK3 circRNA in the human hepatoma cell line Hep3B. Same experimental setup as in 12A), using 25 nM or 5 nM concentration of the antisense oligonucleotides CRM0170, CRM0171 or CRM0172 (SEQ ID NOs 2264, 374 and 2265 respectively) or scrambled control (Scr. Control) or Mock. Results were normalized to GAPDH expression levels. HIPK3 levels are shown as % of mock. C) Knockdown of the CORO1c circRNA in the human hepatoma cell line Hep3B. Same experimental setup as in 9A), using 25 nM or 5 nM concentration of the antisense oligonucleotides CRM0173, CRM0174 or CRM0175 (SEQ ID NOs 2267, 2275 and 2268 respectively) or scrambled control (Scr. Control) or Mock. Results were normalized to GAPDH expression levels. CORO1c levels are shown as % of mock. D) Knockdown of the PVT1 circRNA in the human hepatoma cell line Hep3B. Same experimental setup as in 12A), using 25 nM or 5 nM concentration of the antisense oligonucleotides CRM0176, or CRM0177 (SEQ ID NOs 2268 and 2269 respectively) or scrambled control (Scr. Control) or Mock. Results were normalized to GAPDH expression levels. PVT1 levels are shown as % of mock. E) Knockdown of the FIRRE circRNA in the human hepatoma cell line Hep3B. Same experimental setup as in 9A), using 25 nM or 5 nM concentration of the antisense oligonucleotides CRM0178, CRM01179 or CRM0180 (SEQ ID NOs 2270, 2271 and 2272 respectively) or scrambled control (Scr. Control) or Mock. Results were normalized to GAPDH expression levels. FIRRE levels are shown as % of mock. F) Knockdown of the CCT3 circRNA in the human hepatoma cell line Hep3B. Same experimental setup as in 9A), using 25 nM or 5 nM concentration of the antisense oligonucleotides CRM0181 or CRM0182 (SEQ ID NOs 2273 and 2274 respectively) or scrambled control (Scr. Control) or Mock. Results were normalized to GAPDH expression levels. CCT3 levels are shown as % of mock.

FIG. 13. Effect of circRNA knockdown by antisense oligonucleotides on cancer cell proliferation in A) the human lung carcinoma cell line A549, B) the human hepatoma cell line Hep3B and C) the human liver adenocarcinoma cell line SK-Hep-1. The effect of circRNA knockdown on cell proliferation in each cell line was tested using antisense oligonucleotides CRM0171 (circHIPK3), CRM0168 (circFAT1), CRM0173 (circCORO1C), CRM0177 (circPVT1), CRM0178 (circFIRRE), CRM0182 (circCCT3) (SEQ ID NOs 374, 2262, 2266, 2269, 2270, and 2274 respectively).

FIG. 14. RNase R treatment of total RNA from A549, Hep3B and SK-Hep-1 cells to validate the circular nature of the circRNAs identified. Experimental conditions are described in example 18. After RNase R treatment of the total RNA from each cell line, the amount of circular RNA and of linear RNA was quantified using QPCR. A) Shows results from the A549 cell line, B) shows results from the Hep3B cell line, and C) shows results from the SK-Hep-1 cell line.

FIG. 15 Shows the effect of ciRS-7 knockdown by antisense oligonucleotides on miR-7 target mRNAs in A549 cells. Results show effect after 48 hours and after 72 hours.

FIG. 16 Knockdown of ciRS-7 by perfect match gapmer antisense oligonucleotide CRM0106 (SEQ ID NO: 360) compared to different mismatched gapmer antisense oligonucleotides CRM220-227 in cultured SK-Hep1 cells. The scrambled sequence gapmer CRM0023 was used as a negative control in the experiment.

DETAILED DESCRIPTION

Definitions

“Back-splice junction” of a circRNA as referred to herein means the region of a circular RNA, where its 3′ and 5′ ends are joined covalently together to result in a circular form.

The term “therapeutically effective amount”, or “effective amount” or “effective dose”, refers to an amount of a therapeutic agent, which confers a desired therapeutic effect on an individual in need of the agent. The effective amount may vary among individuals depending on the health and physical condition of the individual to be treated, the taxonomic group of the individuals to be treated, the formulation of the composition, the method of administration, assessment of the individual’s medical condition, and other relevant factors.

The term “treatment” refers to any administration of a therapeutic medicament, herein comprising an antisense oligonucleotide that partially or completely cures or reduces one or more symptoms or features of a given disease.

The term “small interfering RNA (siRNA)” refers to are small pieces of double-stranded (ds) RNA, usually between 16 to 30 nucleotides long, with 3′ overhangs (2 nucleotides) at each end that can be used to “interfere” with the translation of proteins by binding to and promoting the degradation of messenger RNA (mRNA) at specific sequences.

“Antisense oligonucleotide” means a single-stranded oligonucleotide having a nucleobase sequence that permits hybridization to a corresponding region or segment of a target nucleic acid.

The antisense oligonucleotide of the present invention is preferably a gapmer.

A “gapmer” is a chimeric antisense compound, in which an internal region having a plurality of nucleosides (such as a region of at least 6 or 7 DNA nucleotides), which is capable of recruiting RNAse H activity, such as RNAseH, which region is positioned between external wings at each end, having one or more nucleosides, wherein the nucleosides comprising the internal region are chemically distinct from the nucleoside or nucleosides comprising the external wings.

The internal region of a gapmer may be referred to as the “gap”.

The external regions of a gapmer may be referred to as the “wings”.

A “mixmer” is an antisense compound, which in contrast to a gapmer does not have an internal region with a plurality of DNA nucleosides capable of recruiting RNase H activity. A mixmer is an antisense compound which has a mixture of stretches of affinity enhancing nucleotide analogues such as LNA nucleotides mixed with e.g. DNA nucleotides so that the antisense compound does not comprise a contiguous stretch of DNA that exceeds 3, 4 or 5 in length.

“Nucleoside analogues” are described by e.g. Freier & Altmann; Nucl. Acid. Res., 1997, 25, 4429 - 4443 and Uhlmann; Curr. Opinion in Drug Development, 2000, 3(2), 293-213, and examples of suitable and preferred nucleoside analogues are provided by WO2007031091, which are hereby incorporated by reference.

“5-methylcytosine” means a cytosine modified with a methyl group attached to the 5′ position. A 5-methylcytosine is a modified nucleobase.

“2′—O—methoxyethyl” (also 2′-MOE and 2′—O(CH^~)^~-OCH3) refers to an O-methoxy-ethyl modification at the 2′ position of a furanose ring.

“2′-MOE nucleoside” (also 2′—O—methoxyethyl nucleoside) means a nucleoside comprising a 2′-MOE modified sugar moiety.

A “locked nucleic acid” or “LNA” is often referred to as inaccessible RNA, and is a modified RNA nucleobase. The ribose moiety of an LNA nucleobase is modified with an extra bridge connecting the 2′ oxygen and 4′ carbon. An LNA oligonucleotide offers substantially increased affinity for its complementary strand, compared to traditional DNA or RNA oligonucleotides. In some aspects bicyclic nucleoside analogues are LNA nucleotides, and these terms may therefore be used interchangeably, and is such embodiments, both are characterized by the presence of a linker group (such as a bridge) between C2′ and C4′ of the ribose sugar ring. When used in the present context, the terms “LNA unit”, “LNA monomer”, “LNA residue”, “locked nucleic acid unit”, “locked nucleic acid monomer” or “locked nucleic acid residue”, refer to a bicyclic nucleoside analogue. LNA units are described in inter alia WO 99/14226, WO 00/56746, WO 00/56748, WO 01/25248, WO 02/28875, WO 03/006475, WO2015071388, and WO 03/095467.

“Beta-D-Oxy LNA”, is a preferred LNA variant.

“Bicyclic nucleic acid” or “BNA” or “BNA nucleosides” means nucleic acid monomers having a bridge connecting two carbon atoms between the 4′ and 2′position of the nucleoside sugar unit, thereby forming a bicyclic sugar. Examples of such bicyclic sugar include, but are not limited to A) pt-L-methyleneoxy (4′—CH2—0—2′) LNA, (B) P-D-Methyleneoxy (4′—CH2—0-2′) LNA, (C) Ethyleneoxy (4′— (CH2)2—0-2′) LNA, (D) Aminooxy (4′-CH2-0-N(R)-2′) LNA and (E) Oxyamino (4′—CH2—N(R)—0—2′) LNA.

As used herein, LNA compounds include, but are not limited to, compounds having at least one bridge between the 4′ and the 2′ position of the sugar wherein each of the bridges independently comprises 1 or from 2 to 4 linked groups independently selected from —[C(R^~)(R2)],,-, —C(R^~)═C(R2)—, —C(R^~)═N, —C(═NREM)—, —C(═O)—, —C(═S)—, —O—, —S(═O) -and -N(R&)-; wherein: x is 0, 1, or 2; n is 1, 2, 3, or 4; each R& and R2 is, independently, H, a protecting group, hydroxyl, C»C» alkyl, substituted C» (—CHz—) group connecting the 2′ oxygen atom and the 4′ carbon atom, for which the term methyleneoxy (4′—CH&-0-2′) LNA is used. Furthermore; in the case of the bicylic sugar moiety having an ethylene bridging group in this position, the ethyleneoxy (4′—CH&CH&-0-2′) LNA is used. n -L- methyleneoxy (4′—CH&-0-2′), an isomer of methyleneoxy (4′—CH&-0-2′) LNA is also encompassed within the definition of LNA, as used herein.

In some embodiments, the nucleoside unit is an LNA unit selected from the list of beta-D-oxy-LNA, alpha-L-oxy-LNA, beta-D-amino-LNA, alpha-L-amino-LNA, beta-D-thio-LNA, alpha-L-thio-LNA, 5′-methyl-LNA, beta-D-ENA and alpha-L-ENA.

“cEt″or “constrained ethyl” means a bicyclic sugar moiety comprising a bridge connecting the 4′-carbon and the 2′-carbon, wherein the bridge has the formula: 4′—CH(CHq)—0-2′.

“Constrained ethyl nucleoside” (also cEt nucleoside) means a nucleoside comprising a bicyclic sugar moiety comprising a 4′—CH(CH3)—0-2′ bridge. cEt and some of its properties is described in Pallan et al. Chem Commun (Camb). 2012, August 25; 48(66): 8195-8197.

“Tricyclo (tc)-DNA” belongs to the class of conformationally constrained DNA analogs that show enhanced binding properties to DNA and RNA. Structure and method of production may be seen in Renneberg et al. Nucleic Acids Res. 2002 Jul 1; 30(13): 2751-2757.

“2′-fluoro”, as referred to herein is a nucleoside comprising a fluoro group at the 2′ position of the sugar ring. 2′-fluorinated nucleotides are described in Peng et al. J Fluor Chem. 2008 September; 129(9): 743-766.

“2′—O—methyl”, as referred to herein, is a nucleoside comprising a sugar comprising an —OCH₃ group at the 2′ position of the sugar ring.

“Conformationally Restricted Nucleosides (CRN)” and methods for their synthesis, as referred to herein, are described in WO2013036868, which is hereby incorporated by reference. CRN are sugar-modified nucleosides, in which, similar to LNA, a chemical bridge connects the C2′ and C4′ carbons of the ribose. However, in a CRN, the C2′ - C4’ bridge is one carbon longer than in an LNA molecule. The chemical bridge in the ribose of a CRN locks the ribose in a fixed position, which in turn restricts the flexibility of the nucleobase and phosphate group. CRN substitution within an RNA- or DNA-based oligonucleotide has the advantages of increased hybridization affinity and enhanced resistance to nuclease degradation.

“Unlocked Nucleic Acid” or “UNA”, is as referred to herein unlocked nucleic acid typically where the C2 -C3 C-C bond of the ribose has been removed, forming an unlocked “sugar” residue (see Fluiter et al., Mol. Biosyst., 2009, 10, 1039, hereby incorporated by reference, and Snead et al. Molecular Therapy-Nucleic Acids (2013) 2, e103;).

“Cancer” is also known as malignant neoplasm, which is a term for diseases, in which abnormal cells divide without control, and can invade nearby tissues or spread to other parts of the body.

A “circRNA-positive cancer” is a cancer that expresses a particular circRNA. In example, “ciRS-7 positive cancer” is a cancer which expresses ciRS-7.

“Hepatocellular carcinoma” (HCC) is the most common type of liver cancer. Carcinoma means that it is a cancer found in tissues that cover or line the surfaces of the liver. This is the most common liver cancer type.

Internucleoside linkages are in preferred embodiments phosphorothioate linkages, however, it is recognized that the inclusion of phosphodiester linkages, such as one or two linkages, into an otherwise phosphorothioate oligonucleotide, particularly between or adjacent to nucleotide analogue units can modify the bioavailability and/or bio-distribution of an oligonucleotide as described in WO2008/053314, hereby incorporated by reference. In some embodiments, where suitable and not specifically indicated, all remaining linkage groups are either phosphodiester or phosphorothioate, or a mixture thereof.

The term” circRNA” (circular RNA) refers to a type of RNA, which forms a covalently closed continuous loop where the 3′ and the 5′ ends are joined together, unlike the linear RNA.

The term “unassisted uptake” refers to a transfection method in which cells are transfected with antisense oligonucleotides essentially as described in Soifer et al. (Methods Mol Biol. 2012; 815: 333-46).

The term “GaINAc” or “GaINAc Conjugate” Moieties as referred to herein is a galactose derivative, preferably an N-acetyl- galactosamine (GaINAc) conjugate moiety. More preferably a trivalent N-acetylgalactosamine moiety is used. GalNAc conjugation of antisense oligonucleotides is known previously as described in WO2015071388. Targeting to hepatocytes in the liver can be greatly enhanced by the addition of a conjugate moiety

“Target region” means a portion of a target nucleic acid to which one or more antisense compounds is targeted.

“Targeted delivery” as used herein means delivery, wherein the antisense oligonucleotide has either been formulated in a way that will facilitate efficient delivery in specific tissues or cells, or wherein the antisense oligonucleotide in other ways has been for example modified to comprise a targeting moiety, or in other way has been modified in order to facilitate uptake in specific target cells.

The term “siRNA as used herein is a single-stranded RNA molecule (usually from 21 to 25 nucleotides in length) produced by the cleavage and processing of double-stranded RNA; siRNAs bind to complementary sequences in mRNA and bring about the cleavage and degradation of the targeted mRNA. As used herein, an siRNA may be designed to target a circRNA backsplice junction, in a way to that the region of complementarity overlaps the junction by at least 3 nucleotides. The design and production of siRNAs is well known in the art.

Compounds

Suitably the antisense oligonucleotides of the invention are capable of down-regulating their targets, i.e. a circRNA or a lincRNA selected from the lists below.

Preferred compounds according to the present invention are selected from the list of anyone of SEQ ID NO’s: 360-2148 and anyone of SEQ ID NO’s: 2285-2299.

Modulation of circRNA

The present invention relates to chemically-modified antisense oligonucleotides (ASOs) designed to modulate ncRNAs for treatment of human disease, such as cancer. In one aspect, the present invention relates to chemically-modified antisense oligonucleotides designed to modulate circRNAs. The ASOs of the invention recruit RNase H activity for degradation of the target circRNA and comprise phosphorothioate internucleotide linkages, to enhance their pharmacokinetic properties in vivo. These features make the ASO compounds of the invention highly useful as novel medicaments, in particular as anti-cancer therapeutics.

The present invention provides novel methods for modulating the expression of circRNAs in cells. In one aspect of the invention, the invention provides an antisense oligonucleotide consisting of a sequence of 14-22 nucleobases in length that is complementary to an endogenous circRNA, and wherein the antisense oligonucleotide is a gapmer comprising a central region of 6 to 16 consecutive DNA nucleotides flanked in each end by wings each comprising 1 to 5 nucleotide analogues, and wherein the antisense oligonucletide comprises at least 1, or 2, or 3, or 4, or from 5 to 21, such as from 6 to 21, such as from 8 to 21, such as from 9 to 21 phosphorothioate internucleotide linkages, and wherein all internucleotide bonds in the DNA stretch are phosphorothioate linkages. These antisense oligonucleotides have surprisingly been found to be able to efficiently knockdown circRNAs in cells.

In some embodiments of the present invention, the antisense oligonucleotide according to the invention is designed to have a sequence of complementarity to a circRNA, which overlaps the circRNA back-splice junction by at least 3 nucleotides.

In preferred embodiments, the antisense oligonucleotide of the invention is complementary to, and thereby targets a circRNA which is anyone of a circRNA selected from the list of ciRS-7, circPVT1, circHIPK3, circSRY, circSLC35E2B, circCDK11A, circUNKNOWN00000001, circARHGAP32, circSLC8A3, circHERC2, circZFAND6, circRP1-168P16.1, circAURKC, circAFTPH, circSCD, circSMC3, circSNORA23|IPO7.1, circZNF124.1, circSNX5|OVOL2, circRALY, circTFPI, circAHSG.1, circAHSG.2, circAHSG.3, circUBXN7, circAFP, circHIST1H3A, circHIST1H3C.1, circANAPC2, circRMRP|RMRP, circCENPI, circFIRRE, circMBNL3, circGPC3 and circFAT1.

In another preferred embodiments, the antisense oligonucleotide of the invention is targeted to a circRNA which is selected from the list of anyone of ciRS-7, circFAT1, circPVT1, circHIPK3, circSRY, circSLC35E2B, circCDK11A, circUNKNOWN00000001, circARHGAP32, circSLC8A3, circHERC2, circZFAND6, circRP1-168P16.1, circAURKC, circAFTPH, circSCD, circSMC3, circSNORA23|IPO7.1, circZNF124.1, circSNX5|OVOL2, circRALY, circTFPI, circAHSG.1, circAHSG.2, circAHSG.3, circUBXN7, circAFP, circHIST1H3A, circHIST1H3C.1, circANAPC2, circRMRP|RMRP, circCENPI, circFIRRE, circMBNL3, circGPC3, circPROSER2, circMALRD1, circFAM208B, circMCU, circKIF20B, circABCC2, circEIF4G2|SNORD97.1, circEIF4G2|SNORD97.2, circEIF4G2|SNORD97.3, circEIF4G2|SNORD97.4, circEIF4G2 |SNORD97.5, circEIF4G2|SNORD97.6, circEIF4G2|SNORD97.7, circEIF4G2|SNORD97.8, circEIF4G2|SNORD97.9, circEIF4G2|SNORD97.10, circlGF2, circQSER1, circUNKNOWN00000002, circCHD1L, circPRUNE, circSLC27A3, circGATAD2B, circKIAA0907, circCCT3, circPLEKHM2, circVWCE, circATF6, circMALAT1.1, circMALAT1.2, circMALAT1.3, circMALAT1.4, circMALAT1.5, circMALAT1.6, circMALAT1.7, circMALAT1.8, circMALAT1.9, circMALAT1.10, circMALAT1.11, circMALAT1.12, circMALAT1.13, circUNKNOWN00000003, circMALAT1.14, circMALAT1.15, circMALAT1.16, circMALAT1.17, circMALAT1.18, circMALAT1.19, circUCK2, circSUCO, circRAB6A, circRPS3|SNORD15B.1, circRPS3|SNORD15B.2, circRPS3|SNORD15B.3, circRSF1, circABL2, circGNB1, circRPLP2|SNORA52, circPICALM.1, circPICALM.2, circSNORA23|IPO7.2, circSNORA23|IPO7.3, circCFH, circSLC41A2.1, circSLC41A2.2, circCORO1C, circEIF4G3|RP11-487E1.2, circNAA25, circMED13L, circLPGAT1|RN7SL344P, circAACS, circTP53BP2, circSOX5, circDNAH14, circKDM1A|MIR3115, circTTC13, circEGLN1, circTCEA3, circTOMM20|SNORA14B, circSCCPDH, circZNF124.2, circGLS2, circR3HDM2, circDHDDS, circSNORA73A|RCC1|SNHG3.1, circSNORA73AI RCC1|SNHG3.2, circSNORA61|SNHG12, circCEP83|RBMS2P1, circFGD6, circPUM1, circTMCO3|RP11-230F18.6, circPTP4A2, circZMYM5, circN6AMT2, circRPL21|SNORA27, circGTF2F2, circZMYM4, circLINC00355, circUNKNOWN00000004, circFARP1, circDYNC1H1, circCDC42BPB, circCCNB1IP1|SNORA79|AL355075.1, circRPPH1|RPPH1.1, circRPPH1|RPPH1.2, circRPPH1|RPPH1.3, circRPPH1|RPPH1.4, circSNORD8|CHD8.1, circSNORD8|CHD8.2, circPPP1R3E, circCHMP4A|RP11-468E2.1|AL136419.6, circUNKNOWN00000005, circSEC23A, circSNORD46|RPS8, circSAMD4A, circPCNX, circPSEN1, circFCF1, circSCARNA13|SNHG10.1, circSCARNA13|SNHG10.2, circSCARNA13|SNHG10.3, circUNKNOWN00000006, circTJP1, circRP11-632K20.7, circTTBK2, circPPIB, circUBE2Q2, circETFA, circSEC11A, circPDE8A, circDAB1|OMA1, circABHD2, circlQGAP1.1, circlQGAP1.2, circCHD2, circIGF1R, circNPRL3, circNDE1, circABCC1, circRPS2|SNORA64, circPOLR3E, circATXN2L, circMVP, circASPHD1, circITGAL, circRP5-857K21.6.1, circRP5-857K21.6.2, circRP5-857K21.6.3, circRP5-857K21.6.4, circZNF720, circLONP2, circCHD9, circSLC7A6, circCARHSP1, circFANCA, circRAD51D|RAD51L3-RFFL, circHDAC5, circUTP18, circSRSF1, circPPM1D, circBRIP1, circPRKCA.1, circPRKCA.2, circEIF4A1|SNORD10| RP11-186B7.4|SENP3-EIF4A1.1, circEIF4A1|SNORD10|RP11-186B7.4|SENP3-EIF4A1.2, circPGS1, circRPTOR, circRPL26|RP11-849F2.7, circRP11-206L10.8, circPIAS2, circTYMS, circPPP4R1, circZNF91, circWDR62, circADCK4, circARHGAP35, circNUCB1, circSNORD33| RPL13A.1, circSNORD33| RPL13A.2, circSNORD33| RPL13A.3, circMUC16, circLZIC, circSNX5|SNORD17|OVOL2.1, circSNX5|SNORD17|OVOL2.2, circSNORA71A|SNHG17, circPLTP, circTMEM230, circCYP24A1, circZBTB46, circGART, circRAB3GAP1, circDYRK1A, circUNKNOWN00000007, circCOL18A1.1, circCOL18A1.2, circNBAS, circCH507-513H4.1.1, circCH507-513H4.1.2, circCH507-513H4.1.3, circANKAR, circGLS, circBMPR2, circRHBDD1, circATG16L1|SCARNA5, circDGKD, circPASK, circPPP6R2, circBIRC6, circPRKD3, circKIAA1841|RP11-493E12.3, circRTKN, circELMOD3, circREV1, circZBTB20, circTIMMDC1, circACAD9, circPLXND1, circHDAC11, circCEP70, circRNF13.1, circRNF13.2, circGOLIM4, circEIF4A2|SNORD2.1, circEIF4A2|SNORD2.2, circSDHAP1, circSETD2, circSCAP, circUSP4, circRPL29, circPHF7, circNEK4, circFLNB, circSLC25A26, circNFKB1, circFIP1L1|RP11-231C18.3, circTBC1D14, circALB.1, circALB.2, circALB.3, circNUP54, circAFF1, circSLC12A7 | MIR4635, circMAN2A1.1, circMAN2A1.2, circAFF4, circUBE2D2, circANKHD1|ANKHD1-EIF4EBP3, circMAPK9, circGPBP1, circCEP72, circRP11-98J23.2, circFAM169A, circWDR41, circRASGRF2, circRHOBTB3, circCEP85L, circARID1B.1, circARID1B.2, circTULP4|RP11-732M18.4, circTULP4, circTMEM181, circHIST1H3B, circHIST1H3C.2, circUNKNOWN00000008, circC6orf136, circHLA-C|HLA-B|XXbac-BPG248L24.10|WASF5P|XXbac-BPG248L24.13.1, circHLA-C|HLA-B|XXbac-BPG248L24.10|WASF5P|XXbac-BPG248L24.13.2, circFKBP5, circCNPY3, circSRF, circRN7SK, circFARS2, circMLIP, circZNF292, circPNRC1, circUNKNOWN00000009, circNDUFB2, circKMT2C, circESYT2, circMPP6, circHERPUD2, circOGDH, circZNF680, circKDELR2|DAGLB, circZDHHC4, circCCZ1B, circPOM121, circBAZ1B, circGTF2I, circSNORA14A, circCDK14, circCCDC132, circTRRAP|MIR3609, circCYP3A7|CYP3A7-CYP3A51P, circCCAT1.1, circCCAT1.2, circCCAT1.3, circCCAT1.4, circCCAT1.5, circCCAT1.6, circCCAT1.7, circASAP1, circPTK2.1, circPTK2.2, circSLC45A4, circADGRB1, circRBPMS, circFGFR1, circHOOK3, circASPH, circTMEM245, circUNKNOWN00000010, circHSPA5, circGLE1, circFOCAD, circNFX1, circUBAP2, circKDM4C|RP11-146B14.1, circAGTPBP1, circFAM120A.1, circFAM120A.2, circHIATL1, circPPP2R3B, circATRX, or circTBL1X.

In such preferred embodiments, the antisense oligonucleotide of the invention is at least 80%, such as at least 85%, such as at least 90 %, such as at least 95%, such as at least 100% complementary to a sequence of between 14 and 22 nucleotides in length and which sequence is located within anyone of SEQ ID NOs: 1 - 359 and 2260, which are the sequences of the circRNA back-splice junctions in the above list of circRNAs. In a preferred embodiment, the antisense oligonucleotide that is complementary to a sequence within anyone of SEQ ID NOs: 1 - 359 and 2260, will be designed so that the region of complementarity overlaps the back-splice junction (see Tabel 1) by at least 3 nucleotides.

The back-splice junctions were identified as described in example nr. 4. Each back-splice junction was uniquely identified in the hg38 genome by the chromosome name (chrName), position of the donor and acceptor (posAcceptor and posDonor), and the strand of the chromosome (strand). A unique backsplice ID (bsID) was generated from this info ([chrName]:[posAcceptor]-[posDonor]|[strand], e.g. X:140783175-140784661|+).Vertical lines in sequences denote the back-splice junction in each circRNA.

Back-splice junction-encompassing sequences identified in cancer-associated circRNAs.
SEQ ID NO	bsID	Parental gene	Parent gene name	Back-splice junction sequence	circRNA name
1	X:140783175-140784661|+	ENSG00000281508	CDR1-AS	GUGUCUGCAAUAUCCAGG| GUUUCCGAUGGCACCUGU	ciRS-7
2	8:127890588-127890999|+	ENSG00000249859	PVT1	CGCUCAGCUGGGCUUGAG | GCCUGAUCUUUUGGCCAG	circPVT1
3	11:33286412-33287512|+	ENSG00000110422	HIPK3	ACAAUCUCGGUACUACAG | GUAUGGCCUCACAAGUCU	circHIPK3
4	Y:2787700-2786854|-	ENSG00000184895	SRY	AAGGCCUUAUUCAUUUCA | GUAACAAAGAAUCUGGUA	circSRY
5	1:1719456-1655368|-	ENSG00000189339	SLC35E2B	AGACUCUAUGGAAGACAG | AGGAGAAGAAGAUGAUUC	circSLC35E2B
6	1:1734836-1669663|-	ENSG00000008128	CDK11A	GCCCGGGUUUUCUUUACG | GACGUCCCAGUGAUCGGG	circCDK11A
7	10:94588228-94594855|+	UNKNOWNOOOOOOO 1	UNKNOWN00000001	AGUUGAUCAUCCAUAAAA | AUUUUAACACCUUUCUUA	circUNKNOWN00000001
8	11:129124895 -129123445|-	ENSG00000134909	ARHGAP32	GAGUUCGGCAGCAUACAG | GCAAGAGGCGCAGAUGUU	circARHGAP32
9	14:70168485-70166638|-	ENSG00000100678	SLC8A3	CAAGAAUGAUGAAACUGU | GUCUCUGGCCUAUCAGGA	circSLC8A3
10	15:28273005-28245880|-	ENSG00000128731	HERC2	CCUGGCCUGGCAUAAUGG | GGAUGUUCACGGAACGCC	circHERC2
11	15:80098415-80122801|+	ENSG00000086666	ZFAND6	AAACAGAAGAUGUGCAGG | GAAUGAAUCUGAAGUCUG	circZFAND6
12	16:89431327-89418283|-	ENSG00000261692	RP1-168P16.1	CUUUCAGCUAUGGAAUCG | CCCGUGCAGCCUGCCAGG	circRP1-168P16.1
13	19:57211353-57248701|+	ENSG00000105146	AURKC	CCCAAGGCACCUGUCCAG | GCGACAAAGGAAAACCUA	circAURKC
14	2:64551442-64553410|+	ENSG00000119844	AFTPH	UCAGCCACUUCAGUUCAG | GUGUAAAUUAAUUAUUUG	circAFTPH
15	10:100361145 -100361314|+	ENSG00000099194	SCD	UGCUCCAGAUAACUCUCU | CUCUUCUAGGCCCAUUGU	circSCD
16	10:110596397 -110598291|+	ENSG00000108055	SMC3	AAAACCUUCAUGCCUAAG | GUGACCAAGUCAGCCAUC	circSMC3
17	11:9428767-9428954|+	ENSG00000201998 |ENSG00000205339	SNORA23|IPO7	UCCAAAUUCCCACACACA | UGGCUGCUGUAAUGUGUG	circSNORA23|IPO7.1
18	1:247159814-247138715|-	ENSG00000196418	ZNF124	UUAUGGGUUUCUACUCUA | AACUCGGUUGCCUUUGAG	circZNF124.1
19	20:17957038-17955364|-	ENSG00000089006 |ENSG00000125850	SNX5|OVOL2	GACUAUGCUGGGCUUAUU | CUGAGAUCUGUAUCUGUG	circSNX5|OVOL2
20	20:34029768-34031605|+	ENSG00000125970	RALY	AGCUCAUCAUUGUUACUG | AGCUGCAGAGAUCCUUUG	circRALY
21	2:187465961-187465763|-	ENSG00000003436	TFPI	GAAACAACCAUUUCAUUC | UUGGGGAUUUAAUAUUUU	circTFPI
22	3:186617235-186618631|+	ENSG00000145192	AHSG	CAAGUGUAACCUGCUGGC | CCCGCUGAACGACACCAG	circAHSG.1
23	3:186620981-186621179|+	ENSG00000145192	AHSG	UUGACGGUAAGCCACCAU | UUUGUCCAAGCCUGGGCA	circAHSG.2
24	3:186620982-186621220|+	ENSG00000145192	AHSG	GACCUUACAAAAACCAUU | UUGUCCAAGCCUGGGCAU	circAHSG.3
25	3:196352732-196352547|-	ENSG00000163960	UBXN7	AAAUCUGAGAUCUAAUUC | AUGAGCCACUGCGCCCGA	circUBXN7
26	4:73440693-73443441|+	ENSG00000081051	AFP	GGACCCGAACUUUCCAAG | ACAUAACUGUUUUCUUGC	circAFP
27	6:26020635-26020938|+	ENSG00000275714	HIST1H3A	GGUCCAAGCAAAGGCUCU | GCGCGAGAUCCGCCGUUA	circHIST1H3A
28	6:26045383-26045792|+	ENSG00000278272	HIST1H3C	CCCAAAGAUAUCCAGCUG | ACACUUUUGUGUGUGCUC	circHIST1H3C.1
29	9:137175708-137175499|-	ENSG00000176248	ANAPC2	AGCCCGUGCCCAGGCUGC | GUGAGCCCACCAGCCCCU	circANAPC2
30	9:35657983-35657774|-	ENSG00000269900 |ENSG00000277027	RMRP|RMRP	UCCGCGCACCAACCACAC | UGAGGACUCUGUUCCUCC	circRMRP|RMRP
31	X:101162107-101162293|+	ENSG00000102384	CENPI	AGACCAUGCCUGUACUAA | UUUUUGAUUUUUUAGUAG	circCENPI
32	X:131794467-131749305|-	ENSG00000213468	FIRRE	AGGAGAUACUUUAUGAGG | AGACUAAGGUGUCAGUAU	circFIRRE
33	X:132378685-132378526|-	ENSG00000076770	MBNL3	UUUACACAAAUGCCAUUU | GUCAUCUUCAGCUGAGAA	circMBNL3
34	X:133754177-133753481|-	ENSG00000147257	GPC3	GGAAAGCUGACCACCACU | AGGCCUUUGAAAUUGUUG	circGPC3
35	10:11851996-11852216|+	ENSG00000148426	PROSER2	UCCAGAAGCUUCACUUUG | GAGUGAGCUGUUGCCGCA	circPROSER2
36	10:19257683-19283182|+	ENSG00000204740	MALRD1	AUCAGUGGAUCAUACACA | AUAUUGGUGGAGGCUUCA	circMALRD1
37	10:5709529-5714208|+	ENSG00000108021	FAM208B	UGGGUGAUCCAGCCAAAG | CAUUUAUGACAUUAACAG	circFAM208B
38	10:72715110-72715903|+	ENSG00000156026	MCU	AAACUUGAACAUUCGCAG | GUCUUUCACUACCAUUCC	circMCU
39	10:89751345-89762836|+	ENSG00000138182	KIF20B	AGUAAUGAAAUGGAGGAG | AUCUAAAUGUUAAAGAGA	circKIF20B
40	10:99834379-99834536|+	ENSG00000023839	ABCC2	AUUUAUGUAUCUGUUCAG | GAUAUUUCCACAGUGGAU	circABCC2
41	11:10801577-10801475|-	ENSG00000110321 |ENSG00000238622	EIF4G2|SNORD97	AGCGAAGAUUAUGAGAUA | AGAGGACUUUAUGCUGGA	circEIF4G2|SNORD 97.1
42	11:10801579-10801476|-	ENSG00000110321 |ENSG00000238622	EIF4G2|SNORD97	GAGCGAAGAUUAUGAGAU | UAAGAGGACUUUAUGCUG	circEIF4G2|SNORD 97.2
43	11:10801593-10801475|-	ENSG00000110321 |ENSG00000238622	EIF4G2|SNORD97	AGCGAAGAUUAUGAGAUA | AAAAGACGCGUUAUUAAG	circEIF4G2|SNORD 97.3
44	11:10801594-10801474|-	ENSG00000110321 |ENSG00000238622	EIF4G2|SNORD97	GCGAAGAUUAUGAGAUAU | AAAAAGACGCGUUAUUAA	circEIF4G2|SNORD 97.4
45	11:10801594-10801481|-	ENSG00000110321 |ENSG00000238622	EIF4G2|SNORD97	CCUGUGAGCGAAGAUUAU | AAAAAGACGCGUUAUUAA	circEIF4G2|SNORD 97.5
46	11:10801601-10801479|-	ENSG00000110321 |ENSG00000238622	EIF4G2|SNORD97	UGUGAGCGAAGAUUAUGA | UGAUUAUAAAAAGACGCG	circEIF4G2|SNORD 97.6
47	11:10801601-10801488|-	ENSG00000110321 |ENSG00000238622	EIF4G2|SNORD97	CCAGCGUCCUGUGAGCGA | UGAUUAUAAAAAGACGCG	circEIF4G2|SNORD 97.7
48	11:10801606-10801493|-	ENSG00000110321 |ENSG0000023862 2	EIF4G2|SNORD97	AAUGUCCAGCGUCCUGUG | CCCGAUGAUUAUAAAAAG	circEIF4G2|SNORD 97.8
49	11:10801608-10801467|-	ENSG00000110321 |ENSG0000023862 2	EIF4G2|SNORD97	UUAUGAGAUAUGAGGGCA | UGCCCGAUGAUUAUAAAA	circEIF4G2|SNORD 97.9
50	11:10801608-10801468|-	ENSG00000110321 |ENSG00000238622	EIF4G2|SNORD97	AUUAUGAGAUAUGAGGGC | UGCCCGAUGAUUAUAAAA	circEIF4G2|SNORD 97.10
51	11:2132056-2131827|-	ENSG00000167244	IGF2	ACAGCACACAAACGCACA | CAGCACACACACAAACGC	circlGF2
52	11:32927156-32935436|+	ENSG00000060749	QSER1	AUAAAAAGAAGAAAACAG | UUUAAGCUAUGAAGAAGG	circQSER1
53	11:33287512-33286412|-	UNKNOWN00000002	UNKNOWN00000002	AGACUUGUGAGGCCAUAC | CUGUAGUACCGAGAUUGU	circUNKNOWN00000002
54	1:147275353-147285488|+	ENSG00000131778	CHD1L	GGCUGAACAUAAGAAAAA | GUGGAGUUGGCAUGAACU	circCHD1L
55	1:151024610-151025674|+	ENSG00000143363	PRUNE	CAAAGUUUGAUGUAUCAG | AAGUGACACAGCCCUAGA	circPRUNE
56	1:153778949-153779098|+	ENSG00000143554	SLC27A3	UGACUCCCAGUUUCAGAU | CUCAACUCUCUAAUCUGC	circSLC27A3
57	1:153813453-153811730|-	ENSG00000143614	GATAD2B	GCCUCCUUGGUAUGCCAG | GCAAAAGCUGUGCCUCAC	circGATAD2B
58	1:155921919-155921374|-	ENSG00000132680	KIAA0907	CCAGCUAGCACUGGACAG | GUUCAUGCUGAAUACUCU	circKIAA0907
59	1:156334919-156333546|-	ENSG00000163468	CCT3	CAUCAGUAAUUAUUCUUG | ACUAUUGCAGAUAUCAUC	circCCT3
60	1:15717892-15721389|+	ENSG00000116786	PLEKHM2	CCAGCACAGACUGGGAAG | GCCGUGCCUGGCUGUACC	circPLEKHM2
61	11:61278477-61276592|-	ENSG00000167992	VWCE	GCUGUACUUGUGUUCCAG | GCUGUUUUCACAGUGGUG	circVWCE
62	1:161778243-161784097|+	ENSG00000118217	ATF6	UCAACUCAGCAUGUUCCU | AUUCUGCUCUCUUUGCUG	circATF6
63	11:65499621-65499850|+	ENSG00000251562	MALAT1	AACUUAGAAGAAAAUUGG | UAGGAUGAAACAAUUUGG	circMALAT1.1
64	11:65499631-65499877|+	ENSG00000251562	MALAT1	ACAAGAUAGAAAAUGAAA | CAAUUUGGAGAAGAUAGA	circMALAT1.2
65	11:65499633-65499735|+	ENSG00000251562	MALAT1	AAUUAGAAGAUAAAAACA | AUUUGGAGAAGAUAGAAG	circMALAT1.3
66	11:65499645-65499748|+	ENSG00000251562	MALAT1	AAACAUACUUUUAGAAGA | UAGAAGUUUGAAGUGGAA	circMALAT1.4
67	11:65499647-65499757|+	ENSG00000251562	MALAT1	UUUAGAAGAAAAAAGAUA | GAAGUUUGAAGUGGAAAA	circMALAT1.5
68	11:65499650-65499859|+	ENSG00000251562	MALAT1	GAAAAUUGGAAGAUAGAA | GUUUGAAGUGGAAAACUG	circMALAT1.6
69	11:65499650-65499870|+	ENSG00000251562	MALAT1	GAUAGAAACAAGAUAGAA | GUUUGAAGUGGAAAACUG	circMALAT1.7
70	11:65499665-65499846|+	ENSG00000251562	MALAT1	UACAAACUUAGAAGAAAA | CUGGAAGACAGAAGUACG	circMALAT1.8
71	11:65499673-65499854|+	ENSG00000251562	MALAT1	UAGAAGAAAAUUGGAAGA | CAGAAGUACGGGAAGGCG	circMALAT1.9
72	11:65499696-65499841|+	ENSG00000251562	MALAT1	AAAUGUACAAACUUAGAA | AAGAAUAGAGAAGAUAGG	circMALAT1.10
73	11:65499698-65499846|+	ENSG00000251562	MALAT1	UACAAACUUAGAAGAAAA | GAAUAGAGAAGAUAGGGA	circMALAT1.11
74	11:65499720-65499848|+	ENSG00000251562	MALAT1	CAAACUUAGAAGAAAAUU | AGAAGAUAAAAACAUACU	circMALAT1.12
75	11:65499750-65499872|+	ENSG00000251562	MALAT1	UAGAAACAAGAUAGAAAA | AAGAUAAAUUUAAACCUG	circMALAT1.13
76	11:65499751-65499641|-	UNKNOWN0000003	UNKNOWN00000003	ACUUCAAACUUCUAUCUU | UUUUCUUCUAAAAGUAUG	circUNKNOWN00000003
77	11:65499790-65499904|+	ENSG00000251562	MALAT1	AGAGUUUCAGAUAGAAAA | AAGACAAGCUAGGAAACA	circMALAT1.14
78	11:65499798-65499925|+	ENSG00000251562	MALAT1	AAAACAAGCUAAGACAAG | CUAGGAAACAAAAAGCUA	circMALAT1.15
79	11:65499936-65500058|+	ENSG00000251562	MALAT1	UUCUGGUGGUGCAGAAGU | AUAGAAGAUAGAAAAAUA	circMALAT1.16
80	11:65500207-65500413 |+	ENSG00000251562	MALAT1	CCAGGUGCUACACAGAAG | GCUUUUGGAAGAGUUAGA	circMALAT1.17
81	11:65500459-65500625|+	ENSG00000251562	MALAT1	GAAAAAGGAUUCCAGGAA| CCAGUGUUUGAUGAAGCU	circMALAT1.18
82	11:65500517-65500646|+	ENSG00000251562	MALAT1	GCGAGUGCAAUUUGGUGA | AGAUAGGAAAAGAGUCCA	circMALAT1.19
83	1:165890203-165891323|+	ENSG00000143179	UCK2	CUUUGUCUCCCAUUCCCG | UCUUCCGUGUGUGCUAAG	circUCK2
84	1:172551511-172557795|+	ENSG00000094975	SUCO	GAUAAUUUAAAAAAUGAG | GCUUCCCAGCUGGCGUGU	circSUCO
85	11:73718719-73707419|-	ENSG00000175582	RAB6A	GGAUACAAUGUAAAGCAG | GUACGAUUGCAAUUAUGG	circRAB6A
86	11:75404420-75404564|+	ENSG00000149273 |ENSG00000207445	RPS3|SNORD15B	AGAGGCAUUUGUCUGAGA| CUUCAGUGAUGACACGAU	circRPS3 | SNORD15 B.1
87	11:75404420-75404566|+	ENSG00000149273 |ENSG00000207445	RPS3|SNORD15B	AGGCAUUUGUCUGAGAAG | CUUCAGUGAUGACACGAU	circRPS3 | SNORD15 B.2
88	11:75404420-75404567|+	ENSG00000149273 |ENSG00000207445	RPS3|SNORD15B	GGCAUUUGUCUGAGAAGG | CUUCAGUGAUGACACGAU	circRPS3 | SNORD15 B.3
89	11:77693612-77683709|-	ENSG00000048649	RSF1	GAAAUGUAUAAGCUACAG | AUUCUUCUGUGUGACUCU	circRSF1
90	1:179133375-179131310|-	ENSG00000143322	ABL2	CACUCAGCAUCACUAAAG | AUCACUUUGCCAGCUGUG	circABL2
91	1:1806539-1804418|-	ENSG00000078369	GNB1	AGCUGGCAGGACACACAG | GCUUCUCGUCAGUGCCUC	circGNB1
92	11:811681-811816|+	ENSG00000177600 | ENSG00000199785	RPLP2|SNORA52	GGCACUUCUAGACACUCU | GGUCCAUCCUAAUCCCUG	circRPLP2 | SNORA5 2
93	11:86003452-85996825|-	ENSG00000073921	PICALM	UAGCAAGUACAUGGGGAG | GCCCCUAGCAGUCUUCUU	circPICALM.1
94	11:86031612-85996825|-	ENSG00000073921	PICALM	UAGCAAGUACAUGGGGAG | ACUUAAUUCAGUGCACAA	circPICALM.2
95	11:9428765-9428954|+	ENSG00000201998 |ENSG00000205339	SNORA23|IPO7	UCCAAAUUCCCACACACA | CAUGGCUGCUGUAAUGUG	circSNORA23|IPO7. 2
96	11:9428767-9428952|+	ENSG00000201998 |ENSG00000205339	SNORA23|IPO7	CCUCCAAAUUCCCACACA | UGGCUGCUGUAAUGUGUG	circSNORA23|IPO7. 3
97	1:196725120-196728523|+	ENSG00000000971	CFH	CAGAAGUGAACUGCUCAA| AAAGAGAAUGCGAACUUC	circCFH
98	12:104928695 -104909654|-	ENSG00000136052	SLC41A2	UCCAGAUUAUCCACUGCA| AUCCAGUCCUUCUGUGGA	circSLC41A2.1
99	12:104928695 -104927972|-	ENSG00000136052	SLC41A2	GUACUGGAUAUAGUACAG | AUCCAGUCCUUCUGUGGA	circSLC41A2.2
100	12:108654411 -108652271|-	ENSG00000110880	CORO1C	CAAAUGUGAGAUUGCCAG | AAAAAUAUGCAGGAACCA	circCORO1C
101	1:21089214-21050865|-	ENSG00000075151 | ENSG00000236073	EIF4G3 | RP11-487E1.2	UCCCCUGGACUCUCUCAA| AAUUCCUAGAGGACCUGU	circEIF4G3 | RP11-487E1.2
102	12:112078742 -112075677|-	ENSG00000111300	NAA25	GCGCCUCUUACUAAAAAA | UCUAUAUCGGCACAGGAU	circNAA25
103	12:116237706 -116230532|-	ENSG00000123066	MED13L	GAUUUAUUUAUUUUUCAG | GCUGAACUCACGGGAAUC	circMED13L
104	1:211793191-211778917|-	ENSG00000123684 | ENSG00000241395	LPGAT1|RN75L344P	CACACAUGUACAUUACAG | UGAUGGAAUGGGGAGAAG	circLPGAT1 |RN7SL 344P
105	12:125114476-125118766|+	ENSG00000081760	AACS	CCUGGUUGACAGGAUAGG |GGCACCCUCAUCCAGCAU	circAACS
106	1:223806948-223804173|-	ENSG00000143514	TP53BP2	UAAGCAAUGGGAAACUUG | GUUAAUAGUCCUAGGAUG	circTP53BP2
107	12:23896025-23845982|-	ENSG00000134532	SOX5	UCAAAAACGAGCCGGAAG | GAUGUCUUCCAAGCGACC	circSOX5
108	1:224952669-224974154|+	ENSG00000185842	DNAH14	UAAGACAGAGAAGAGCAG | CCAGUUCCUUUAUAGUUU	circDNAH14
109	1:23030468-23050521|+	ENSG00000004487 |ENSG00000263793	KDM1A| MIR3115	UUCAUUAGAAACCGCACA | GUAGAGUACAGAGAGAUG	circKDM1A| MIR31 15
110	1:230961304-230954332|-	ENSG00000143643	TTC13	UUUUCAACAAUGCUUCAG | AGUCAUCCUUUUUGAACU	circTTC13
111	1:231374100-231370561|-	ENSG00000135766	EGLN1	ACCAGCAUAUGCUACAAG | GCCAUGGUUGCUUGUUAU	circEGLN1
112	1:23419140-23408663|-	ENSG00000204219	TCEA3	AAGACCAUCGGUGGAAAG | GAAGGGGCCCUGGACCUU	circTCEA3
113	1:235127934-235127809|-	ENSG00000173726 | ENSG00000207181	TOMM20|SNORA14B	GUCUUAUUUCAUACCUGC | AUUCUUAAACCCUCUUGG	circTOMM20|SNO RA14B
114	1:246726891-246740302|+	ENSG00000143653	SCCPDH	CCAGAAAUAAAAUGAAUG | GAAGACCAACACUGUCAU	circSCCPDH
115	1:247159814-247155565|-	ENSG00000196418	ZNF124	AGCUGAGGCAAGACUUCU | AACUCGGUUGCCUUUGAG	circZNF124.2
116	12:56478263-56477659|-	ENSG00000135423	GLS2	GUCAGCUCCCUGAUCAAG | GUGGCAGCCUACAUCCCU	circGLS2
117	12:57398199-57395748|-	ENSG00000179912	R3HDM2	GGCUGAGCAUUUAUUCAG | AGUCUCGCUCUUUUGCCU	circR3HDM2
118	1:26446315-26447661|+	ENSG00000117682	DHDDS	AGGCCUGUUGGAUCCCAG | GGAGAAACUGCAGAAGCA	circDHDDS
119	1:28507387-28507570|+	ENSG00000180198 |ENSG00000242125| ENSG00000274266	SNORA73A|RCC1|SNHG3	AAACCAUGCAGGAAACAG | GUCACUCUCCCCGGGCUC	circSNORA73A | RCC 1|SNHG3.1
120	1:28507388-28507564|+	ENSG00000180198 |ENSG00000242125 |ENSG00000274266	SNORA73A|RCC1|SNHG3	GGAGACAAACCAUGCAGG | UCACUCUCCCCGGGCUCU	circSNORA73A | RCC 1|SNHG3.2
121	1:28579894-28579763|-	ENSG00000197989 |ENSG00000278274	SNORA61|SNHG12	GGCUAGUUUCAGACAGGU | AUCCUCCUGAUCCCUUUC	circSNORA61 | SNH G12
122	12:94424903-94424426|-	ENSG00000173588 | ENSG00000213250	CEP83 | RBMS2P1	AGGUGUUGGCUUUGCAAG | CCAUAUGUGUCAUUGGCU	circCEP83| RBMS2P1
123	12:95211268-95208842|-	ENSG00000180263	FGD6	CAGACAUCAGCAUUCCAG | AGAUAAAGAAGCCACCAG	circFGD6
124	1:30981406-30980061|-	ENSG00000134644	PUM1	CUGCAGCAGCGACACUAG | CUGUUCCAAAGACCUAAU	circPUM1
125	13:113495501 -113520734|+	ENSG00000150403 | ENSG00000276916	TMCO3| RP11-230F18.6	CGCCAGUGCAUCUUCUAG | CUGAAAAUGUGUGUCUGA	circTMCO3 | RP11-230F18.6
126	1:31919659-31915894|-	ENSG00000184007 |ENSG00000269967	PTP4A2	GAAGGAAUCCACGUUCUA | GUUUUUCGUUGGAAUAUA	circPTP4A2
127	13:19852191-19851354|-	ENSG00000132950	ZMYM5	CAACUCAUCAUAGUCCUG | GUUCAUUGGCAUGGAAAA	circZMYM5
128	13:20732122-20731840|-	ENSG00000150456	N6AMT2	AGAUUCUGCUGUGCACAG | AAUCGCAUGUGUGAGUGC	circN6AMT2
129	13:27255210-27255522|+	ENSG00000122026 | ENSG00000207051	RPL21|SNORA27	GUAUCCUGUCAGAGGAAA| UGCUGGUAUAUAACAUUG	circRPL21|SNORA2 7
130	13:45151686-45207506|+	ENSG00000188342	GTF2F2	CUACAUGCGAUUAAAAAG | GUGUCAUUUACUUUGAAU	circGTF2F2
131	1:35358924-35361790|+	ENSG00000146463	ZMYM4	GAACCUGACAAUGCUCAA| GUGGUGGUAUCAUGGAUA	circZMYM4
132	13:64034538-64002384|-	ENSG00000227674	LINC00355	AGUCACUGAUGCUCAAAC| GCCUCCAUUUGCUGUUUG	circLINC00355
133	13:64219224-64245479|+	UNKNOWN00000004	UNKNOWN00000004	ACGGUAGUGGUUGCUAAG | GACAUUGUUGGUGAAUUU	circUNKNOWN000 00004
134	13:98278192-98278430|+	ENSG00000152767	FARP1	UGUGUGAGCAUUGUGUAU | GUUCUGUGUGUCUUUGUG	circFARP1
135	14:102040235 -102040674 | +	ENSG00000197102	DYNC1H1	GUGAAGAAACACCUGCAA | GGAGCCCACCUACGAUGC	circDYNC1H1
136	14:103012189 -103003927|-	ENSG00000198752	CDC42BPB	CAGGACGAGAACCACCUG | CUAAACCAUUUACACAGC	circCDC42BPB
137	14:20323329-20323178|-	ENSG00000100814 |ENSG00000222489 |ENSG00000281684	ccNB1IP1|SNORA79| AL355075.1	UUGCGGAGUCAAACAAUU | UUUGAUGGCUGUUCCUCU	circCCNB1IP1|SNO RA79|AL355075.1
138	14:20343169-20343070|-	ENSG00000259001 |ENSG00000277209	RPPH1|RPPH1	UACUCUCCUCCGCCCAUU | GAACAGACUCACGGCCAG	circRPPH1|RPPH1.1
139	14:20343196-20343073|-	ENSG00000259001 |ENSG00000277209	RPPH1|RPPH1	GACUACUCUCCUCCGCCC | GGCGGAUGCCUCCUUUGC	circRPPH1|RPPH1.2
140	14:20343278-20343146|-	ENSG00000259001 |ENSG00000277209	RPPH1|RPPH1	AGACUCACGGCCAGCGAA| GUGAGUUCCCAGAGAACG	circRPPH1|RPPH1.3
141	14:20343292-20343176|-	ENSG00000259001 |ENSG00000277209	RPPH1|RPPH1	GCGGAUGCCUCCUUUGCC| UGAGCUUCGGGGAGGUGA	circRPPH1|RPPH1.4
142	14:21397402-21397291|-	ENSG00000100888 | ENSG00000200785	SNORD8|CHD8	CAUGAAGAUCUGAGGGGC| UCCCAAUGAUGAGUUGCC	circSNORD8 | CHD8.1
143	14:21397403-21397291|-	ENSG00000100888 | ENSG00000200785	SNORD8|CHD8	CAUGAAGAUCUGAGGGGC| GUCCCAAUGAUGAGUUGC	circSNORD8 | CHD8.2
144	14:23302160-23301878|-	ENSG00000235194	PPP1R3E	GCCCUGGGCUCCCUCCUC | GUAGGCGGCGGGGGCACC	circPPP1R3E
145	14:24211852-24209884|-	ENSG00000254505 |ENSG00000254692| ENSG00000260669	CHMP4A|RP11-468E2.1|AL136419.6	AGCAGUUGGCUGAGUGGG | CCUACUCCACUGGACUCC	circCHMP4A | RP11-468E2.1|AL136419 .6
146	14:34554913-34551713|-	UNKNOWN00000005	UNKNOWN00000005	UCCAGAGUGCAGAUGAUG | AGAAAUCACAGAGUUGCA	circUNKNOWN000 00005
147	14:39033640-39033513|-	ENSG00000100934	SEC23A	AUAAAGACACUCCUAUUA | AAAGCACCAAGCCUCUAA	circSEC23A
148	1:44776139-44776644 |+	ENSG00000142937 | ENSG00000200913	SNORD46| RPS8	UGCCUUGCUCUCCUUGGU | GGUGGGUGCGAGCGUGGG	circSNORD46| RPS8
149	14:54702061-54702581|+	ENSG00000020577	SAMD4A	GAACCAGCACAAGUACAA | GAAUCAUUAACCAAUGGC	circSAMD4A
150	14:70988566-70995926|+	ENSG00000100731	PCNX	GUUUGCACGAUGAACUUG | CAGCACAAGCCAGCGAGG	circPCNX
151	14:73147794-73148095|+	ENSG00000080815	PSEN1	AACCACCUGAGCAAUACU | ACCUAAUCUGGGAGCCUG	circPSEN1
152	14:74735857-74736088|+	ENSG00000119616	FCF1	GAUGCUGUUUUGCCACUG | UGCCUGGCCUGCUCACUU	circFCF1
153	14:95533539-95533354|-	ENSG00000247092| ENSG00000252481	SCARNA13|SNHG10	CUAAGUACUGCCACAAGU |GCCUGCUCGAGAGCCAGC	circSCARNA13 | SNHG110.1
154	14:95533548-95533356|-	ENSG00000247092 |ENSG00000252481	SCARNA13|SNHG10	CACUAAGUACUGCCACAA| CUGAGGCAUGCCUGCUCG	circSCARNA13 | SNHG10.2
155	14:95533605-95533408|-	ENSG00000247092 |ENSG00000252481	SCARNA13|SNHG10	AGAAGCUUUGCAGUCGAG | GGUUGGUGGUACCCUCGA	circSCARNA13 | SNH G10.3
156	14:99458278-99465814|+	UNKNOWN00000006	UNKNOWN00000006	UCUUACCCAUUUUUCUGA | CUGGAUGACUUUAUAGAA	circUNKNOWN00000006
157	15:29773358-29761138|-	ENSG00000104067	TJP1	GCAGCCAAGCAAUGGCAG | GCUCCUGGAUUUGGAUUU	circTJP1
158	15:32533369-32522447|-	ENSG00000223509	RP11-632K20.7	ACUGCCCCUGGACCACAG | GUUAUCCAAGGACAUGGA	circRP11-632K20.7
159	15:42878685-42872610|-	ENSG00000128881	TTBK2	UUUUGAAAAAGCUGCAAG | GUUAAAUGGAAACCACCC	circTTBK2
160	15:64156725-64156161|-	ENSG00000166794	PPIB	ACCAUGCCCUCCUGCUUC | GUGAGUUGUGGAAGCAAG	circPPIB
161	15:75859877-75873569|+	ENSG00000140367	UBE2Q2	AGGCAAGACCAUUUAAAU | CUUCGUCAGCAAUUGAAG	circUBE2Q2
162	15:76292701-76287845|-	ENSG00000140374	ETFA	UGAGAACUAUUUAUGCAG | GUGGCACAAGAUCUCUGU	circETFA
163	15:84691645-84680712|-	ENSG00000140612	SEC11A	UGUGGGGAGAGCCAGGGG | CUCUAUUAUCAAGUCCUA	circSEC11A
164	15:85064369-85067205|+	ENSG00000073417	PDE8A	UGCAGAGGCACUGUGCAG | GUAGCAGUAGCUGAUGUG	circPDE8A
165	1:58536742-58506059|-	ENSG00000162600 | ENSG00000173406	DAB1|OMA1	GAUAGACUUAUACCUCAG | GGGCAUAAGGAAAUGGUG	circDAB1|OMA1
166	15:89113724-89116522|+	ENSG00000140526	ABHD2	UCCUCUUCUGACCAAAGA| CUUUUAGGUUUGUUUGAA	circABHD2
167	15:90439331-90443479|+	ENSG00000140575	IQGAP1	AUAUAAACAAAGUCAAUA| UUUGUACCUGUUCAAGCU	circlQGAP1.1
168	15:90441505-90443479|+	ENSG00000140575	IQGAP1	AUAUAAACAAAGUCAAUA| UACAUGCUGCUGUUAUUG	circlQGAP1.2
169	15:92996956-93002318|+	ENSG00000173575	CHD2	AAAGAUAAGAAAGAGAAG | GAAAAGGACCAGGGAAAA	circCHD2
170	15:98707561-98708108|+	ENSG00000140443	IGF1R	CAAACCGCUGCCAGAAAA| UCUGCGGGCCAGGCAUCG	circIGF1R
171	16:100510-98144|-	ENSG00000103148	NPRL3	GACCUGGCCUUGCUGCAG | CCUGUGCACGUCGGGCGU	circNPRL3
172	16:15700735-15700927|+	ENSG00000072864	NDE1	GAACAGAGAACUUAACAG | CCACCGUGCCUGGCCCCU	circNDE1
173	16:16007815-16016622|+	ENSG00000103222	ABCC1	GAAACCAUCCACGACCCU | GACUGGAAUGUCACGUGG	circABCC1
174	16:1963149-1962930|-	ENSG00000140988 | ENSG00000207405	RPS2|SNORA64	UGUAGGGCCACCAGCUGC | GUACCCGGCUGUCCUGGA	circRPS2 | SNORA64
175	16:22308147-22309511|+	ENSG00000058600	POLR3E	CUGCACUCUACAGGCAAG | UACCCUGUGCGUCCAGCC	circPOLR3E
176	16:28835758-28835908|+	ENSG00000168488	ATXN2L	CAGGAUUCUGUGGUCUUC| GUAAGAGCCCAGCUGUCC	circATXN2L
177	16:29833732-29834067|+	ENSG00000013364	MVP	GCAAGGAGAGGGUGACAG | GACAUCACACCCCUGCAG	circMVP
178	16:29905787-29906128|+	ENSG00000174939	ASPHD1	CCUAGUACAACCAAACAG | GCUCCCCCGAAGAUGGGC	circASPHD1
179	16:30483826-30484264|+	ENSG00000005844	ITGAL	AGAUCUAUGUCAUUGAGG | GACAGAGGUGUUCCGGGA	circITGAL
180	1:631070-	ENSG00000237973	RP5-857K21.6	ACAGCUCUAAGCCUCCUU |	circRP5-857K21.6.1
	631182|+			CUGAUGUUCGCCGACCGU
181	1:631070-631265|+	ENSG00000237973	RP5-857K21.6	CACAGCCCAUGCAUUUGU | CUGAUGUUCGCCGACCGU	circRP5-857K21.6.2
182	1:631070-631364|+	ENSG00000237973	RP5-857K21.6	UAUGGCGUUUCCCCGCAU | CUGAUGUUCGCCGACCGU	circRP5-857K21.6.3
183	1:631070-631373|+	ENSG00000237973	RP5-857K21.6	UCCCCGCAUAAACAACAU | CUGAUGUUCGCCGACCGU	circRP5-857K21.6.4
184	16:31722625-31723354|+	ENSG00000197302	ZNF720	CAGUAGCCAUCCAGCCAG | GGACUGUUGACAUUCAGG	circZNF720
185	16:48256609-48277480|+	ENSG00000102910	LONP2	GCAGCAGCUCUGCUUGAG | UUGGUUGAAAUGUUGGAU	circLONP2
186	16:53141178-53157542|+	ENSG00000177200	CHD9	CUAUGUUUACAGCGACAG | UCAUUUUUUGAGACCAGU	circCHD9
187	16:68266592-68275250|+	ENSG00000103064	SLC7A6	UGGCUGCUGCUUGCAUAU | AGUUUAUGUGGCCGAGGC	circSLC7A6
188	16:8859336-8858349|-	ENSG00000153048	CARHSP1	CUUCCUGCACAUCUCUGA| GUCAGCCAUGUCAUCUGA	circCARHSP1
189	16:89783103-89782858|-	ENSG00000187741	FANCA	GCUGGGGACAUUACUGAG | GUGCACAUUCUCCACCCA	circFANCA
190	17:35103454-35103354|-	ENSG00000185379 |ENSG0000026761 8	RAD51D | RAD51L3-RFFL	UCCCUGGUUCCCCACUGC | GUGAGUGAUGUGGCAGAG	circRAD51D | RAD5 1L3-RFFL
191	17:44083855-44083544|-	ENSG00000108840	HDAC5	GCUGCAGGAGAGCUCAAG | GCCCCAUCAGCCAGAAGA	circHDAC5
192	17:51263273-51268905|+	ENSG00000011260	UTP18	GGAAAACAUCUUCAGAUG | GUUCAAGAACAUGAAGAC	circUTP18
193	17:58006412-58005869 |-	ENSG00000136450	SRSF1	GGCACUGGUGUCGUGGAG | GUGGCGGAGCUCCCCGAG	circSRSF1
194	17:60623520-60648083|+	ENSG00000170836	PPM1D	GAGAAAAAAUACCUGAUG | CGGAAUGGCCAAAGACUA	circPPM1D
195	17:61780402-61776400|-	ENSG00000136492	BRIP1	UUCUUGCCAUCUUACAAG | GCCUUUUCAGAUAUUAAU	circBRIP1
196	17:66496200-66514467|+	ENSG00000154229	PRKCA	UCAUCCUGGGAUUCAAAC| UUUGCUGUUUUGUGGUCC	circPRKCA.1
197	17:66513335-66514467|+	ENSG00000154229	PRKCA	UCAUCCUGGGAUUCAAAC | UGAAGCCUGAGACCUGCC	circPRKCA.2
198	17:7576810-7576952 |+	ENSG00000161960|ENSG00000238917|ENSG00000264772|ENSG00000277957	EIF4A1|SNORD10|RP11-186B7.4 | SENP3-EIF4A1	GUCUUUGUACUCUGAGAG | GCUCUGUGAUGGAGCCCA	circEIF4A1 | SNORD 10|RP11-186B7.4| SENP3-EIF4A1.1
199	17:7576810-7576953 |+	ENSG00000161960|ENSG00000238917|ENSG00000264772|ENSG00000277957	EIF4A1|SNORD10|RP11-186B7.4 | SENP3-EIF4A1	UCUUUGUACUCUGAGAGC | GCUCUGUGAUGGAGCCCA	circEIF4A1 | SNORD 10|RP11-186B7.4| SENP3-EIF4A1.2
200	17:78400676-78400856|+	ENSG00000087157	PGS1	UGGUGCAUCCUUACAAAG | UGCAAACCUGAGUGACUC	circPGS1
201	17:80619626-80643811|+	ENSG00000141564	RPTOR	GAGAACUGGCAGCCAAGG | CUCAUUUGGUGGCAACGC	circRPTOR
202	17:8379519-8379345|-	ENSG00000161970 | ENSG00000263809	RPL26|RP11-849F2.7	ACCUCAGGUGAUUUGCCU | CACUGCAGCCUCCACCUC	circRPL26| RP11-849F2.7
203	1:810171-805798|-	ENSG00000230092	RP11-206L10.8	UUCAAUUAUGUGGUCAAA| UAUCUUAAAUAGUGAAGA	circRP11-206L10.8
204	18:46821073-46815311|-	ENSG00000078043	PIAS2	AUUCCAGUUGAUCCCCAG | GGUUCUCAUGUAUCAGCC	circPIAS2
205	18:670691-671452|+	ENSG00000176890	TYMS	GAGCCACUGAAAAUUCAG | AUCUUCCUCUGAUGGCGC	circTYMS
206	18:9595154-9583116|-	ENSG00000154845	PPP4R1	AGUGAUCCUUCACGUUGG | UUGGUGUGGAUGACUACA	circPPP4R1
207	19:23362726-23358429|-	ENSG00000167232	ZNF91	GACCUUUUCUAUGGAAAG | GUAUAUGUCCUCAUUUUC	circZNF91
208	19:36089037-36089307|+	ENSG00000075702	WDR62	CCAGGACCGCAAUGUGAG | GCAACAGAGACAUCCAGA	circWDR62
209	19:40702600-40700472|-	ENSG00000123815	ADCK4	AAGCACGAAGUCCCCUUC| GUGAGCUGAGUGCCCUGA	circADCK4
210	19:46918487-46937409|+	ENSG00000160007	ARHGAP35	AGUACAUUGAAGCCACAG | GAAGAAAUGUUGGCUAUU	circARHGAP35
211	19:48913010-48913565|+	ENSG00000104805	NUCB1	CCUUCUUCAUACUGCAUG | GCCACCCGGGACCUUGCC	circNUCB1
212	19:49490618-49490707|+	ENSG00000142541 | ENSG00000199631	SNORD33|RPL13A	UCUGAGGCCACCCCAUGG | CCGGUGAUGAGAACUUCU	circSNORD33| RPL1 3A.1
213	19:49490620-49490698|+	ENSG00000142541 | ENSG0000019963 1	SNORD33|RPL13A	GCACUACCAUCUGAGGCC | GGUGAUGAGAACUUCUCC	circSNORD33| RPL1 3A.2
214	19:49490629-49490695|+	ENSG00000142541 | ENSG00000199631	SNORD33|RPL13A	CAUGCACUACCAUCUGAG | AACUUCUCCCACUCACAU	circSNORD33| RPL1 3A.3
215	19:8876659-8876368|-	ENSG00000181143	MUC16	CAGGGUCAUCGCACUAAG | CCGGGGUGGUCAGCGAGG	circMUC16
216	1:9934861-9931890|-	ENSG00000162441	LZIC	AAGUCUCUACAGACCUUG | GCUAUUCAGGCAGCUAUC	circLZIC
217	20:17962878-17962711|-	ENSG00000089006|ENSG00000125850|ENSG00000212232	SNX5|SNORD17|OVOL2	AGUGGUGAAAAUCUGAUC| UGUUCUAGGAACUUGAGG	circSNX5 | SNORD17 |OVOL2.1
218	20:17962879-17962711|-	ENSG00000089006 |ENSG0000012585 0|ENSG00000212232	SNX5|SNORD17|OVOL2	AGUGGUGAAAAUCUGAUC| CUGUUCUAGGAACUUGAG	circSNX5 | SNORD17 |OVOL2.2
219	20:38427443-38427304|-	ENSG00000196756 |ENSG00000225091	SNORA71A|SNHG17	GAAGCUUUCACACAACUC | UCCUGCAUCCGAAAGUGA	circSNORA71A|SN HG17
220	20:45902605-45902266|-	ENSG00000100979	PLTP	GCAGCUGGACCUGCGCAG | AGCCCAGCAGUGAUUGAC	circPLTP
221	20:5109446-5106187|-	ENSG00000089063	TMEM230	GGCUACAUCAGCAAAGGG | CUGUGUCAGCGUGUUAUG	circTMEM230
222	20:54171671-54157168|-	ENSG00000019186	CYP24A1	AGCGAUAAUACGCCUCAG | GGAAGGGGAAGACUGGCA	circCYP24A1
223	20:63790791-63775677|-	ENSG00000130584	ZBTB46	GGGCCCACUCGCUGUCCC | AGUCUGUAGAAGAGGCGA	circZBTB46
224	21:33535321-33534578|-	ENSG00000159131	GART	CUGCAGCUUCAUUUUGAG | CCAUCUCAAUCAGUGACC	circGART
225	2:135090997-135093694|+	ENSG00000115839	RAB3GAP1	ACAUUGCCUGGUAAGAUG | GGUAUAUUUACUUCUGGC	circRAB3GAP1
226	21:37420298-37472881|+	ENSG00000157540	DYRK1A	CAACCUCUAACUAACCAG | UGUUAUAGUUUUGCCGCU	circDYRK1A
227	21:43786514-43787130|+	UNKNOWN00000007	UNKNOWN00000007	CUGACAUACCCACUGUGC | ACCUGACAUACCCACUGU	circUNKNOWN000 00007
228	21:45474703-45474804|+	ENSG00000182871	COL18A1	GGGCAGGAGACACCGUGG | ACAUGGACCCACAGCCUC	circCOL18A1.1
229	21:45476519-45476868|+	ENSG00000182871	COL18A1	AGUGUGCGUAUUGUGUGU | GUGUGUGUGGUGUGUAAC	circCOL18A1.2
230	2:15558635-15551492|-	ENSG00000151779	NBAS	UUAUUGGGAAAUGUCAAG | CCUAGAGGCAACCAAAAA	circNBAS
231	21:8213100-8213555|+	ENSG00000278996	CH507-513H4.1	GUCGUCCGCCGUCGCGCG | UCGGCCCCGGCCGGGUGG	circCH507-513H4.1.1
232	21:8213118-8213463|+	ENSG00000278996	CH507-513H4.1	CGGGAGCCCGCCCCGCGG | AAGGUCCCGUGCCCGUCG	circCH507-513H4.1.2
233	21:8213164-8213555|+	ENSG00000278996	CH507-513H4.1	GUCGUCCGCCGUCGCGCG | GGGGCGUGUUGCGUGCGG	circCH507-513H4.1.3
234	2:189728659-189744789|+	ENSG00000151687	ANKAR	UUCCUAUCUUUAAAAGAG | GAGGUGAAGCUGUCAUAG	circANKAR
235	2:190900563-190924594|+	ENSG00000115419	GLS	UUAGACUUCUACUUCCAG | AUGUGUUCAGAGCAACAU	circGLS
236	2:202464808-202467690|+	ENSG00000204217	BMPR2	CUGACACAACACCACUCA | CUUCGCAGAAUCAAGAAC	circBMPR2
237	2:226864603-226867319|+	ENSG00000144468	RHBDD1	UCAUUUAUUCUCACCAGG | GUUCAGCCGUCUGUAUAU	circRHBDD1
238	2:233275831-233276005|+	ENSG00000085978 | ENSG00000252010	ATG16L1|SCARNA5	UUUUCAAUCUGAGACCUC| AUGUGUAUGGGAUCAUGG	circATG16L1 | SCAR NA5
239	2:233388256-233390484|+	ENSG00000077044	DGKD	GUCAACAACAGUUUUACG | ACCAUCAUCAAAGAGGGG	circDGKD
240	2:241140754-241140520|-	ENSG00000115687	PASK	GAUGCCAAGACCACAGAG | AAGACAGAUGGAGCUCCU	circPASK
241	22:50372019-50394136|+	ENSG00000100239	PPP6R2	GGAGAAGGUCCGCUUCAA| GUAAAGAGAUUAUAAAUC	circPPP6R2
242	2:32377587-32406558|+	ENSG00000115760	BIRC6	GAUCAGAUUCUGUGACAG | CUAAACCAGGUGGACAGG	circBIRC6
243	2:37317180-37316236|-	ENSG00000115825	PRKD3	UCCAUAGUUUAUCAAAAG | GCUAACUAUAUGUCAGAA	circPRKD3
244	2:61112521-61118117|+	ENSG00000162929 |ENSG00000274769	KIAA1841| RP11-493E12.3	UCAAAGGAAGCAAAAGAA| AGUCUUGUUCUGUCAUCC	circKIAA1841| RP11 -493E12.3
245	2:74428943-74428847|-	ENSG00000114993	RTKN	UCACCCUUGCCAGUCAUG | UGGUCCUCGUUACCACCU	circRTKN
246	2:85368685-85369831|+	ENSG00000115459	ELMOD3	GACCUUUCCCCCUUCAAG | UUGUGAGUACAGAGGUGG	circELMOD3
247	2:99464986-99449335|-	ENSG00000135945	REV1	AGAAUGGAUUGUGGAAAG | AAGCUCCACCAUGAGGCG	circREV1
248	3:114351879-114350273|-	ENSG00000181722	ZBTB20	ACAUGUUCGUACACACAG | GUGACAUCAGUUGCAAGG	circZBTB20
249	3:119503531-119517316|+	ENSG00000113845	TIMMDC1	GCUAAAACUGGAAGAGUG | CAAUCUGCACAUCGUGCU	circTIMMDC1
250	3:128901349-128902506|+	ENSG00000177646	ACAD9	UUUCGUUGCGGCCUCCUC | GUGAGUUGCCAGCCACAG	circACAD9
251	3:129586720-129585951|-	ENSG00000004399	PLXND1	GUGCGCCAGGAGUACCCA | AUCAACCUGAACGAGAGC	circPLXND1
252	3:13500712-13502981|+	ENSG00000163517	HDAC11	GGGACCGCUUUGCCAAGC | GGGGUGGCUUCCACCACU	circHDAC11
253	3:138572933-138570317|-	ENSG00000114107	CEP70	GAGCAGAAAACUUUACAG | UAACUAUGUUUCCGGUAG	circCEP70
254	3:149846010-149912084|+	ENSG00000082996	RNF13	UUGAUAGUCAUUUUCAUG | GUGAUUUUACAACGAGAU	circRNF13.1
255	3:149846010-149921228|+	ENSG00000082996	RNF13	UACAUAAAUUCAAGAAAG | GUGAUUUUACAACGAGAU	circRNF13.2
256	3:168041475-168036835|-	ENSG00000173905	GOLIM4	ACCCGAGAGGUGCAGGAG | AGACUGUAUACAAUUUGA	circGOLIM4
257	3:186784800-186784930|+	ENSG00000156976 |ENSG00000238942	EIF4A2 | SNORD2	AAGUGACAAUUUGAUGUG | AAAUGAUGGCAAUCAUCU	circEIF4A2 | SNORD 2.1
258	3:186784800-186784945|+	ENSG00000156976 |ENSG0000023894 2	EIF4A2 | SNORD2	GUGGGAUCGGUAAAUGUG | AAAUGAUGGCAAUCAUCU	circEIF4A2 | SNORD 2.2
259	3:195960087-1959591821-	ENSG00000185485	SDHAP1	UAUCUGGACUUUGAAAUU | UGCACAGCCAGAGAACAA	circSDHAP1
260	3:47106121-47097954|-	ENSG00000181555	SETD2	UCUCGUAAGAAGGAUUCA | GAACACCUUUGUCCUAGA	circSETD2
261	3:47428671-47425484|-	ENSG00000114650	SCAP	GCCCACCCUCAAUGGCGG | UAUGUGGGUGCCCCGGUG	circSCAP
262	3:49335597-49335019|-	ENSG00000114316	USP4	UGUGAGGAGAGGUUGAAG | GUAUCUUAUUGACAGCCG	circUSP4
263	3:51995042-51994151|-	ENSG00000162244	RPL29	UGGGGACCCACAUGCUGC | GUGAGUGCACUGAAUCAC	circRPL29
264	3:52412810-52414588|+	ENSG00000010318	PHF7	GUGCAUUAUUUCUGUCUU | CUGGAAGAGCCUGUAUUG	circPHF7
265	3:52741500-52737585|-	ENSG00000114904	NEK4	GAUGAAUUUGAUAGAGAG | GAAAGGAAACAGAUUCAU	circNEK4
266	3:58125580-58126763|+	ENSG00000136068	FLNB	GAGGAGCCCACAUCCCCG | GUCUCCAUGUAGUGGAGG	circFLNB
267	3:66243202-66263380|+	ENSG00000144741	SLC25A26	AGCACAGUUUUAAGAGAG | CUGCUGCAUUUUUUAUCA	circSLC25A26
268	4:102525511-102537957|+	ENSG00000109320	NFKB1	UCUUACCCUCAGGUCAAA | CUUCAGAAUGGCAGAAGA	circNFKB1
269	4:53414614-53428184|+	ENSG00000145216 |ENSG00000282278	FIP1L1 | RP11-231C18.3	CUCUGAUUCCACCACCGG | AAACAGCACUUCUUCUCA	circFIP1L1 | RP11-231C18.3
270	4:6923372-6924112|+	ENSG00000132405	TBC1D14	UAGUAACUUCUUUGCAAG | UUUCUCCUUGGACCAAGA	circTBC1D14
271	4:73404341-73406704|+	ENSG00000163631	ALB	AUUAGUGAAUGAAGUAAC | CUUUAUUUCCCUUCUUUU	circALB.1
272	4:73413492-73413603|+	ENSG00000163631	ALB	AAGGAUGUUUGCAAAAAC | CUCUGUUGGAAAAAUCCC	circALB.2
273	4:73415067-73417639|+	ENSG00000163631	ALB	AUGUUGUAAACAUCCUGA | UUACUCUGUCGUGCUGCU	circALB.3
274	4:76144474-76134174|-	ENSG00000138750	NUP54	AACAUUGCCAGAUGAUCA | GUGGGUUUGGAGGAUUUG	circNUP54
275	4:87046165-87047595|+	ENSG00000172493	AFF1	CCUUCUCAGUCAGUUGAG | UUUGUACAAUGACGACAG	circAFF1
276	5:1065479-1057470|-	ENSG00000113504 | ENSG00000263834	SLC12A7| MIR4635	CCUCUUCAGCAUGAAGCC | AACAUACGGUCCCUAAUG	circSLC12A7 | MIR4 635
277	5:109713519-109716265|+	ENSG00000112893	MAN2A1	AUUCCCAUAACGACCCAG | GGCCAGCUCUCAAUGUUG	circMAN2A1.1
278	5:109713519-109729514|+	ENSG00000112893	MAN2A1	GAAGGAUGCUGUUAAAAG | GGCCAGCUCUCAAUGUUG	circMAN2A1.2
279	5:132893119-1328921631-	ENSG00000072364	AFF4	AGCUCCAAGGAGGUUAAG | AAUGAAGAUGAUAACCGA	circAFF4
280	5:139600371-139614967|+	ENSG00000131508	UBE2D2	CACUAACUAUUUCAAAAG | GAAUUGAAUGAUCUGGCA	circUBE2D2
281	5:140440118-140445976|+	ENSG00000131503 | ENSG00000254996	ANKHD1|ANKHD1-EIF4EBP3	CACUUGCUUGCUACAAAG | UCGCAGUCUAGCAGAAGC	circANKHD1 | ANKH D1-EIF4EBP3
282	5:180280609-180261683|-	ENSG00000050748	MAPK9	GCUGGUAUAAUUCAUAGA | GGAUCUGAAACUUGCCCA	circMAPK9
283	5:57246299-57251142|+	ENSG00000062194	GPBP1	ACUUGAGGCAGAACACAG | AAUAUCCUCCGAAUCCUA	circGPBP1
284	5:618989-655585|+	ENSG00000112877	CEP72	GUUAGCACCUUCACUCCG | CUGAGCUUCAGUCAUUGU	circCEP72
285	5:69914157-69916256|+	ENSG00000198237	RP11-98J23.2	CUUGUAAGGCUUCACCAG | GAUGGUGAUUGCUCACAC	circRP11-98J23.2
286	5:74841680-74834425|-	ENSG00000198780	FAM169A	AUUCAGUUAAGCCUACAG | AGGAUGGCAUUCCCUGUG	circFAM169A
287	5:77464810-77463094|-	ENSG00000164253	WDR41	GCUGAUAGAACAGUUAUU | AUUUGCAUCUGCUGGUGA	circWDR41
288	5:81123641-81127164|+	ENSG00000113319	RASGRF2	GACAUGGGAGUCCACCAG | CAGUCCUAGAGUCUGCAC	circRASGRF2
289	5:95755395-95763621|+	ENSG00000164292	RHOBTB3	UUAAAAACACCAGGAAAG | AAAAAAUGCCUGUCUUAA	circRHOBTB3
290	6:118566317-118511297|-	ENSG00000111860	CEP85L	UAUGUGGCUAGUUUGCAG | AUCAUUCAACUUCAAGUG	circCEP85L
291	6:157036834-157084906|+	ENSG00000049618	ARID1B	CUCCUGCAAGUAUCCCAG | GUUGAAGUCUUGGCCUCG	circARID1B.1
292	6:157084661-157110562|+	ENSG00000049618	ARID1B	CAAUGCCACAGGAAAGAG | GAUCUGUCUGGCUCCAUU	circARID1B.2
293	6:158312050-158314269|+	ENSG00000130338 |ENSG0000027402 3	TU LP4| RP11-732M18.4	CGGGGCCACAAUAGCGAG | AUUUGUAAGACUCCAGGG	circTULP4| RP11-732M18.4
294	6:158448995-158452269|+	ENSG00000130338	TULP4	UCCGCUCAGGGCUGAAAG | GUGCUGUUUGGCACGGCC	circTULP4
295	6:158583953-158585426|+	ENSG00000146433	TMEM181	ACCCUCACAUGUGCAGGG | CUAAAGCCAAUUCAAAUA	circTMEM181
296	6:26031841-26031708|-	ENSG00000274267	HIST1H3B	CCAUCCAUGCUAAGCGAG | AAAUCGCCCAAGACUUCA	circHIST1H3B
297	6:26045383-26045863|+	ENSG00000278272	HIST1H3C	AAAAGGCUCUUUUCAGAG | ACACUUUUGUGUGUGCUC	circHIST1H3C.2
298	6:27293887-27293974|+	UNKNOWN0000000 8	UNKNOWN00000008	GUACGGGCCUUUGGCUUU | GGUCGGCCGGUUAGCUCA	circUNKNOWN00000008
299	6:30650993-30651467|+	ENSG00000204564	C6orf136	CAAAGACGAGCAUUACCG | CUUCCCAAGCUCUUCCUU	circC6orf136
300	6:31354061-31268939|-	ENSG00000204525 | ENSG00000229836 | ENSG00000231402 | ENSG00000234745 | ENSG00000256166	HLA-C| HLA-B | XXbac-BPG248L24.10|WASF5P | XXbac-BPG248L24.13	CUGUUCCAGAGAGGUGGG | CUGGAUGUCUCCAUCUCU	circHLA-C |HLA-B | XXbac-BPG248L24.10|WA SF5P|XXbac-BPG248L24.13.1
301	6:31354666-31269965|-	ENSG00000204525 | ENSG00000229836 | ENSG00000231402 | ENSG00000234745 | ENSG00000256166	HLA-C| HLA-B | XXbac-BPG248L24.10|WASF5P | XXbac-BPG248L24.13	GUAGGAGGAAGAGCUCAG | GUGGAAAAGGAGGGAGCU	circHLA-C |HLA-B | XXbac-BPG248L24.10|WA SF5P|XXbac-BPG248L24.13.2
302	6:35587095-35580159|-	ENSG00000096060	FKBP5	GUCCUGGUUAGAGAUGGA | UACCAAAGAAAAAUUGGA	circFKBP5
303	6:42934474-42935671|+	ENSG00000137161	CNPY3	AGCAAUCGAUUUGCCAAG | UGUGUAAAUAUGUUGCUG	circCNPY3
304	6:43178882-43179067|+	ENSG00000112658	SRF	UGGCUGGCCAGUCCCUGC | GUAGGUAGGGAUAUCUUU	circSRF
305	6:52995710-52995833|+	ENSG00000202198	RN7SK	GAGUAGCUGCGCUCCCCU | UCCUCCCUCACCGCUCCA	circRN7SK
306	6:5404541-5431173|+	ENSG00000145982	FARS2	AACAACUGGUCAAUUCAG | UUAUUUGCUGGUAUAAAG	circFARS2
307	6:54121446-54169573|+	ENSG00000146147	MLIP	GGUCGAGAAACCAAAUAU | GUCUCUGCUGGUGGUUCU	circMLIP
308	6:87215902-87218732|+	ENSG00000188994	ZNF292	CAUUGGAUAAGGAUAAAG | ACACUCCUAGAAUAUGCA	circZNF292
309	6:89083752-89084644|+	ENSG00000146278	PNRC1	AUCUGUGGCACAAUCAAU | GUUUUAAAAUCAAAGAUG	circPNRC1
310	7:100024308-100023418|-	UNKNOWN00000009	UNKNOWN00000009	UGUGUUUCUUUACUAUUC | CUCGUGACUGUAAGAGGC	circUNKNOWN00000009
311	7:140702865-140704964|+	ENSG00000090266	NDUFB2	CAGCCUCACUCUGUACAA | UGCCGGUGGUGGUGUGCA	circNDUFB2
312	7:152250967-152249875|-	ENSG00000055609	KMT2C	AUAGUCUUCUUAUUGCUG | AUUAUAACAAUGAAAUGG	circKMT2C
313	7:158764854-158759485|-	ENSG00000117868	ESYT2	UCAGCAAGGAACCUUCCG | GGUGUUCUAAGGAUACAU	circESYT2
314	7:24620051-24668661 |+	ENSG00000105926	MPP6	UUGGAACUACGGUGCCAU | GACUAAAUCAUUUUGCUA	circMPP6
315	7:35673279-35667433|-	ENSG00000122557	HERPUD2	UCCAUAUGUAAUGCAAGG | UUGACGAAGGAUCAGAGA	circHERPUD2
316	7:44674410-44675269|+	ENSG00000105953	OGDH	CUGGAGGCAGCUGAUGAG | GUUUGAGGAGUUCCUACA	circOGDH
317	7:64544433-64543706|-	ENSG00000173041	ZNF680	UGGUAGCCAAACCCCCAG | GGACCACUGACAUUUAGG	circZNF680
318	7:6466243-6466115|-	ENSG00000136240 | ENSG00000164535	KDELR2| DAGLB	UGGUGGCCGGCGUAGUCC | GAGACCAUCACCACCCAC	circKDELR2| DAGLB
319	7:6585015-6585261|+	ENSG00000136247	ZDHHC4	ACGGUCUUUCUUAUUCAG | GUGUGUGUAACUGGUGUG	circZDHHC4
320	7:6822365-6814763|-	ENSG00000146574	CCZ1B	AGGCACAUCGAACCUGAG | CUUUUUAAUGGUACAUUU	circCCZ1B
321	7:72890626-72891111|+	ENSG00000196313	POM121	CAUGUCAACAUAGUCCAG | GGGCCAGUGUCAUUCAAA	circPOM121
322	7:73470484-73469516|-	ENSG00000009954	BAZ1B	AGGAUUACUGUCCUCGCA | UGAAACUGGAACGCCAAG	circBAZ1B
323	7:74705163-74716951|+	ENSG00000263001	GTF2l	UGGAAGUACCAGCAGAAG | GUGGUCGUGUGAUGGUAA	circGTF2l
324	7:75943780-75943917|+	ENSG00000127948 | ENSG00000201643	SNORA14A	UUCAUACCUGCAACAUCU | AUUGCAUUCUUAAACCCU	circSNORA14A
325	7:90726566-90726813|+	ENSG00000058091	CDK14	CACUCCAGCCCCAGCUCG | AUAUGUGUCACAAAGAUG	circCDK14
326	7:93291702-93297244|+	ENSG00000004766	CCDC132	UUUCAAGAAUUACCAUAG | CAUGUUACACCAGACAGC	circCCDC132
327	7:98881699-98881886|+	ENSG00000196367 | ENSG00000266019	TRRAP| MIR3609	CUGAUAAGAUCUGAUUGC | CAAAGUGAUGAGUAAUAC	circTRRAP|MIR360 9
328	7:99722019-99721866|-	ENSG00000160870 |ENSG00000282301	CYP3A7|CYP3A7-CYP3A51P	GUUUUGCCAAGUAUUUUG | AAAUAGUUCUCCUUCACU	circCYP3A7 | CYP3A 7-CYP3A51P
329	8:127218967-127218809|-	ENSG00000247844	CCAT1	UGCCACUUACCAGGUUGG | GCCAGGCACUACUCUGUC	circCCAT1.1
330	8:127218967-127218814|-	ENSG00000247844	CCAT1	AGCCCUGCCACUUACCAG | GCCAGGCACUACUCUGUC	circCCAT1.2
331	8:127220406-127218809|-	ENSG00000247844	CCAT1	UGCCACUUACCAGGUUGG | GAUUUAAUGGCAAGAUGC	circCCAT1.3
332	8:127223645-127218809|-	ENSG00000247844	CCAT1	UGCCACUUACCAGGUUGG | GAGCCUGACAUCAUGGUG	circCCAT1.4
333	8:127223667-127218809|-	ENSG00000247844	CCAT1	UGCCACUUACCAGGUUGG | UUAUUAAUGGCUCUCCUA	circCCAT1.5
334	8:127224685-127218809|-	ENSG00000247844	CCAT1	UGCCACUUACCAGGUUGG | GACUGUAUUGUCUGCUAG	circCCAT1.6
335	8:127227542-127218809|-	ENSG00000247844	CCAT1	UGCCACUUACCAGGUUGG | AAAGAGACAGAACAAUGU	circCCAT1.7
336	8:130180881-130152735|-	ENSG00000153317	ASAP1	ACCAUCUCACAUGCCACA | UACAAAAAUUGAGAAAGA	circASAP1
337	8:140706206-140700890|-	ENSG00000169398	PTK2	AAAGAGGAAAGAUUUCUG | CCCAGCAGACCGGGUUAU	circPTK2.1
338	8:140890770-140864311|-	ENSG00000169398	PTK2	AAUUUCUUCUAUCAACAG | AAUAUGACAGAUACCUAG	circPTK2.2
339	8:141254630-141253988|-	ENSG00000022567	SLC45A4	CAAUACUGUUGCAGAUUG | AUCAUCCAGUCACUCGAU	circSLC45A4
340	8:142501136-142501376|+	ENSG00000181790	ADGRB1	AUGGUGGUGGUAGUGAUG | UGCUUAUAGUGGAGGUGA	circADGRB1
341	8:30474778-30479378|+	ENSG00000157110	RBPMS	GCAAAGAAUGCUUUGAAU | GUCCGGACCCUAUUUGUC	circRBPMS
342	8:38457535-38457355|-	ENSG00000077782	FGFR1	CGACCUUGCCUGAACAAG | GGUCAGUUUGAAAAGGAG	circFGFR1
343	8:42957093-42964475|+	ENSG00000168172	HOOK3	CCAAGAAGAAACAUUCAG | CUGAUGAGUAAAGAAUCU	circHOOK3
344	8:61684189-61680967|-	ENSG00000198363	ASPH	AUGCCAAAGUUUUAUUAG | AGACAAAGCAUGGAGGAC	circASPH
345	9:109108571-109106507|-	ENSG00000106771	TMEM245	AUGGAAAAGAGUCUUCUG | AUCUGGACGUUGGUGGUU	circTMEM245
346	9:114074050-114078172|+	UNKNOWN00000010	UNKNOWN00000010	GCGCUCACCGCCAGGCAG | UAAUGGUGGGUCCAUGAU	circUNKNOWN00000010
347	9:125238678-125238150|-	ENSG00000044574	HSPA5	CCAACUGUUACAAUCAAG | GAACCAUCCCGUGGCAUA	circHSPA5
348	9:128508875-128515640|+	ENSG00000119392	GLE1	CACAGAAUGAAAGGAACA | GAUGUUUUAGAAGAAUGU	circGLE1
349	9:20881870-20933104|+	ENSG00000188352	FOCAD	CACUAGUCUUGAAUACAA | CUUUGGAGGAAUUUUUUA	circFOCAD
350	9:33351559-33352720|+	ENSG00000086102	NFX1	AUCUAGUACUUAUCAAAG | UUUCGGAGCAACAUCCCC	circNFX1
351	9:33948588-33948373|-	ENSG00000137073	UBAP2	CAGUCCUCAGUCAUCUUG | UCAUCCGUCCUUGGCUCA	circUBAP2
352	9:6880011-6893233|+	ENSG00000107077 |ENSG00000274527	KDM4C | RP11-146B14.1	GGAAAAGUUGCCAAAUUG | GUAUGCUAUACCUCCGGA	circKDM4C|RP11-146B14.1
353	9:85633375-85596361|-	ENSG00000135049	AGTPBP1	UGACAUUUGUUACUAUAA | GACUAUGAUUUAAUCUCC	circAGTPBP1
354	9:93471140-93476339|+	ENSG00000048828	FAM120A	CCACUAGCCUCACUAAAG | GUUGCACAGAGCAUUGAG	circFAM120A.1
355	9:93471140-93497600|+	ENSG00000048828	FAM120A	GUUUUCCAGCAUUCACAG | GUUGCACAGAGCAUUGAG	circFAM120A.2
356	9:94429188-94438529|+	ENSG00000148110	HIATL1	GAUGAGGAUCAGCCCAUG | GUUCUACAUGAAACAUUU	circHIATL1
357	X:362333-361404|-	ENSG00000167393	PPP2R3B	AUGGGCCUGGUGGCCAAG | AUGGUGUUUUAACAUCAC	circPPP2R3B
358	X:77656654-77652113|-	ENSG00000085224	ATRX	CGAGAAAAAUUGAGAGAG | UGAGCAGUGAAGAUUCAG	circATRX
359	X:9568616-9569271|+	ENSG00000101849	TBL1X	UGGUGUGCUGUGUGUGUG | GUGUGCUGUAUGUCUGUC	circTBL1X
2260	4:186709846-186706562|-	ENSG00000083857	FAT1	AAATAGGTGAAGAGACAG|AT TCCCGACAGTTAAGCA	circFAT1

In some embodiments, the antisense oligonucleotide of the invention and according to the above embodiments, comprises in total at least three sugar-modified nucleobases that enhance the binding affinity of the antisense oligonucleotide to the circRNA. In one such embodiment, the antisense oligonucleotide according to the invention, comprises a total of at least three sugar-modified nucleobases that enhance the binding affinity of the antisense oligonucleotide to the circRNA, and wherein the antisense oligonucleotide comprises a gap of at least 7, 8, 9, 10, 11, 12, 13 or 14 DNA units, flanked in each end by wings comprising at least one sugar-modified nucleobase.

In some embodiments, the antisense oligonucleotide according to anyone of the above embodiments, comprises sugar-modified nucleobase units selected from the list of LNA (Locked nucleic acid), beta-D-oxy LNA, alpha-L-oxy-LNA, beta-D-amino-LNA, alpha-L-amino-LNA, beta-D-thio-LNA, alpha-L-thio-LNA, 5′-methyl-LNA, beta-D-ENA and alpha-L-ENA, 2′Fluoro, 2′-O-methyl, 2′-methoxyethyl (2′-MOE), 2′cyclic ethyl (cET), UNA and Conformationally Restricted Nucleoside (CRN). In some embodiments, the antisense oligonucleotide comprises only LNA nucleobases in the wings, and in some embodiments, the antisense oligonucleotide of the invention comprises a mixture of LNA and one or more other nucleobase units, such as a mixture of LNA and one or more of tricyclo-DNA, 2′-fluoro, 2′-O-methyl, 2′methoxyethyl (2′-MOE), 2′cyclic ethyl (cET), UNA and Conformationally Restricted Nucleoside (CRN) nucleobase units. In some preferred embodiments, the antisense oligonucleotide comprises a 5′ wing of 2, 3 or 4 LNA nucleobase units, such as in a non-limiting example Beta-D-Oxy LNA units, a central region of 6 to 16 consecutive DNA nucleotides and a 3′ end wing of 2, 3 or 4 LNA nucleobase units, such as in a non-limiting example Beta-D-Oxy LNA units. Where X represents the central region of 6-16 DNA nucleotides, and 2, 3 or 4 represent number of LNA in the wings, an antisense oligonucleotide of the invention may be designed to be complementary to a region overlapping the back-splice junction of anyone of SEQ ID NOs: 1 - 359, and wherein the antisense oligonucleotide is a gapmer that is designed as a 2 × 2, or a 2 × 3, or a 2 × 4, or a 3 × 2, or a 3 × 3, or a 3 × 4, or a 4 × 2, or a 4 × 3, or a 4 × 4 oligonucleotide.

In a preferred embodiment the DNA region X is anyone of 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 nucleotides in length, such as anyone of 10, 11, 12, 13, 14, 15 or 16 nucleotides in length. In some embodiments, the gap region “X” may comprise one or more gap shortening LNA nucleotides in order to decrease off target effects (as described in Rukov et al. 2015, Nucleic Acids Res. 2015 Sep 30;43(17):8476-87). In some embodiments, one or more LNA nucleotides are inserted in the DNA gap in order to decrease gapsize to be a maximum of 4 DNA, or 5 DNA, or 6 DNA or 7 DNA, or 8 DNA or 9 DNA or 10 DNA or 11 DNA or 12 DNA in length. In some preferred embodiments according to the invention as described throughout the application, each cytosine is a 5-methylcytosine. In some preferred embodiments, the LNA units in the wings of the antisense oligonucleotide of the invention are Beta-D-Oxy LNA and the target region is anyone of SEQ ID NOs: 1- 359 and 2260. In some embodiments, the nucleoside analogues in the wings are not LNA, but tricyclo-DNA and the target region is anyone of SEQ ID NOs: 1- 359 and 2260. In some embodiments, the nucleoside analogues in the wings are not LNA but 2′-Fluoro and the target region is anyone of SEQ ID NOs: 1- 359 and 2260. In some embodiments, the nucleoside analogues in the wings are not LNA but 2′-O-methyl and the target region is anyone of SEQ ID NOs: 1- 359 and 2260. In some embodiments, the nucleoside analogues in the wings are not LNA but 2′-MOE and the target region is anyone of SEQ ID NOs: 1 - 359 and 2260. In some embodiments, the nucleoside analogues in the wings are not LNA but 2′cyclic ethyl (cET) and the target region is anyone of SEQ ID NOs: 1 - 359 and 2260. In some embodiments, the nucleoside analogues in the wings are not LNA but UNA and the target region is anyone of SEQ ID NOs: 1 -359 and 2260. In some embodiments, the nucleoside analogues in the wings are not LNA but CRN and the target region is anyone of SEQ ID NOs: 1 - 359 and 2260. In some embodiments, the nucleoside analogues in the wings are partly LNA but mixed with another nucleotide analogue selected from the list of tricyclo-DNA, 2′-Fluoro, 2′-O-methyl, 2′-methoxyethyl (2′-MOE), 2′cyclic ethyl (cET), UNA, and Conformationally Restricted Nucleoside (CRN) and the target region is anyone of SEQ ID NOs: 1 - 359 and 2260.

In some embodiments, all internucleoside linkages of the antisense oligonucleotide according to the invention are phosphorothioate linkages. In some embodiments, the antisense oligonucleotide of the invention comprises at least one phosphorothioate internucleoside linkage. In some embodiments, the antisense oligonucleotide of the invention comprises at least two phosphorothioate internucleoside linkages, which are the 5′ most linkage and the 3′ most linkage of the antisense oligonucleotide. In some embodiments, the antisense oligonucleotide of the invention comprises at least two phosphorothioate internucleoside linkages, which are the 5′ most linkage and the 3′ most linkage, and wherein all the internucleoside linkages in the DNA gap are phosphorothioate linkages. In certain embodiments, the oligonucleotide comprises at least a total of 6 phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least a total of 8 phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least a total of 10 phosphorothioate internucleoside linkages.

In certain embodiments, the antisense oligonucleotide of the present invention, are designed to comprise wings that comprise 1, 2, 3, 4, 5, or 6 sugar modified nucleobase units, such as 2 to 5 modified nucleobase units, such as 2-4 sugar modified nucleobase units.

In certain preferred embodiments, the antisense oligonucleotide according to the present invention is anyone of the antisense oligonucleotides presented in Table 2, corresponding to anyone of SEQ ID NOs: 360 - 2148 and 2285-2299.

The antisense oligonucleotides (ASOs) of the present invention are listed in Table 2 (LNA, such as in a non-limiting example Beta-D-Oxy LNA units = uppercase, DNA = lowercase, complete phosphorothioate backbone, LNA cytosine units are LNA 5-methylcytosines).

Gapmer antisense oligonucleotides targeting back-splice junction-encompassing sequences for modulation of cancer-associated circRNAs (target sequences are shown in Table 1 for the individual circRNAs)
SEQ ID NO	Oligonucleotide (5′-3′)	Target name
360	GTgccatcggaaaccCT	ciRS-7
361	CATcggaaaccctggatAT	ciRS-7
362	TCggaaaccctggatatTG	ciRS-7
363	ATcggaaaccctGGA	ciRS-7
364	AAccctggatattGCA	ciRS-7
365	GAaaccctggatattGC	ciRS-7
366	CAtcggaaaccctggaTA	ciRS-7
367	ATcggaaaccctggataTT	ciRS-7
368	AAagatcaggcCTCA	circPVT1
369	AGatcaggcctcaaGC	circPVT1
370	AAagatcaggcctCAAG	circPVT1
371	CAaaagatcaggcctCAA	circPVT1
372	AAagatcaggcctcaagCC	circPVT1
373	AGgccatacctgtAG	circHIPK3
374	GCcatacctgtagtAC	circHIPK3
375	GGccatacctgtagtAC	circHIPK3
376	GAggccatacctgtagTA	circHIPK3
377	ATacctgtagtaccgagAT	circHIPK3
378	TTGTtactgaaATGA	circSRY
379	ATTCtttgttacTGAA	circSRY
380	AGattctttgttaCTGA	circSRY
381	TCtttgttactgaaATGA	circSRY
382	GATtctttgttactgAAAT	circSRY
383	CTtcttctcctctGT	circSLC35E2B
384	TCctctgtcttccaTA	circSLC35E2B
385	TCttcttctcctctgTC	circSLC35E2B
386	TCtcctctgtcttccaTA	circSLC35E2B
387	CTtctcctctgtcttcAT	circSLC35E2B
388	ACtgggacgtccgTA	circCDK11A
389	ACtgggacgtccgtAA	circCDK11A
390	ACtgggacgtccgtaAA	circCDK11A
391	ACtgggacgtccgtaaAG	circCDK11A
392	ACtgggacgtccgtaaaGA	circCDK11A
393	AGGTgttaaaattTT	circUNKNOWN00000001
394	AGGTgttaaaatTTTT	circUNKNOWN00000001
395	AATTtttatggatGATC	circUNKNOWN00000001
396	GTTAaaatttttatGGAT	circUNKNOWN00000001
397	AAAGgtgttaaaattTTTA	circUNKNOWN00000001
398	TGcgcctctgccTG	circARHGAP32
399	CTtgcctgtatgctGC	circARHGAP32
400	CGcctcttgcctgtaTG	circARHGAP32
401	CGcctcttgcctgtatGC	circARHGAP32
402	ATctgcgcctcttgcctGT	circARHGAP32
403	GCcagagacacagTT	circSLC8A3
404	CCagagacacagtTTC	circSLC8A3
405	TAggccagagacacaGT	circSLC8A3
406	AGgccagagacacagTT	circSLC8A3
407	GAcacagtttcatcattCT	circSLC8A3
408	GAacatccccaTTAT	circHERC2
409	CGtgaacatccccaTT	circHERC2
410	CGtgaacatccccatTA	circHERC2
411	TGaacatccccattatGC	circHERC2
412	GAacatccccattatgcCA	circHERC2
413	ATtccctgcacatCT	circZFAND6
414	TCattccctgcacaTC	circZFAND6
415	TCagattcattccctGC	circZFAND6
416	AGattcattccctgcaCA	circZFAND6
417	GActtcagattcattccCT	circZFAND6
418	AGgctgcacgggcGA	circRP1-168P16.1
419	AGgctgcacgggcgAT	circRP1-168P16.1
420	AGgctgcacgggcgaTT	circRP1-168P16.1
421	AGgctgcacgggcgatTC	circRP1-168P16.1
422	AGgctgcacgggcgattCC	circRP1-168P16.1
423	CTttgtcgcctggAC	circAURKC
424	TCctttgtcgcctgGA	circAURKC
425	TTtcctttgtcgcctGG	circAURKC
426	TTcctttgtcgcctggAC	circAURKC
427	TTcctttgtcgcctggaCA	circAURKC
428	ATTAatttacaCCTG	circAFTPH
429	ACacctgaactgAAGT	circAFTPH
430	TTAcacctgaactGAAG	circAFTPH
431	ATTAatttacacctGAAC	circAFTPH
432	TAatttacacctgaacTGA	circAFTPH
433	AGAgagagttaTCTG	circSCD
434	GAgagagttatcTGGA	circSCD
435	CCtagaagagagagaGT	circSCD
436	AGagagagagttatcTGG	circSCD
437	TAgaagagagagagTATC	circSCD
438	ACttggtcacctTAG	circSMC3
439	ACttggtcaccttaGG	circSMC3
440	TCaccttaggcatgaAG	circSMC3
441	TTggtcaccttaggcaTG	circSMC3
442	CTtggtcaccttaggcaTG	circSMC3
443	ACagcagccatgtGT	circSMC3
444	AGccatgtgtgtggGA	circSNORA23|IPO7.1
445	CCatgtgtgtgggaaTT	circSNORA23|IPO7.1
446	CAttacagcagccatgTG	circSNORA23|IPO7.1
447	CAcattacagcagccatGT	circSNORA23|IPO7.1
448	CAACcgagtttaGAG	circZNF124.1
449	CAACcgagtttagaGT	circZNF124.1
450	AAggcaaccgagttTAG	circZNF124.1
451	AGtttagagtagaaacCC	circZNF124.1
452	AACcgagtttagagtaGAA	circZNF124.1
453	GATCtcagaataAGC	circSNX5 | OVOL2
454	ATCtcagaataagcCC	circSNX5 | OVOL2
455	GATCtcagaataagcCC	circSNX5 | OVOL2
456	ACagatctcagaataAGC	circSNX5 | OVOL2
457	AGatacagatctcagAATA	circSNX5 | OVOL2
458	TGCagctcagtaaCA	circRALY
459	AGCtcagtaacaaTGA	circRALY
460	TGcagctcagtaaCAAT	circRALY
461	GCagctcagtaacaatGA	circRALY
462	CTgcagctcagtaacaaTG	circRALY
463	AATccccaagaATGA	circTFPI
464	AATCcccaagaaTGAA	circTFPI
465	CCccaagaatgaaatGG	circTFPI
466	AATCcccaagaatgaAAT	circTFPI
467	CAAgaatgaaatggtTGTT	circTFPI
468	CGttcagcggggcCA	circAHSG.1
469	CGttcagcggggcCAG	circAHSG.1
470	TGtcgttcagcggggCC	circAHSG.1
471	CAgcggggccagcaggTT	circAHSG.1
472	TGtcgttcagcggggcCAG	circAHSG.1
473	GCTTggacaaaaTGG	circAHSG.2
474	TGgacaaaatggtGGC	circAHSG.2
475	TTggacaaaatggtGGC	circAHSG.2
476	GGcttggacaaaatggTG	circAHSG.2
477	TTggacaaaatggtggcTT	circAHSG.2
478	CTTggacaaaaTGGT	circAHSG.3
479	TTGGacaaaatgGTTT	circAHSG.3
480	GCttggacaaaatgGTT	circAHSG.3
481	CAggcttggacaaaatGG	circAHSG.3
482	CAAaatggtttttgtaAGG	circAHSG.3
483	GTGgctcatgaaTTA	circUBXN7
484	CAgtggctcatgAATT	circUBXN7
485	CTCatgaattagaTCTC	circUBXN7
486	GGctcatgaattagatCT	circUBXN7
487	TCatgaattagatctcAGA	circUBXN7
488	CAgttatgtctTGGA	circAFP
489	AACAgttatgtctTGG	circAFP
490	TATgtcttggaaaGTTC	circAFP
491	CAgttatgtcttggAAAG	circAFP
492	GTtatgtcttggaaagTTC	circAFP
493	CGcgcagagccttTG	circHIST1H3A
494	CTcgcgcagagcctTT	circHIST1H3A
495	TCgcgcagagcctttGC	circHIST1H3A
496	CGcgagagcctttgcTT	circHIST1H3A
497	ATctcgcgcagagccttTG	circHIST1H3A
498	GTgtcagctggaTAT	circHIST1H3C.1
499	ACacaaaagtgtCAGC	circHIST1H3C.1
500	TGtcagctggatatcTT	circHIST1H3C.1
501	TGtcagctggatatctTT	circHIST1H3C.1
502	ACaaaagtgtcagctggAT	circHIST1H3C.1
503	GTgggctcacgcaGC	circANAPC2
504	CTcacgcagcctggGC	circANAPC2
505	CTggtgggctcacgcAG	circANAPC2
506	GGctggtgggctcacgCA	circANAPC2
507	TCacgcagcctgggcacGG	circANAPC2
508	TCagtgtggttgGTG	circRMRP|RMRP
509	CCtcagtgtggttgGT	circRMRP|RMRP
510	GAgtcctcagtgtggTT	circRMRP|RMRP
511	TCctcagtgtggttggTG	circRMRP|RMRP
512	ACagagtcctcagtgtgGT	circRMRP|RMRP
513	AAATtagtacaGGCA	circCENPI
514	AAtcaaaaattagtAC	circCENPI
515	AAATtagtacaggCATG	circCENPI
516	TCaaaaattagtacAGGC	circCENPI
517	AAattagtacaggcatGGT	circCENPI
518	ACaccttagtctcCT	circFIRRE
519	GTctcctcataaaGTA	circFIRRE
520	CCttagtctcctcatAA	circFIRRE
521	TAgtctcctcataaagTA	circFIRRE
522	TCtcctcataaagtatcTC	circFIRRE
523	ATGAcaaatggCATT	circMBNL3
524	AGatgacaaatgGCAT	circMBNL3
525	GAagatgacaaatGGCA	circMBNL3
526	CTgaagatgacaaatGGC	circMBNL3
527	GAagatgacaaatggCATT	circMBNL3
528	GGcctagtggtggTC	circGPC3
529	CCtagtggtggtcaGC	circGPC3
530	TTcaaaggcctagtgGT	circGPC3
531	AGgcctagtggtggtcAG	circGPC3
532	CCtagtggtggtcagctTT	circGPC3
533	ACTccaaagtgaAGC	circPROSER2
534	AGctcactccaaagTG	circPROSER2
535	TCactccaaagtgaaGC	circPROSER2
536	ACagctcactccaaagTG	circPROSER2
537	GCtcactccaaagtgaaGC	circPROSER2
538	CTccaccaataTTGT	circMALRD1
539	CACcaatattgtGTAT	circMALRD1
540	AATattgtgtatgATCC	circMALRD1
541	CAatattgtgtatgaTCC	circMALRD1
542	GCctccaccaatattgtGT	circMALRD1
543	CAtaaatgcttTGGC	circFAM208B
544	CAtaaatgctttgGCT	circFAM208B
545	TGtcataaatgctTTGG	circFAM208B
546	TTAAtgtcataaatGCTT	circFAM208B
547	GTcataaatgctttggcTG	circFAM208B
548	AGtgaaagaccTGCG	circMCU
549	AGtgaaagacctgCGA	circMCU
550	AAagacctgcgaaTGTT	circMCU
551	GTagtgaaagacctgcGA	circMCU
552	GAaagacctgcgaatgtTC	circMCU
553	TAgatctcctcCATT	circKIF20B
554	GAtctcctccatttCA	circKIF20B
555	AAcatttagatctCCTC	circKIF20B
556	TTagatctcctccattTC	circKIF20B
557	TTtaacatttagatctCCT	circKIF20B
558	AATAtcctgaaCAGA	circABCC2
559	TATCctgaacagATAC	circABCC2
560	AATatcctgaacaGATA	circABCC2
561	GAaatatcctgaacAGAT	circABCC2
562	ATatcctgaacagataCAT	circABCC2
563	GTcctcttatctCAT	circEIF4GC|SNORD 97.1
564	TCCtcttatctcaTAA	circEIF4GC|SNORD 97.1
565	AGtcctcttatctcaTA	circEIF4GC|SNORD 97.1
566	ATaaagtcctcttatCTC	circEIF4G2|SNORD 97.1
567	GTcctcttatctcataaTC	circEIF4G2|SNORD 97.1
568	AGtcctcttaaTCTC	circEIF4G2|SNORD 97.2
569	CTTAatctcataATCT	circEIF4G2|SNORD 97.2
570	GTcctcttaatctcaTA	circEIF4G2|SNORD 97.2
571	GTcctcttaatctcaTAA	circEIF4G2|SNORD 97.2
572	TTaatctcataatcttCGC	circEIF4G2|SNORD 97.2
573	CGcgtctttttATCT	circEIF4G2|SNORD 97.3
574	GCgtctttttatctCA	circEIF4G2|SNORD 97.3
575	CGtctttttatctCATA	circEIF4G2|SNORD 97.3
576	CGtctttttatctcATAA	circEIF4G2|SNORD 97.3
577	GTctttttatctcatAATC	circEIF4G2|SNORD 97.3
578	CGCgtctttttaTAT	circEIF4G2|SNORD 97.4
579	GCgtctttttataTCT	circEIF4G2|SNORD 97.4
580	ACgcgtctttttaTATC	circEIF4G2|SNORD 97.4
581	GCgtctttttatatctCA	circEIF4G2|SNORD 97.4
582	CGtctttttatatctcATA	circEIF4G2|SNORD 97.4
583	CGCGtctttttaTAA	circEIF4G2|SNORD 97.5
584	CGTCtttttataaTCT	circEIF4G2|SNORD 97.5
585	CGTCtttttataatCTT	circEIF4G2|SNORD 97.5
586	CTttttcataatcttcGCT	circEIF4G2|SNORD 97.5
587	TTtataatcttcgctcaCA	circEIF4G2|SNORD 97.5
588	TCATcataatcTTCG	circEIF4G2|SNORD 97.6
589	AAtcatcataatcTTC	circEIF4G2|SNORD 97.6
590	AATCatcataatcTTCG	circEIF4G2|SNORD 97.6
591	TCatcataatcttcgcTC	circEIF4G2|SNORD 97.6
592	TATaatcatcataatCTTC	circEIF4G2|SNORD 97.6
593	TCatcgctcacagGA	circEIF4G2|SNORD 97.7
594	AAtcatcgctcacAGG	circEIF4G2|SNORD 97.7
595	ATaatcatcgctcaCAG	circEIF4G2|SNORD 97.7
596	TTataatcatcgctCACA	circEIF4G2|SNORD 97.7
597	CTttttataatcatcgCTC	circEIF4G2|SNORD 97.7
598	ATcgggcacaggaCG	circEIF4G2|SNORD 97.8
599	TCgggcacaggacgCT	circEIF4G2|SNORD 97.8
600	ATcatcgggcacaggAC	circEIF4G2|SNORD 97.8
601	ATcatcgggcacaggaCG	circEIF4G2|SNORD 97.8
602	TTataatcatcgggcacAG	circEIF4G2|SNORD 97.8
603	GCatgccctcataTC	circEIF4G2|SNORD 97.9
604	GCatgccctcatatCT	circEIF4G2|SNORD 97.9
605	ATaatcatcgggcatGC	circEIF4G2|SNORD 97.9
606	GCatgccctcatatctCA	circEIF4G2|SNORD 97.9
607	GCatgccctcatatctcAT	circEIF4G2|SNORD 97.9
608	GCagccctcatatCT	circEIF4G2|SNORD 97.10
609	GCagccctcatatcTC	circEIF4G2|SNORD 97.10
610	TAatcatcgggcagcCC	circEIF4G2|SNORD 97.10
611	GCagccctcatatctcAT	circEIF4G2|SNORD 97.10
612	GCagccctcatatctcaTA	circEIF4G2|SNORD 97.10
613	GCtgtgtgcgtttGT	circlGF2
614	GTgctgtgtgcgttTG	circlGF2
615	GTgtgctgtgtgcgtTT	circlGF2
616	TGtgctgtgtgcgtttGT	circlGF2
617	TGtgtgtgctgtgtgcgTT	circlGF2
618	TCATagcttaaACTG	circQSER1
619	GCttaaactgttTTCT	circQSER1
620	CATagcttaaactGTTT	circQSER1
621	TTCatagcttaaacTGTT	circQSER1
622	AGcttaaactgttttcTTC	circQSER1
623	GTACtacaggtatGG	circUNKNOWN00000002
624	GTactacaggtatgGC	circUNKNOWN00000002
625	CTcggtactacaggtAT	circUNKNOWN00000002
626	ATctcggtactacaggTA	circUNKNOWN00000002
627	CTcggtactacaggtatGG	circUNKNOWN00000002
628	CCActttttctTATG	circCHD1L
629	GCcaactccactttTT	circCHD1L
630	ATgccaactccacttTT	circCHD1L
631	CAactccactttttctTA	circCHD1L
632	CActttttcttatgttcAG	circCHD1L
633	TGTcacttctgATAC	circPRUNE
634	TCActtctgataCATC	circPRUNE
635	TGtcacttctgataCAT	circPRUNE
636	TGtcacttctgatacATC	circPRUNE
637	CTtctgatacatcaaaCTT	circPRUNE
638	AGAgagttgagATCT	circSLC27A3
639	GTTGagatctgaAACT	circSLC27A3
640	ATTagagagttgaGATC	circSLC27A3
641	TTagagagttgagaTCTG	circSLC27A3
642	AGAgagttgagatctgAAA	circSLC27A3
643	ACagcttttgcctGG	circGATAD2B
644	TTgcctggcataccAA	circGATAD2B
645	TTttgcctggcatacCA	circGATAD2B
646	TTttgcctggcataccAA	circGATAD2B
647	CAGcttttgcctggcatAC	circGATAD2B
648	CAtgaacctgtcCAG	circKIAA0907
649	CAgcatgaacctgtCC	circKIAA0907
650	AAcctgtccagtgctAG	circKIAA0907
651	TCagcatgaacctgtcCA	circKIAA0907
652	CAgcatgaacctgtccaGT	circKIAA0907
653	GCAAtagtcaaGAAT	circCCT3
654	ATCTgcaatagtCAAG	circCCT3
655	TCTgcaatagtcaAGAA	circCCT3
656	GCAAtagtcaagaaTAAT	circCCT3
657	GCAAtagtcaagaatAATT	circCCT3
658	ACggccttcccagTC	circPLEKHM2
659	ACggccttcccagtCT	circPLEKHM2
660	CAcggccttcccagtCT	circPLEKHM2
661	GGcacggccttcccagTC	circPLEKHM2
662	CGgccttcccagtctgtGC	circPLEKHM2
663	TGTgaaaacagcCTG	circVWCE
664	CAgcctggaacacaAG	circVWCE
665	AGcctggaacacaagTA	circVWCE
666	AAcagcctggaacacAAG	circVWCE
667	AGcctggaacacaagtaCA	circVWCE
668	GCAgaataggaACAT	circATF6
669	AATaggaacatgCTGA	circATF6
670	AATaggaacatgcTGAG	circATF6
671	GAgcagaataggaaCATG	circATF6
672	AGagagcagaataggaaCA	circATF6
673	TTTCatcctacCAAT	circMALAT1.1
674	TGtttcatcctacCAA	circMALAT1.1
675	TGtttcatcctaccaAT	circMALAT1.1
676	ATtgtttcatccatcCAA	circMALAT1.1
677	ATtgtttcatcctaccaAT	circMALAT1.1
678	TTGTttcatttTCTA	circMALAT1.2
679	CTTCtccaaattgTTT	circMALAT1.2
680	CTccaaattgtttCATT	circMALAT1.2
681	TTctccaaattgtttCAT	circMALAT1.2
682	TCttctccaaattgtttCA	circMALAT1.2
683	TTCTccaaattGTTT	circMALAT1.3
684	CCAAattgttttTATC	circMALAT1.3
685	CCAaattgtttttaTCT	circMALAT1.3
686	TAtcttctccaaatTGTT	circMALAT1.3
687	CTtctccaaattgttttTA	circMALAT1.3
688	ACTTctatcttCTAA	circMALAT1.4
689	TCAaacttctatCTTC	circMALAT1.4
690	CTTcaaacttctaTCTT	circMALAT1.4
691	TCaaacttctatctTCA	circMALAT1.4
692	TTCtatcttctaaaGTAT	circMALAT1.4
693	TCAAacttctaTCTT	circMALAT1.5
694	CTTCaaacttctATCT	circMALAT1.5
695	CACttcaaacttcTATC	circMALAT1.5
696	TCcacttcaaacttcTAT	circMALAT1.005
697	CActtcaaacttctatCTT	circMALAT1.5
698	CCACttcaaacTTCT	circMALAT1.6
699	CACttcaaacttCTAT	circMALAT1.6
700	TCcacttcaaacttCTA	circMALAT1.6
701	CCacttcaaacttctaTC	circMALAT1.6
702	AAACttctatcttccaATT	circMALAT1.6
703	CCACttcaaacTTCT	circMALAT1.7
704	CACttcaaacttCTAT	circMALAT1.7
705	TCAaacttctatctTGT	circMALAT1.7
706	CCacttcaaacttctaTC	circMALAT1.7
707	AActtctatcttgtttCTA	circMALAT1.7
708	TGTcttccagttTTC	circMALAT1.8
709	GTcttccagttttcTT	circMALAT1.8
710	TCcagttttcttcTAAG	circMALAT1.8
711	TCtgtcttccagttttCT	circMALAT1.8
712	TGtcttccagttttcttCT	circMALAT1.8
713	CCcgtacttctgtCT	circMALAT1.9
714	CCgtacttctgtctTC	circMALAT1.9
715	TCccgtacttctgtcTT	circMALAT1.9
716	CGtacttctgtcttccAA	circMALAT1.9
717	ACttctgtcttccaattTT	circMALAT1.9
718	TCTCtattctttTCT	circMALAT1.10
719	TCTtttctaagtTTGT	circMALAT1.10
720	ATTCttttctaagTTTG	circMALAT1.10
721	TTCtctattcttttCTAA	circMALAT1.10
722	CTctattcttttctaaGTT	circMALAT1.10
723	TCTCtattctttTCT	circMALAT1.11
724	CTAttcttttcttCTA	circMALAT1.11
725	TCtctattcttttCTTC	circMALAT1.11
726	CTatcttctctattcTTT	circMALAT1.11
727	CTctattcttttcttcTAA	circMALAT1.11
728	TTtatcttctaatTT	circMALAT1.12
729	TCTAattttcttCTAA	circMALAT1.12
730	CTTctaattttctTCTA	circMALAT1.12
731	TCTaattttcttctaAGT	circMALAT1.12
732	TCtaattttcttctaAGTT	circMALAT1.12
733	TAaatttatctttTT	circMALAT1.13
734	TTaaatttatctttTT	circMALAT1.13
735	TTtaaatttatctttTT	circMALAT1.13
736	GTttaaatttatctttTT	circMALAT1.13
737	GGTTtaaatttatctTTTT	circMALAT1.13
738	AAaaagatagaagTT	circUNKNOWN00000003
739	AAaaagatagaagtTT	circUNKNOWN00000003
740	AAaaagatagaagttTG	circUNKNOWN00000003
741	AAaaagatagaagtttGA	circUNKNOWN00000003
742	AAaaagatagaagtttGAA	circUNKNOWN00000003
743	CTAgcttgtctTTTT	circMALAT1.14
744	CCtagcttgtctttTT	circMALAT1.14
745	TCctagcttgtctttTT	circMALAT1.14
746	TTcctagcttgtcttTT	circMALAT1.14
747	TTtcctagcttgtctttTT	circMALAT1.14
748	CTagcttgtcttaGC	circMALAT1.15
749	TCctagcttgtctTAG	circMALAT1.15
750	TTtcctagcttgtctTA	circMALAT1.15
751	TTcctagcttgtcttaGC	circMALAT1.15
752	TTgtttcctagcttgtcTT	circMALAT1.15
753	CTatacttctgcACC	circMALAT1.16
754	TCttctatacttcTGC	circMALAT1.16
755	TTctatacttctgcaCC	circMALAT1.16
756	TAtcttctatacttctGC	circMALAT1.16
757	ATcttctatacttctgcAC	circMALAT1.16
758	AAagccttctgTGTA	circMALAT1.17
759	AAagccttctgtGTAG	circMALAT1.17
760	TTccaaaagccttctGT	circMALAT1.17
761	CAaaagccttctgtgtAG	circMALAT1.17
762	CTtccaaaagccttctgTG	circMALAT1.17
763	ACactggttcctgGA	circMALAT1.18
764	TCaaacactggttCCT	circMALAT1.18
765	CAtcaaacactggttCC	circMALAT1.18
766	TTcatcaaacactgGTTC	circMALAT1.18
767	TCaaacactggttcctgGA	circMALAT1.18
768	TCctatcttcaCCAA	circMALAT1.19
769	CCtatcttcaccAAAT	circMALAT1.19
770	TTcctatcttcacCAAA	circMALAT1.19
771	TTtcctatcttcacCAAA	circMALAT1.19
772	CTtttcctatcttcaccAA	circMALAT1.19
773	ACacggaagacgGGA	circUCK2
774	ACGgaagacgggaATG	circUCK2
775	ACacggaagacggGAAT	circUCK2
776	CGgaagacgggaatggGA	circUCK2
777	AAgacgggaatgggagaCA	circUCK2
778	TGggaagcctcaTTT	circSUCO
779	GCtgggaagcctcaTT	circSUCO
780	GCtgggaagcctcatTT	circSUCO
781	CAgctgggaagcctcaTT	circSUCO
782	CAgctgggaagcctcatTT	circSUCO
783	TTgcaatcgtaCCTG	circRAB6A
784	CAatcgtacctgcTTT	circRAB6A
785	CAatcgtacctgcttTA	circRAB6A
786	GCaatcgtacctgcttTA	circRAB6A
787	ATtgcaatcgtacctgcTT	circRAB6A
788	ATCactgaagtCTCA	circRPS3|SNORD15 B.1
789	TCatcactgaagTCTC	circRPS3|SNORD15 B.1
790	TGtcatcactgaagTCT	circRPS3|SNORD15 B.1
791	GTcatcactgaagtctCA	circRPS3|SNORD15 B.1
792	CAtcactgaagtctcagAC	circRPS3|SNORD15 B.1
793	AAGCttctcagaCAA	circRPS3|SNORD15 B.2
794	AAGCttctcagaCAAA	circRPS3|SNORD15 B.2
795	AAGCttctcagacaaAT	circRPS3|SNORD15 B.2
796	AAGcttctcagacaaATG	circRPS3|SNORD15 B.2
797	AAgcttctcagacaaatGC	circRPS3|SNORD15 B.2
798	ACtgaagccttcTCA	circRPS3|SNORD15 B.3
799	ACtgaagccttctCAG	circRPS3|SNORD15 B.3
800	GTcatcactgaagccTT	circRPS3|SNORD15 B.3
801	GTcatcactgaagcctTC	circRPS3|SNORD15 B.3
802	AAgccttctcagacaaaTG	circRPS3|SNORD15 B.3
803	AGAagaatctgTAGC	circRSF1
804	AGAatctgtagcTTAT	circRSF1
805	GAagaatctgtagCTTA	circRSF1
806	CAgaagaatctgtagCTT	circRSF1
807	AGaagaatctgtagctTAT	circRSF1
808	GAtctttagtgATGC	circABL2
809	CTggcaaagtgaTCTT	circABL2
810	AAGtgatctttagTGAT	circABL2
811	CTggcaaagtgatcttTA	circABL2
812	CTggcaaagtgatctttAG	circABL2
813	CGagaagcctgtGTG	circGNB1
814	TGacgagaagcctgTG	circGNB1
815	ACtgacgagaagcctGT	circGNB1
816	TGacgagaagcctgtgTG	circGNB1
817	CActgacgagaagcctgTG	circGNB1
818	GAccagagtgtcTAG	circRPLP2 | SNORA52
819	ATtaggatggacCAGA	circRPLP2 | SNORA52
820	GGatggaccagagtgTC	circRPLP2 | SNORA52
821	ACcagagtgtctagaaGT	circRPLP2 | SNORA52
822	TTaggatggaccagagtGT	circRPLP2 | SNORA52
823	GGgcctccccatgTA	circPICALM.1
824	GGgcctccccatgtAC	circPICALM.1
825	GGcctccccatgtacttGC	circPICALM.1
826	ACTGaattaagTCTC	circPICALM.2
827	AAttaagtctccCAT	circPICALM.2
828	GAattaagtctccccAT	circPICALM.2
829	TGcactgaattaagtCTC	circPICALM.2
830	ACtgaattaagtctcccCA	circPICALM.2
831	ACagcagccatgtGT	circSNORA23|IP07.2
832	CAtgtgtgtgggGAA	circSNORA23|IP07.2
833	CCatgtgtgtgtgggAA	circSNORA23|IP07.2
834	AGccatgtgtgtgtggGA	circSNORA23|IP07.2
835	ATgtgtgtgtgggaattTG	circSNORA23|IP07.2
836	ACagcagccatgtGT	circSNORA23|IP07.3
837	TTacagcagccatgTG	circSNORA23|IP07.3
838	ACagcagccatgttGG	circSNORA23|IP07.3
839	ACattacagcagccatGT	circSNORA23|IP07.3
840	CAttacagcagccatgtGT	circSNORA23|IPO7.3
841	CTTtttgagcaGTTC	circCFH
842	GCattctctttttGAG	circCFH
843	TCgcattctctttttGA	circCFH
844	GTtcgcattctcttttTG	circCFH
845	ATtctctttttgagcagTT	circCFH
846	GATTgcagtggATAA	circSLC41A2.1
847	GAaggactggattGCA	circSLC41A2.1
848	TGgattgcagtggaTAA	circSLC41A2.1
849	CAgaaggactggattgCA	circSLC41A2.1
850	TGgattgcagtggataaTC	circSLC41A2.1
851	GActggatctgTACT	circSLC41A2.2
852	GAtctgtactatATCC	circSLC41A2.2
853	TGgatctgtactaTATC	circSLC41A2.2
854	GAtctgtactatatcCAG	circSLC41A2.2
855	AGaaggactggatctgtAC	circSLC41A2.2
856	GCatatttttcTGGC	circCORO1C
857	GCatatttttctggCA	circCORO1C
858	ATttttctggcaatCTC	circCORO1C
859	ATttttctggcaatctCA	circCORO1C
860	CAtatttttctggcaatCT	circCORO1C
861	CCTCtaggaatttTG	circEIF4G3| RP11-487E1.2
862	CTAggaattttgAGAG	circEIF4G3| RP11-487E1.2
863	TAGgaattttgagaGAG	circEIF4G3| RP11-487E1.2
864	GAattttgagagagtcCA	circEIF4G3| RP11-487E1.2
865	AGgaattttgagagagtCC	circEIF4G3| RP11-487E1.2
866	CCgatatagatttTT	circNAA25
867	TGccgatatagattTT	circNAA25
868	TGccgatatagatttTT	circNAA25
869	TGtgccgatatagattTT	circNAA25
870	TGtgccgatatagatttTT	circNAA25
871	TGagttcagccTGAA	circMED13L
872	CCgtgagttcagccTG	circMED13L
873	CGtgagttcagcctgAA	circMED13L
874	CGtgagttcagcctgaAA	circMED13L
875	TGagttcagcctgaaaAAT	circMED13L
876	ATCActgtaatGTAC	circLPGAT1|RN7SL344P
877	CCatcactgtaatGTA	circLPGAT1|RN7SL344P
878	TTccatcactgtaaTGT	circLPGAT1|RN7SL344P
879	TCcatcactgtaatgTAC	circLPGAT1|RN7SL344P
880	TCcatcactgtaatgtaCA	circLPGAT1|RN7SL344P
881	GCccctatcctgtCA	circAACS
882	GTgcccctatcctgTC	circAACS
883	GTgcccctatcctgtCA	circAACS
884	GGgtgcccctatcctgTC	circAACS
885	GCccctatcctgtcaacCA	circAACS
886	AGGactattaaCCAA	circTP53BP2
887	TTaaccaagtttcCCA	circTP53BP2
888	ACTAttaaccaagTTTC	circTP53BP2
889	TAaccaagtttcccatTG	circTP53BP2
890	CTattaaccaagtttccCA	circTP53BP2
891	AAgacatccttcCGG	circSOX5
892	AAgacatccttccgGC	circSOX5
893	ACatccttccggctcGT	circSOX5
894	AAgacatccttccggcTC	circSOX5
895	CGcttggaagacatcctTC	circSOX5
896	GGaactggctgctCT	circDNAH14
897	AAggaactggctgCTC	circDNAH14
898	TAaaggaactggctgCT	circDNAH14
899	AAaggaactggctgctCT	circDNAH14
900	ATaaaggaactggctgcTC	circDNAH14
901	TGtactctactgTGC	circKDM1A|MIR3115
902	TGtactctactgtgCG	circKDM1A|MIR3115
903	TGtactctactgtgcGG	circKDM1A|MIR3115
904	CTctgtactctactgtGC	circKDM1A|MIR3115
905	TCtgtactctactgtgcGG	circKDM1A|MIR3115
906	AAAGgatgactCTGA	circTTC13
907	AGgatgactctgaaGC	circTTC13
908	AAAGgatgactctGAAG	circTTC13
909	ACtctgaagcattgttGA	circTTC13
910	ATgactctgaagcattgTT	circTTC13
911	CAtggccttgtagCA	circEGLN1
912	TGgccttgtagcatAT	circEGLN1
913	CAtggccttgtagcaTA	circEGLN1
914	CAtggccttgtagcatAT	circEGLN1
915	AAcaagcaaccatggccTT	circEGLN1
916	CCttcctttccacCG	circEGLN3
917	CTtcctttccaccgAT	circEGLN3
918	CCttcctttccaccAT	circEGLN3
919	TTcctttccaccgatgGT	circEGLN3
920	TTcctttccaccgatggTC	circEGLN3
921	GTTTaagaatgCAGG	circTOMM20|SNORA14B
922	AAGAatgcaggtaTGA	circTOMM20|SNORA14B
923	TTTaagaatgcagGTAT	circTOMM20|SNORA14B
924	GGtttaagaatgcaggTA	circTOMM20|SNORA14B
925	TAAGaatgcaggtatGAAA	circTOMM20|SNORA14B
926	GTCttccattcATTT	circSCCPDH
927	AGtgttggtcttccAT	circSCCPDH
928	GTtggtcttccattcAT	circSCCPDH
929	GTcttccattcattttAT	circSCCPDH
930	CTtccattcattttattTC	circSCCPDH
931	AACCgagttagaAGT	circZNF124.2
932	AACcgagttagaAGTC	circZNF124.2
933	CCgagttagaagtcTTG	circZNF124.2
934	AAaggcaaccgagttAGA	circZNF124.2
935	AAggcaaccgagttagaAG	circZNF124.2
936	CCaccttgatcagGG	circGLS2
937	TGccaccttgatcaGG	circGLS2
938	ATgtaggctgccaccTT	circGLS2
939	AGgctgccaccttgatCA	circGLS2
940	ATgtaggctgccaccttGA	circGLS2
941	GCGagactctgaATA	circR3HDM2
942	GACTctgaataaaTGC	circR3HDM2
943	GActctgaataaaTGCT	circR3HDM2
944	GAgcgagactctgaaTAA	circR3HDM2
945	CGagactctgaataaaTGC	circR3HDM2
946	TGcagtttctcccTG	circDHDDS
947	TCcctgggatccaaCA	circDHDDS
948	AGtttctccctgggaTC	circDHDDS
949	TGcagtttctccctggGA	circDHDDS
950	TTtctccctgggatccaAC	circDHDDS
951	GAgagtgacctGTTT	circSNORA73A|RCC1|SNHG3.1
952	TGacctgtttcctgCA	circSNORA73A|RCC1|SNHG3.1
953	AGagtgacctgtttcCT	circSNORA73A|RCC1|SNHG3.1
954	GGagagtgacctgtttCC	circSNORA73A|RCC1|SNHG3.1
955	TGacctgtttcctgcatGG	circSNORA73A|RCC1|SNHG3.1
956	AGAgtgacctgcaTG	circSNORA73A|RCC1|SNHG3.2
957	GGagagtgacctgcAT	circSNORA73A|RCC1|SNHG3.2
958	GGagagtgacctgcaTG	circSNORA73A|RCC1|SNHG3.2
959	GAgagtgacctgcatgGT	circSNORA73A|RCC1|SNHG3.2
960	ATcaggaggataCCT	circSNORA61|SNHG12
961	GGatcaggaggataCC	circSNORA61|SNHG12
962	GAggatacctgtctgAA	circSNORA61|SNHG12
963	GAggatacctgtctgaAA	circSNORA61|SNHG12
964	GAtacctgtctgaaactAG	circSNORA61|SNHG12
965	ACacatatggcTTGC	circCEP83|RBMS2P1
966	TGacacatatggCTTG	circCEP83|RBMS2P1
967	GAcacatatggcttgCA	circCEP83|RBMS2P1
968	ATgacacatatggcttGC	circCEP83|RBMS2P1
969	ATacatatggcttgcaaAG	circCEP83|RBMS2P1
970	GCttctttatctCTG	circFGD6
971	TTatctctggaaTGCT	circFGD6
972	GGcttctttatctctGG	circFGD6
973	CTttatctctggaatgCT	circFGD6
974	GTggcttctttatctctGG	circFGD6
975	AAcagctagtgtCGC	circPUM1
976	GGaacagctagtgtCG	circPUM1
977	TCtttggaacagctaGT	circPUM1
978	TTtggaacagctagtgTC	circPUM1
979	TTggaacagctagtgtcGC	circPUM1
980	CAgctagaagaTGCA	circTMCO3| RP11-230F18.6
981	TTcagctagaagATGC	circTMCO3| RP11-230F18.6
982	TTcagctagaagatGCA	circTMCO3| RP11-230F18.6
983	CAcattttcagctaGAAG	circTMCO3| RP11-230F18.6
984	GAcacacattttcagcTAG	circTMCO3| RP11-230F18.6
985	AAACtagaacgTGGA	circPTP4A2
986	AAACtagaacgtGGAT	circPTP4A2
987	CCAAcgaaaaactAGAA	circPTP4A2
988	CCAAcgaaaaactaGAAC	circPTP4A2
989	CCAacgaaaaactagaACG	circPTP4A2
990	AACCaggactaTGAT	circZMYM5
991	CAtgccaatgaacCAG	circZMYM5
992	ATgccaatgaaccagGA	circZMYM5
993	CCaatgaaccaggactAT	circZMYM5
994	CAatgaaccaggactatGA	circZMYM5
995	TGcgattctgtgCAC	circN6AMT2
996	ACatgcgattctgtGC	circN6AMT2
997	ACatgcgattctgtgCA	circN6AMT2
998	CAcacatgcgattctgTG	circN6AMT2
999	CAcatgcgattctgtgcAC	circN6AMT2
1000	ATATaccagcaTTTC	circRPL21|SNORA27
1001	CAgcatttcctctgAC	circRPL21|SNORA27
1002	ATaccagcatttcctCT	circRPL21|SNORA27
1003	ATataccagcatttccTC	circRPL21|SNORA27
1004	TTatataccagcatttcCT	circRPL21|SNORA27
1005	CACCttttaatcGC	circGTF2F2
1006	GACacctttttaATCG	circGTF2F2
1007	GAcaccttttaatcGC	circGTF2F2
1008	ATgacacctttttaaTCG	circGTF2F2
1009	CAAagtaaatgacacCTTT	circGTF2F2
1010	TTAccaccacttgaGC	circZMYM4
1011	CCacttgagcattgTC	circZMYM4
1012	CAccacttgagcattGT	circZMYM4
1013	ACcaccacttgagacatTG	circZMYM4
1014	ATaccaaccacttgagcaTT	circZMYM4
1015	AATggaggcgttTGA	circLINC00355
1016	ACcaaatggaggcGTT	circLINC00355
1017	AAtggaggcgtttgaGC	circLINC00355
1018	GCaaatggaggcgtttGA	circLINC00355
1019	AAcagcaaatggaggcgTT	circLINC00355
1020	GTccttagcaacCAC	circUNKNOWN00000004
1021	ATgtccttagcaacCA	circUNKNOWN00000004
1022	CAatgtccttagcaaCC	circUNKNOWN00000004
1023	AAtgtccttagcaaccAC	circUNKNOWN00000004
1024	ATtcaccaacaatgtccTT	circUNKNOWN00000004
1025	GACAcacagaaCATA	circFARP1
1026	GACAcacagaacATAC	circFARP1
1027	AGaacatacacaaTGCT	circFARP1
1028	CACacagaacatacACAA	circFARP1
1029	CAcagaacatacacaatGC	circFARP1
1030	GTgggctccttgcAG	circDYNC1H1
1031	GTgggctccttgcaGG	circDYNC1H1
1032	CGtaggtgggctcctTG	circDYNC1H1
1033	TAggtgggctccttgcAG	circDYNC1H1
1034	TCcttgcaggtgtttctTC	circDYNC1H1
1035	TGgtttagcaggtGG	circCDC42BPB
1036	AATggtttagcagGTG	circCDC42BPB
1037	AATggtttagcaggtGG	circCDC42BPB
1038	TAaatggtttagcagGTG	circCDC42BPB
1039	AAtggtttagcaggtggTT	circCDC42BPB
1040	CCATcaaaaatTGTT	circCCNB1IP1|SNORA79|AL355075.1
1041	AGCcatcaaaaatTGT	circCCNB1IP1|SNORA79|AL355075.1
1042	ACAgccatcaaaaATTG	circCCNB1IP1|SNORA79|AL355075.1
1043	GCcatcaaaaattgTTTG	circCCNB1IP1|SNORA79|AL355075.1
1044	AGgaacagccatcaaaAAT	circCCNB1IP1|SNORA79|AL355075.1
1045	TGttcaatgggcgGA	circRPPH1|RPPH1.1
1046	TTcaatgggcggagGA	circRPPH1|RPPH1.1
1047	TTcaatgggcggaggAG	circRPPH1|RPPH1.1
1048	CGtgagtctgttcaatGG	circRPPH1|RPPH1.1
1049	CGtgagtctgttcaatgGG	circRPPH1|RPPH1.1
1050	GCatccgccgggcGG	circRPPH1|RPPH1.2
1051	CGccgggcggaggaGA	circRPPH1|RPPH1.2
1052	CGccgggcggaggagAG	circRPPH1|RPPH1.2
1053	GGcatccgccgggcggAG	circRPPH1|RPPH1.2
1054	GCcgggcggaggagagtAG	circRPPH1|RPPH1.2
1055	AActcacttcgCTGG	circRPPH1|RPPH1.3
1056	GGgaactcacttcgCT	circRPPH1|RPPH1.3
1057	GGaactcacttcgctGG	circRPPH1|RPPH1.3
1058	CTgggaactcacttcgCT	circRPPH1|RPPH1.3
1059	TGggaactcacttcgctGG	circRPPH1|RPPH1.3
1060	TCaggcaaaggagGC	circRPPH1|RPPH1.4
1061	CCgaagctcaggcaAA	circRPPH1|RPPH1.4
1062	CGaagctcaggcaaaGG	circRPPH1|RPPH1.4
1063	CGaagctcaggcaaagGA	circRPPH1|RPPH1.4
1064	CGaagctcaggcaaaggAG	circRPPH1|RPPH1.4
1065	CAttgggagccccTC	circSNORD8|CHD8.2
1066	CTcatcattgggagCC	circSNORD8|CHD8.2
1067	GGagcccctcagatcTT	circSNORD8|CHD8.2
1068	GGagcccctcagatctTC	circSNORD8|CHD8.2
1069	TCatcattgggagccccTC	circSNORD8|CHD8.2
1070	GAcgcccctcagaTC	circSNORD8|CHD8.2
1071	TCatcattgggacgCC	circSNORD8|CHD8.2
1072	CAtcattgggacgccCC	circSNORD8|CHD8.2
1073	GAcgcccctcagatctTC	circSNORD8|CHD8.2
1074	GAcgcccctcagatcttCA	circSNORD8|CHD8.2
1075	CGccgcctacgagGA	circPPP1R3E
1076	TAcgaggagggagcCC	circPPP1R3E
1077	CCtacgaggagggagCC	circPPP1R3E
1078	CCcgccgcctacgaggAG	circPPP1R3E
1079	GCccccgccgcctacgaGG	circPPP1R3E
1080	CAgtggagtaggcCC	circCHMP4A|RP11-468E2.1|AL136419.6
1081	CAgtggagtaggccCA	circCHMP4A|RP11-468E2.1|AL136419.6
1082	CAgtggagtaggcccAC	circCHMP4A|RP11-468E2.1|AL136419.6
1083	GGagtaggcccactcaGC	circCHMP4A|RP11-468E2.1|AL136419.6
1084	AGgcccactcagccaacTG	circCHMP4A|RP11-468E2.001|AL136419.6
1085	GATttctcatcATCT	circUNKNOWN00000005
1086	ATttctcatcatcTGC	circUNKNOWN00000005
1087	TTtctcatcatctgCAC	circUNKNOWN00000005
1088	GAtttctcatcatctgCA	circUNKNOWN00000005
1089	AActctgtgatttctcATC	circUNKNOWN00000005
1090	GTGcttttaataGGA	circSEC23A
1091	CTTGgtgcttttaaTA	circSEC23A
1092	TTggtgcttttaaTAGG	circSEC23A
1093	TTggtgcttttaataGGA	circSEC23A
1094	CTtttaataggagtgtCTT	circSEC23A
1095	CAccaccaaggaGAG	circSNORD46|RPS8
1096	CTcgcacccaccacCA	circSNORD46|RPS8
1097	TCgcacccaccaccaAG	circSNORD46|RPS8
1098	CCcaccaccaaggagaGC	circSNORD46|RPS8
1099	ACcaccaaggagagcaaGG	circSNORD46|RPS8
1100	TGATtcttgtaCTTG	circSAMD4A
1101	GTTAatgattctTGTA	circSAMD4A
1102	GTTaatgattcttGTAC	circSAMD4A
1103	ATgattcttgtacttGTG	circSAMD4A
1104	GTtaatgattcttgtaCTT	circSAMD4A
1105	CTgcaagttcatCGT	circPCNX
1106	TGctgcaagttcatCG	circPCNX
1107	TTGtgctgcaagttcAT	circPCNX
1108	TTgtgctgcaagttcaTC	circPCNX
1109	CTgcaagttcatcgtgcAA	circPCNX
1110	CCcagattaggtaGT	circPSEN1
1111	CCcagattaggtagTA	circPSEN1
1112	TCccagattaggtagTA	circPSEN1
1113	GCtcccagattaggtaGT	circPSEN1
1114	GCtcccagattaggtagTA	circPSEN1
1115	CAggcacagtggCAA	circFCF1
1116	GGcacagtggcaAAAC	circFCF1
1117	CCaggcacagtggcaAA	circFCF1
1118	GCacagtggcaaaacaGC	circFCF1
1119	CCaggcacagtggcaaaAC	circFCF1
1120	TCgagcaggcacTTG	circSCARNA13|SNHG10.1
1121	TCtcgagcaggcacTT	circSCARNA13|SNHG10.1
1122	TCtcgagcaggcacTTG	circSCARNA13|SNHG10.1
1123	CGagcaggcacttgtgGC	circSCARNA13|SNHG10.1
1124	CAggcacttgtggcagtAC	circSCARNA13|SNHG10.1
1125	CAgttgtggcagTAC	circSCARNA13|SNHG10.2
1126	GCatgcctcagttgTG	circSCARNA13|SNHG10.2
1127	CTcagttgtggcagtAC	circSCARNA13|SNHG10.2
1128	AGgcatgcctcagttgTG	circSCARNA13|SNHG10.2
1129	CAgttgtggcagtacttAG	circSCARNA13|SNHG10.2
1130	ACcctcgactgCAAA	circSCARNA13|SNHG10.3
1131	CAaccctcgactgcAA	circSCARNA13|SNHG10.3
1132	TAccaccaaccctcgAC	circSCARNA13|SNHG10.3
1133	AAccctcgactgcaaaGC	circSCARNA13|SNHG10.3
1134	AAccctcgactgcaaagCT	circSCARNA13|SNHG10.3
1135	GTcatccagtcAGAA	circUNKNOWN00000006
1136	GTcatccagtcaGAAA	circUNKNOWN00000006
1137	TAaagtcatccagtCAG	circUNKNOWN00000006
1138	AAgtcatccagtcAGAA	circUNKNOWN00000006
1139	TAtaaagtcatccagtcAG	circUNKNOWN00000006
1140	AGgagcctgccatTG	circTJP1
1141	AGgagcctgccattGC	circTJP1
1142	AAatccaggagcctgCC	circTJP1
1143	AGgagcctgccattgcTT	circTJP1
1144	AAatccaggagcctgccAT	circTJP1
1145	GAtaacctgtggtCC	circRP11-632K20.7
1146	GAtaacctgtggtcCA	circRP11-632K20.7
1147	CTtggataacctgtgGT	circRP11-632K20.7
1148	TTggataacctgtggtCC	circRP11-632K20.7
1149	ATgtccttggataacctGT	circRP11-632K20.7
1150	TAaccttgcagCTTT	circTTBK2
1151	GTTtccatttaacCTT	circTTBK2
1152	TTtccatttaaccttGC	circTTBK2
1153	ATttaaccttgcagctTT	circTTBK2
1154	GGtttccatttaaccttGC	circTTBK2
1155	CAACtcacgaagCAG	circPPIB
1156	CCacaactcacgaaGC	circPPIB
1157	TTccacaactcacGAAG	circPPIB
1158	GCttccacaactcacgAA	circPPIB
1159	TTccacaactcacgaagCA	circPPIB
1160	GCTgacgaagaTTTA	circUBE2Q2
1161	GCTgacgaagatTTAA	circUBE2Q2
1162	GCTGacgaagattTAAA	circUBE2Q2
1163	CAattgctgacgaaGATT	circUBE2Q2
1164	GCTgacgaagatttaaaTG	circUBE2Q2
1165	ATcttgtgccaccTG	circETFA
1166	GCcacctgcataaaTA	circETFA
1167	TGccacctgcataaaTA	circETFA
1168	TGtgccacctgcataaAT	circETFA
1169	CCacctgcataaatagtTC	circETFA
1170	GAtaatagagcCCCT	circSEC11A
1171	TTgataatagagcCCC	circSEC11A
1172	ACTTgataatagagcCC	circSEC11A
1173	CTtgataatagagcccCT	circSEC11A
1174	GActtgataatagagccCC	circSEC11A
1175	GCtacctgcacagTG	circPDE8A
1176	CTactgctacctgcAC	circPDE8A
1177	CTgctacctgcacagTG	circPDE8A
1178	AGctactgctacctgcAC	circPDE8A
1179	TCagctactgctacctgCA	circPDE8A
1180	TTccttatgccccTG	circDAB1|OMA1
1181	TTatgcccctgaggTA	circDAB1|OMA1
1182	TTccttatgcccctgAG	circDAB1|OMA1
1183	ATttccttatgccctGA	circDAB1|OMA1
1184	TAtgccctgaggtataAG	circDAB1|OMA1
1185	CTAAaagtcttTGGT	circABHD2
1186	AAAAgtctttggTCAG	circABHD2
1187	AAacctaaagtcttTG	circABHD2
1188	AACAaacctaaaagTCTT	circABHD2
1189	AACAaacctaaaagtCTTT	circABHD2
1190	CAGGtacaaatATTG	circlQGAP1.1
1191	GGTacaaatattGACT	circlQGAP1.1
1192	CAGgtacaaatatTGAC	circlQGAP1.1
1193	AGGtacaaatattgaCTT	circlQGAP1.1
1194	GAacaggtacaaataTTGA	circlQGAP1.1
1195	AGCatgtatatTGAC	circlQGAP1.2
1196	AGCatgtatattgACT	circlQGAP1.2
1197	GTATattgactttgTTT	circlQGAP1.2
1198	CAgcagcatgtatattGA	circlQGAP1.2
1199	GTatattgatttgtTTAT	circlQGAP1.2
1200	GTccttttccttcTC	circCHD2
1201	CTggtccttttccTC	circCHD2
1202	TTccttctctttctTAT	circCHD2
1203	CTtttccttctctttcTT	circCHD2
1204	TTccttctctttcttatVT	circCHD2
1205	TGgcccgcagattTT	circlGF1R
1206	TGgcccgcagatttTC	circlGF1R
1207	GGcccgcagattttcTG	circlGF1R
1208	CTggcccgcagattttCT	circlGF1R
1209	AGattttctggcagcggTT	circlGF1R
1210	CGtgcacaggctgCA	circNPRL3
1211	GAcgtgcacaggctGC	circNPRL3
1212	CGtgcacaggctgcaGC	circNPRL3
1213	CCcgacgtgcacaggcTG	circNPRL3
1214	CGtgcacaggctgcagcAA	circNPRL3
1215	GGtggctgttaaGTT	circNDE1
1216	GCacggtggctgttAA	circNDE1
1217	CAcggtggctgttaaGT	circNDE1
1218	CGgtggctgttaagttCT	circNDE1
1219	TGgctgttaagttctctGT	circNDE1
1220	GTcagggtcgtGGAT	circABCC1
1221	TCcagtcagggtcgTG	circABCC1
1222	CAttccagtcagggtCG	circABCC1
1223	CAgtcagggtcgtggaTG	circABCC1
1224	ATtccagtcagggtcgtGG	circABCC1
1225	CCgggtacgcagcTG	circRPS2 |SNORA64
1226	ACagccgggtacgcAG	circRPS2 |SNORA64
1227	ACagccgggtacgcaGC	circRPS2 |SNORA64
1228	AGgacagccgggtacgCA	circRPS2 |SNORA64
1229	ACagccgggtacgcagcTG	circRPS2 |SNORA64
1230	CGcacagggtacTTG	circPOLR3E
1231	GAcgcacagggtacTT	circPOLR3E
1232	GTacttgcctgtagaGT	circPOLR3E
1233	GGacgcacagggtactTG	circPOLR3E
1234	GGacgcacagggtacttGC	circPOLR3E
1235	CTcttacgaagacCA	circATXN2L
1236	CTcttacgaagaccAC	circATXN2L
1237	CTcttacgaagacca|CA	circATXN2L
1238	CAgctgggctcttacgAA	circATXN2L
1239	AGctgggctcttacgaaGA	circATXN2L
1240	GTgtgatgtcctgTC	circMVP
1241	TGatgtcctgtcacCC	circMVP
1242	GGtgtgatgtcctgtCA	circMVP
1243	GAtgtvvtgtcaccctCT	circMVP
1244	GTcctgtcaccctctccTT	circMVP
1245	GAgcctgtttggtTG	circASPHD1
1246	GAgcctgtttggttGT	circASPHD1
1247	AAGcctgtttggttgtacTA	circASPHD1
1248	TCtgtccctcaaTGA	circlTGAL
1249	CCtctgtccctcaaTG	circlTGAL
1250	AAcacctctgtccctCA	circlTGAL
1251	CGgaacacctctgtccCT	circlTGAL
1252	GTccctcaatgacatagAT	circlTGAL
1253	ACatcagaaggaGGC	circRP5-857K21.6.1
1254	CGgcgaacatcaGAAG	circRP5-857K21.6.1
1255	CGgcgaacatcagaaGG	circRP5-857K21.6.1
1256	GGcgaacatcagaaggAG	circRP5-857K21.6.1
1257	GAacatcagaaggaggcTT	circRP5-857K21.6.1
1258	GCGaacatcagACAA	circRP5-857K21.6.2
1259	CGgcgaacatcagaCA	circRP5-857K21.6.2
1260	CGgcgaacatcagaCAA	circRP5-857K21.6.2
1261	CGaacatcagacaaaTGC	circRP5-857K21.6.2
1262	CGaacatcagacaaatgCA	circRP5-857K21.6.2
1263	GAacatcagatGCGG	circRP5-857K21.6.3
1264	GCgaacatcagatgCG	circRP5-857K21.6.3
1265	CGaacatcagatgcgGG	circRP5-857K21.6.3
1266	GGcgaacatcagatgcGG	circRP5-857K21.6.3
1267	TCggcgaacatcagatgCG	circRP5-857K21.6.3
1268	GCgaacatcagATGT	circRP5-857K21.6.4
1269	ATCAgatgttgtTTAT	circRP5-857K21.6.4
1270	ATCagatgttgttTATG	circRP5-857K21.6.4
1271	GTcggcgaacatcagaTG	circRP5-857K21.6.4
1272	CAgatgttgtttatgcgGG	circRP5-857K21.6.4
1273	CAacagtccctggCT	circZNF720
1274	GTcaacagtccctgGC	circZNF720
1275	ATgtcaacagtccctGG	circZNF720
1276	GAatgtcaacagtcccTG	circZNF720
1277	AAcagtccctggctggaTG	circZNF720
1278	ACcaactcaagCAGA	circLONP2
1279	ACAtttcaaccaACTC	circLONP2
1280	TCaaccaactcaagCAG	circLONP2
1281	ATttcaaccaactcaaGC	circLONP2
1282	AAcatttcaaccaacTCAA	circLONP2
1283	AAATgactgtcGCTG	circCHD9
1284	AAatgactgtcgCTGT	circCHD9
1285	AAaatgactgtcgCTGT	circCHD9
1286	TGactgtcgctgtaaaCA	circCHD9
1287	TGactgtcgctgtaaacAT	circCHD9
1288	GCCacataaacTATA	circSLC7A6
1289	GCCacataaactaTAT	circSLC7A6
1290	AAActatatgcaaGCAG	circSLC7A6
1291	GCcacataaactatatGC	circSLC7A6
1292	CACataaactatatgCAAG	circSLC7A6
1293	GAcatggctgacTCA	circCARHSP1
1294	CTgactcagagaTGTG	circCARHSP1
1295	CTgactcagagatgtGC	circCARHSP1
1296	ATggctgactcagagaTG	circCARHSP1
1297	GAcatggctgactcagaGA	circCARHSP1
1298	CACCtcagtaaGTC	circFANCA
1299	TGcacctcagtaaTGT	circFANCA
1300	CAcctcagtaatgtcCC	circFANCA
1301	AAtgtcacctcagTAAT	circFANCA
1302	AAtgtgcacctcagtaaTG	circFANCA
1303	TCACtcacgcagtGG	circRAD51D|RAD51L3–RFFL
1304	ACatcactcacgcaGT	circRAD51D|RAD51L3–RFFL
1305	CCacatcactcacgcAG	circRAD51D|RAD51L3–RFFL
1306	AVatcactcacgcagtGG	circRAD51D|RAD51L3–RFFL
1307	GCcacatcactcacgcaGT	circRAD51D|RAD51L3–RFFL
1308	GGgccttgagctcTC	circHDAC5
1309	GGgccttgagctctCC	circHDAC5
1310	GGccttgagctctcctgCA	circHDAC5
1311	TCttgaaccatCTGA	circUTP18
1312	ATgttcttgaacCATC	circUTP18
1313	TTgaaccatctgaAGAT	circUTP18
1314	TTcttgaaccatctGAAG	circUTP18
1315	TGttcttgaaccatctgAA	circUTP18
1316	CAcctccacgacaCC	circSRSF1
1317	CAcctccacgacacCA	circSRSF1
1318	TCcgccacctccacgAC	circSRSF1
1319	CCgccacctccacgacAC	circSRSF1
1320	CTccgccacctccacgaCA	circSRSF1
1321	CCattccgcatcaGG	circPPM1D
1322	TCcgcatcaggtaTTT	circPPM1D
1323	ATtccgcatcaggtaTT	circPPM1D
1324	CCattccgcatcaggtAT	circPPM1D
1325	GGccattccgcatcaggTA	circPPM1D
1326	GGccttgtaagaTGG	circBRIP1
1327	AAggccttgtaaGATG	circBRIP1
1328	AGgccttgtaagatgGC	circBRIP1
1329	AAaggccttgtaagaTGG	circBRIP1
1330	AAtatctgaaaaggcCTTG	circBRIP1
1331	CAGCaaagtttGAAT	circPRKCA.1
1332	CAGCaaagtttgaATC	circPRKCA.1
1333	AGcaaagtttgaatcCC	circPRKCA.1
1334	AAagtttgaatcccaGGA	circPRKCA.1
1335	CACaaaacagcaaagTTTG	circPRKCA.1
1336	AGGCttcagtttGAA	circPRKCA.2
1337	AGGCttcagtttGAAT	circPRKCA.2
1338	GCttcagtttgaatcCC	circPRKCA.2
1339	GGcttcagtttgaatcCC	circPRKCA.2
1340	TCagtttgaatcccaggAT	circPRKCA.2
1341	GAgcctctcagagTA	circEIF4A1|SNORD1 0|RP11- 186B7.4|SENP3- EIF4A1.1
1342	CAtcacagagcctcTC	circEIF4A1|SNORD1 0|RP11- 186B7.4|SENP3- EIF4A1.1
1343	CTccatcacagagccTC	circEIF4A1|SNORD1 0|RP11- 186B7.4|SENP3- EIF4A1.1
1344	CAtcacagagcctctcAG	circEIF4A1|SNORD1 0|RP11- 186B7.4|SENP3- EIF4A1.1
1345	AGcctctcagagtacaaAG	circEIF4A1|SNORD1 0|RP11- 186B7.4|SENP3- EIF4A1.1
1346	CAtcacagagagcgCTC	circEIF4A1|SNORD1 0|RP11- 186B7.4|SENP3- EIF4A1.2
1347	TCcatcacagagcgCT	circEIF4A1|SNORD1 0|RP11- 186B7.4|SENP3- EIF4A1.2
1348	AGcgctctcagagtaCA	circEIF4A1|SNORD1 0|RP11- 186B7.4|SENP3- EIF4A1.2
1349	CAtcacagagcgctctCA	circEIF4A1|SNORD1 0|RP11- 186B7.4|SENP3- EIF4A1.2
1350	ATcacagagcgctctcaGA	circEIF4A1|SNORD1 0|RP11- 186B7.4|SENP3- EIF4A1.2
1351	CAggtttgcacTTTG	circPGS1
1352	ACtcaggtttgcaCTT	circPGS1
1353	CTcaggtttgcacttTG	circPGS1
1354	TCactcaggtttgcacTT	circPGS1
1355	TCaggtttgcactttgtAA	circPGS1
1356	ACCaaatgagccTTG	circRPTOR
1357	CCaccaaatgagccTT	circRPTOR
1358	CCaccaaatgagcctTG	circRPTOR
1359	TGccaccaaatgagccTT	circRPTOR
1360	TGccaccaaatgagcctTG	circRPTOR
1361	GTgaggcaaatcACC	circRPL26|RP11-849F2.7
1362	TGcagtgaggcaAATC	circRPL26|RP11-849F2.7
1363	GCagtgaggcaaatcAC	circRPL26|RP11-849F2.7
1364	CTgcagtgaggcaaatCA	circRPL26|RP11-849F2.7
1365	GTgaggcaaatcacctgAG	circRPL26|RP11-849F2.7
1366	AAGAtatttgaCCAC	circRP11-206L10.8
1367	GATatttgaccaCATA	circRP11-206L10.8
1368	GATAtttgaccacaTAA	circRP11-206L10.8
1369	TTaagatatttgacCACA	circRP11-206L10.8
1370	TAagatatttgaccaCATA	circRP11-206L10.8
1371	ACatgagaacccTGG	circPIAS2
1372	ATAcatgagaaccCTG	circPIAS2
1373	ATacatgagaaccctGG	circPIAS2
1374	TGatacatgagaacccTG	circPIAS2
1375	TGatacatgagaaccctGG	circPIAS2
1376	CAGaggaagatCTGA	circTYMS
1377	GAGGaagatctgAATT	circTYMS
1378	GAAGatctgaattTTCA	circTYMS
1379	TCAgaggaagatctgAAT	circTYMS
1380	CAtcagaggaagatcTGAA	circTYMS
1381	CAACcaacgtgaAGG	circPPP4R1
1382	AVvaavvaavgtGAAG	circPPP4R1
1383	CAcaccaaccaacgtGA	circPPP4R1
1384	ATccacaccaaccaacGT	circPPP4R1
1385	AVvaavvaavgtgaaggAT	circPPP4R1
1386	GAggacatataCCTT	circZNF91
1387	AGGacatatacctTTC	circZNF91
1388	GAcatatacctttcCAT	circZNF91
1389	GAcatatacctttccaTA	circZNF91
1390	GAcatatacctttccatAG	circZNF91
1391	TGcctcacattgcGG	circWDR62
1392	ATgtctctgttgccTC	circWDR62
1393	TGttgcctcacattgCG	circWDR62
1394	TGtctctgttgcctcaCA	circWDR62
1395	GAtgtctctgttgcctcAC	circWDR62
1396	ACTcagctcacGAAG	circADCK4
1397	GCactcagctcacgAA	circADCK4
1398	GCactcagctcacgaAG	circADCK4
1399	GGcactcagctcacgAA	circADCK4
1400	GGgcactcagctcacgaAG	circADCK4
1401	ATttcttcctgtgGC	circARHGAP35
1402	AAcatttcttccTGTG	circARHGAP35
1403	CCaacatttcttcctGT	circARHGAP35
1404	AGccaacatttcttccTG	circARHGAP35
1405	AAcatttcttcctgtggCT	circARHGAP35
1406	CGggtggccatgcAG	circNUCB1
1407	GTggccatgcagtaTG	circNUCB1
1408	GTggccatgcagtatGA	circNUCB1
1409	CGggtggccatgcagtAT	circNUCB1
1410	GGccatgcagtatgaagAA	circNUCB1
1411	TCatcaccggccaTG	circSNORD33|RPL1 3A.1
1412	TCtcatcaccggccAT	circSNORD33|RPL1 3A.1
1413	TCtcatcaccggccaTG	circSNORD33|RPL1 3A.1
1414	GTtctcatcaccggccAT	circSNORD33|RPL1 3A.1
1415	GTtctcatcaccggccaTG	circSNORD33|RPL1 3A.1
1416	ATcaccggcctcaGA	circSNORD33|RPL1 3A.2
1417	TCtcatcaccggccTC	circSNORD33|RPL1 3A.2
1418	ATcaccggcctcagaTG	circSNORD33|RPL1 3A.2
1419	ATcaccggcctcagatGG	circSNORD33|RPL1 3A.2
1420	GTtctcatcaccggcctCA	circSNORD33|RPL1 3A.2
1421	AGttctcagatGGTA	circSNORD33|RPL1 3A.3
1422	AGttctcagatggTAG	circSNORD33|RPL1 3A.3
1423	AAgttctcagatgGTAG	circSNORD33|RPL1 3A.3
1424	AGaagttctcagatggTA	circSNORD33|RPL1 3A.3
1425	AGaagttctcagatggtAG	circSNORD33|RPL1 3A.3
1426	CGgcttagtgcgaTG	circMUC16
1427	ACcccggcttagtgCG	circMUC16
1428	ACcaccccggcttagTG	circMUC16
1429	ACcccggcttagtgcgAT	circMUC16
1430	CCaccccggcttagtgcGA	circMUC16
1431	GAatagccaagGTCT	circLZIC
1432	CTgaatagccaagGTC	circLZIC
1433	CTgaatagccaaggtCT	circLZIC
1434	GCctgaatagccaaggTC	circLZIC
1435	AAtagccaaggtctgtaGA	circLZIC
1436	TTCCtagaacaGATC	circSNX5|SNORD17 |OVOL2.1
1437	CCtagaacagatcAGA	circSNX5|SNORD17 |OVOL2.1
1438	TTcctagaacagaTCAG	circSNX5|SNORD17 |OVOL2.1
1439	TTcctagaacagatcAGA	circSNX5|SNORD17 |OVOL2.1
1440	AGaacagatcagatttTCA	circSNX5|SNORD17 |OVOL2.1
1441	CTAgaacaggaTCAG	circSNX5|SNORD17 |OVOL2.2
1442	TAGaacaggatcAGAT	circSNX5|SNORD17 |OVOL2.2
1443	CCtagaacaggatcaGA	circSNX5|SNORD17 |OVOL2.2
1444	CCtagaacaggatcagAT	circSNX5|SNORD17 |OVOL2.2
1445	TTcctagaacaggatcaGA	circSNX5|SNORD17 |OVOL2.2
1446	TCggatgcaggaGAG	circSNORA71A|SNH G17
1447	CGgatgcaggagagTT	circSNORA71A|SNH G17
1448	CGgatgcaggagagtTG	circSNORA71A|SNH G17
1449	CGgatgcaggagagttGT	circSNORA71A|SNH G17
1450	AGgagagttgtgtgaaaGC	circSNORA71A|SNH G17
1451	GCtctgcgcaggtCC	circPLTP
1452	TGctgggctctgcgCA	circPLTP
1453	TGctgggctctgcgcAG	circPLTP
1454	AAtcactgctgggctcTG	circPLTP
1455	GCtgggctctgcgcaggTC	circPLTP
1456	GAcacagccctttGC	circTMEM230
1457	CTgacacagcccttTG	circTMEM230
1458	CTgacacagccctttGC	circTMEM230
1459	TGacacagccctttgcTG	circTMEM230
1460	AAcacgctgacacagccCT	circTMEM230
1461	TCcctgaggcgtaTT	circCYP24A1
1462	CTtccctgaggcgtAT	circCYP24A1
1463	CTtccctgaggcgtaTT	circCYP24A1
1464	CCcttccctgaggcgtAT	circCYP24A1
1465	TCcctgaggcgtattatCG	circCYP24A1
1466	GACTgggacagcgAG	circZBTB46
1467	TCttctacagactgGG	circZBTB46
1468	AGactggacagcgaGT	circZBTB46
1469	TCttctacagactgggAV	circZBTB46
1470	CTacagactgggacagcGA	circZBTB46
1471	GAttgagatggCTCA	circGART
1472	CTgattgagatggCTC	circGART
1473	CTgattgagatggctCA	circGART
1474	AGAtggctcaaatGAAG	circGART
1475	TCactgattgagatggcTC	circGART
1476	ACccatcttaccaGG	circRAB3GAP1
1477	ATacccatcttaccAG	circRAB3GAP1
1478	AAtatacccatctTACC	circRAB3GAP1
1479	GAagtaaatataccCATC	circRAB3GAP1
1480	ATatacccatcttaccaGG	circRAB3GAP1
1481	AVActggttagTTAG	circDYRK1A
1482	TATaacactggtTAGT	circDYRK1A
1483	AACTataacactgGTTA	circDYRK1A
1484	CAaaactataacacTGGT	circDYRK1A
1485	TAtaacactggttagtTAG	circDYRK1A
1486	TAtgtcaggtgCACA	circUNKNOWN0000 0007
1487	TAtgtcaggtgcaCAG	circUNKNOWN0000 0007
1488	GGgtatgtcaggtgcAV	circUNKNOWN0000 0007
1489	TAtgtcaggtgcacagTG	circUNKNOWN0000 0007
1490	TAtgtcaggtgcacagtGG	circUNKNOWN0000 0007
1491	GTccatgtccacgGT	circCOL18A1.1
1492	TGggtccatgtccaCG	circCOL18A1.1
1493	CAtgtccacggtgtcTC	circCOL18A1.1
1494	ATgtccacggtgtctcCT	circCOL18A1.1
1495	GTccatgtccacggtgtCT	circCOL18A1.1
1496	ACAcacaatacGCAC	circCOL18A1.2
1497	ACacacacaataCGCA	circCOL18A1.2
1498	ACacacacacaataCGC	circCOL18A1.2
1499	CACacacacaatacgcAC	circCOL18A1.2
1500	CAcacacacacaatacgCA	circCOL18A1.2
1501	CCtctaggcttgaCA	circNBAS
1502	CCtctaggcttgacAT	circNBAS
1503	GCctctaggcttgacAT	circNBAS
1504	TAggcttgacatttccCA	circNBAS
1505	AGgcttgacatttcccaAT	circNBAS
1506	GGgccgacgcgcgAC	circCH507-513H4.1.1
1507	GGGCcgacgcgcgaCG	circCH507-513H4.1.1
1508	GCcgacgcgcgacggCG	circCH507-513H4.1.1
1509	CGacgcgcgacggcggaCG	circCH507-513H4.1.1
1510	CAcgggaccttccGC	circCH507-513H4.1.2
1511	CAcgggaccttccgCG	circCH507-513H4.1.2
1512	GCacgggaccttccgCG	circCH507-513H4.1.2
1513	GGgcacgggaccttccGC	circCH507-513H4.1.2
1514	GGgcacgggaccttccgCG	circCH507-513H4.1.2
1515	CAacacgcccccgCG	circCH507- 513H4.1.3
1516	CAacacgcccccgcGC	circCH507- 513H4.1.3
1517	ACgcaacacgccccGC	circCH507- 513H4.1.3
1518	ACgcaacacgcccccgCG	circCH507- 513H4.1.3
1519	GCacgcaacacgcccccGC	circCH507- 513H4.1.3
1520	CAcctcctcttTTAA	circANKAR
1521	AGcttcacctcctcTT	circANKAR
1522	CTtcacctcctctttTA	circANKAR
1523	CAgcttacacctcctctTT	circANKAR
1524	GCttcacctcctcttttAA	circANKAR
1525	CTCTgaacacatCTG	circGL5
1526	TCTgaacacatcTGGA	circGL5
1527	TCtgaacacatctGGAA	circGL5
1528	TGctctgaacacatctGG	circGL5
1529	TCtgaacacatctggaaGT	circGL5
1530	TGcgaagtgagtGGT	circBMOPR2
1531	TGcgaagtgagtggTG	circBMOPR2
1532	CGaagtgagtggtgTTG	circBMOPR2
1533	CGaagtgagtggtgttGT	circBMOPR2
1534	CGaagtgagtggtgttgTG	circBMOPR2
1535	AGacggctgaaccCT	circRHBDD1
1536	CGgctgaaccctggTG	circRHBDD1
1537	GAcggctgaaccctgGT	circRHBDD1
1538	TGaaccctggtgagaaTA	circRHBDD1
1539	AACcctggtgagaataAAT	circRHBDD1
1540	CCatacacatgaGGT	circATG16L1|SCARNA5
1541	TCccatacacatgaGG	circATG16L1|SCARNA5
1542	GAtcccatacacatgAG	circATG16L1|SCARNA5
1543	ATcccatacacatgagGT	circATG16L1|SCARNA5
1544	TGatcccatacacatgaGG	circATG16L1|SCARNA5
1545	GATGgtcgtaaAACT	circDGKD
1546	GATggtcgtaaaACTG	circDGKD
1547	ATggtcgtaaaacTGTT	circDGKD
1548	TGATggtcgtaaaacTGT	circDGKD
1549	TGgtcgtaaaactgttgTT	circDGKD
1550	CTtctctgtggtCTT	circPASK
1551	GTcttctctgtggtCT	circPASK
1552	CTgtcttctctgtggTC	circPASK
1553	CTccatctgtcttctcTG	circPASK
1554	TCcatctgtcttctctgTG	circPASK
1555	CTttacttgaaGCGG	circPPP6R2
1556	TTTacttgaagcGGAC	circPPP6R2
1557	TCtttacttgaagcgGA	circPPP6R2
1558	TCtttacttgaagcggAC	circPPP6R2
1559	ATAatctctttacttGAAG	circPPP6R2
1560	GTttagctgtcACAG	circBIRC6
1561	GTttagctgtcacaGA	circBIRC6
1562	ACctggtttagctgtCA	circBIRC6
1563	ACctggtttagctgtcAC	circBIRC6
1564	GTttagctgtcacagaaTC	circBIRC6
1565	AGttagcctttTGAT	circPRKD3
1566	AGttagccttttGATA	circPRKD3
1567	ACatatagttagcCTTT	circPRKD3
1568	TGacatatagttagcCTT	circPRKD3
1569	TTagccttttgataaaCTA	circPRKD3
1570	AGactttctttTGCT	circKIAA1841|RP11- 493E12.3
1571	GActttcttttgCTTC	circKIAA1841|RP11- 493E12.3
1572	AAgactttcttttGCTT	circKIAA1841|RP11- 493E12.3
1573	AGactttcttttgcttCC	circKIAA1841|RP11- 493E12.3
1574	ATGacagaacaagacTTTC	circKIAA1841|RP11- 493E12.3
1575	CGaggaccacaTGAC	circRTKN
1576	TAacgaggaccaCATG	circRTKN
1577	TAacgaggaccacaTGA	circRTKN
1578	TGTaacgaggaccacAT	circRTKN
1579	GTaacgaggaccactgAC	circRTKN
1580	TCAcaacttgaAGGG	circELMOD3
1581	ACTcacaacttgAAGG	circELMOD3
1582	ACtcacaacttgaaGGG	circELMOD3
1583	TCtgtactcacaacttGA	circELMOD3
1584	TGtactcacaacttaaGG	circELMOD3
1585	TGgtggagcttcTTT	circREV1
1586	GAgcttctttccaCAA	circREV1
1587	GAgcttctttccacaAT	circREV1
1588	GAgcttctttccacaaTC	circREV1
1589	CTtctttccacaatccaTT	circREV1
1590	ACtgatgtcaccTGT	circZBTB20
1591	TCacctgtgtgtacGA	circZBTB20
1592	TGtcacctgtgtgtaCG	circZBTB20
1593	GAtgtcacctgtgtgtAC	circZBTB20
1594	ATgtcacctgtgtgtacGA	circZBTB20
1595	GCagattgcactCTT	circTIMMDC1
1596	AGattgcactcttcCA	circTIMMDC1
1597	GTgcagattgcactcTT	circTIMMDC1
1598	GCagattgcactcttcCA	circTIMMDC1
1599	ATgtgcagattgcactcTT	circTIMMDC1
1600	CTggcaactcacGAG	circACAD9
1601	CTggcaactcacgaGG	circACAD9
1602	TGgcaactcacgaggAG	circACAD9
1603	CTggcaactcacgaggAG	circACAD9
1604	CAACtcacgaggaggcCGC	circACAD9
1605	TCaggttgattgGGT	circPLXND1
1606	GTtcaggttgattgGG	circPLXND1
1607	TCgttcaggttgattGG	circPLXND1
1608	CGttcaggttgattggGT	circPLXND1
1609	CTcgttcaggttgattgGG	circPLXND1
1610	CCccgcttggcaaAG	circHDAC11
1611	CAccccgcttggcaAA	circHDAC11
1612	TGgaagccaccccgcTT	circGDAC11
1613	TGgaagccaccccgctTG	circGDAC11
1614	TGgaagccacccgcttGG	circGDAC11
1615	TAGTtactgtaAAGT	circCEP70
1616	TAGTtactgtaaAGTT	circCEP70
1617	GAAAcatagttacTGTA	circCEP70
1618	CCggaaacatagttacTG	circCEP70
1619	ACatagttactgtaaAGTT	circCEP70
1620	TCACcatgaaaATGA	circRNF13.1
1621	CACCatgaaaatgACT	circRNF13.1
1622	CACcatgaaaatgACTA	circRNF13.1
1623	GTtgtaaaatcaccaTGA	circRNF13.1
1624	TCgttgtaaaatcaccATG	circRNF13.1
1625	CACCtttcttgaATT	circRNF13.2
1626	ATCacctttcttGAAT	circRNF13.2
1627	CACctttcttgaatTTA	circRNF13.2
1628	GTaaatcacctttCTTG	circRNF13.2
1629	TAaaatcacctttctTGAA	circRNF13.2
1630	GTctctcctgcacCT	circGOLIM4
1631	TGtatacagtctctCC	circGOLIM4
1632	CAgtctctcctgcacCT	circGOLIM4
1633	TCtctcctgcacctctCG	circGOLIM4
1634	AAttgtatacagtctctCC	circGOLIM4
1635	GCcatcatttcaCAT	circEIF4A2|SNORD2.1
1636	CCatcatttcacatCA	circEIF4A2|SNORD2.1
1637	TGccatctttcacaTC	circEIF4A2|SNORD2.1
1638	TTgccatcatttcacaTC	circEIF4A2|SNORD2.1
1639	CCatcatttcacatcaaAT	circEIF4A2|SNORD2.1
1640	TTTcacatttaCCGA	circEIF4A2|SNORD2.2
1641	CAtttcacatttACCG	circEIF4A2|SNORD2.2
1642	ATcatttcacattTACC	circEIF4A2|SNORD2.2
1643	TCatttcacatttacCGA	circEIF4A2|SNORD2.2
1644	GCcatcatttcacatttAC	circEIF4A2|SNORD2.2
1645	TCTggctgtgcaAAT	circSDHAP1
1646	GTGCaaatttcaaAGT	circSDHAP1
1647	GTgcaaatttcaaAGTC	circSDHAP1
1648	TGgctgtgcaaatttCAA	circSDHAP1
1649	GCaaatttcaaagtccaGA	circSDHAP1
1650	GGTgttctgaatcCT	circSETD2
1651	GTgttctgaatccTTC	circSETD2
1652	GTgttctgaatccttCT	circSETD2
1653	TTctgaatccttcttACG	circSETD2
1654	GAcaaaggtgttctgaATC	circSETD2
1655	CAtaccgccattGAG	circSCAP
1656	CAcataccgccattGA	circSCAP
1657	CCcacataccgccatTG	circSCAP
1658	CAcataccgccattgaGG	circSCAP
1659	CCcacataccgccattgAG	circSCAP
1660	AGataccttcaaCCT	circUSP4
1661	GTCaataagataCCTT	circUSP4
1662	AATAagataccttCAAC	circUSP4
1663	GTcaataagatacctTCA	circUSP4
1664	ATaagataccttcaaccTC	circUSP4
1665	ACtcacgcagcatGT	circRPL29
1666	GCactcacgcagcaTG	circRPL29
1667	GCactcacgcagcatGT	circRPL29
1668	GTgcactcacgcagcaTG	circRPL29
1669	TCagtgcactcacgcagCA	circRPL29
1670	GCtcttccagaaGAC	circPHF7
1671	GCtcttccagaagaCA	circPHF7
1672	TTCCagaagacagAAAT	circPHF7
1673	TAcaggctcttccagaAG	circPHF7
1674	CCAgaagacagaaataATG	circPHF7
1675	GTttcctttcctcTC	circNEK4
1676	CTttcctctctaTCAA	circNEK4
1677	GTttcctttcctctcTA	circNEK4
1678	CCtttcctctctatcaAA	circNEK4
1679	TTcctctctatcaaattCA	circNEK4
1680	TAcatggagaccgGG	circFLNB
1681	ACtacatggagaccGG	circFLNB
1682	ACtacatggagaccgGG	circFLNB
1683	CCactacatggagaccGG	circFLNB
1684	CCactacatggagaccgGG	circFLNB
1685	AGCagctctctTAAA	circSLC25A26
1686	GCAgctctcttaaAAC	circSLC25A26
1687	TGcagcagctctcttAA	circSLC25A26
1688	TGcagcagctctcttaAA	circSLC25A26
1689	AGcagctctcttaaaacTG	circSLC25A26
1690	TCtgaagtttgACCT	circNFKB1
1691	ATtctgaagtttGACC	circNFKB1
1692	ATtctgaagtttgaCCT	circNFKB1
1693	CCattctgaagtttgaCC	circNFKB1
1694	CCattctgaagtttgacCT	circNFKB1
1695	TGtttccggtggtGG	circFIP1L1|RP11-231C18.3
1696	AAgtgctgtttccgGT	circFIP1L1|RP11-231C18.3
1697	AGaagtgctgtttccGG	circFIP1L1|RP11-231C18.3
1698	TGctgtttccggtggtGG	circFIP1L1|RP11-231C18.3
1699	AAgtgctgtttccggtgGT	circFIP1L1|RP11-231C18.3
1700	CCAaggagaaaCTTG	circTBC1D14
1701	AAGGagaaacttGCAA	circTBC1D14
1702	CCaaggagaaacttgCA	circTBC1D14
1703	GAGaaacttgcaaaGAAG	circTBC1D14
1704	TTggtccaaggagaaacTT	circTBC1D14
1705	AAGGttacttcATTC	circALB.1
1706	GGGAaataaaggTTAC	circALB.1
1707	ATAaaggttacttCATT	circALB.1
1708	GGAaataaaggttaCTTC	circALB.1
1709	AGggaaataaaggttACTT	circALB.1
1710	TTCcaacagagGTTT	circALB.2
1711	CAacagaggttttTGC	circALB.2
1712	CAacagaggtttttgCA	circALB.2
1713	CAacagaggtttttgCAA	circALB.2
1714	TTttccaacagaggttTTT	circALB.2
1715	ACGAcagagtaATCA	circALB.3
1716	AGTaatcaggatGTTT	circALB.3
1717	CAgagtaatcaggaTGT	circALB.3
1718	AGagtaatcaggatGTTT	circALB.3
1719	GAcagagtaatcaggatGT	circALB.3
1720	CCactgatcatctGG	circNUP54
1721	CCactgatcatctgGC	circNUP54
1722	CActgatcatctggCAA	circNUP54
1723	CActgatcatctggcaAT	circNUP54
1724	AAtcctccaaacccactGA	circNUP54
1725	TGTAcaaactcaACT	circAFF1
1726	GTCAttgtacaaaCTC	circAFF1
1727	GTAcaaactcaacTGAC	circAFF1
1728	GTacaactcaactgACT	circAFF1
1729	TGtacaaactcaactgACT	circAFF1
1730	CGtatgttggctTCA	circSLC12A7|MIR46 35
1731	ACcgtatgttggctTC	circSLC12A7|MIR46 35
1732	GGgaccgtatgttggCT	circSLC12A7|MIR46 35
1733	GAccgtatgttggcttCA	circSLC12A7|MIR46 35
1734	TTagggaccgtatgttgGC	circSLC12A7|MIR46 35
1735	TGgccctgggtcgTT	circMAN2A1.1
1736	GCcctgggtcgttaTG	circMAN2A1.1
1737	GCcctgggtcgttatGG	circMAN2A1.1
1738	CTggccctgggtcgttAT	circMAN2A1.1
1739	TGagagctggccctgggTC	circMAN2A1.1
1740	GCccttttaacagCA	circMAN2A1.2
1741	GCtggcccttttaaCA	circMAN2A1.2
1742	AGagctggcccttttAA	circMAN2A1.2
1743	ATtgagagctggccctTT	circMAN2A1.2
1744	GCccttttaacagcatcCT	circMAN2A1.2
1745	TCattcttaacCTCC	circAFF4
1746	TCAttcttaacctcCT	circAFF4
1747	ATcttcattcttaaCCT	circAFF4
1748	TCttcattcttaacctCC	circAFF4
1749	TCatcttcattcttaacCT	circAFF4
1750	ATCattcaattCCTT	circUBE2D2
1751	ATTCaattcctttTGA	circUBE2D2
1752	GAtcattcaattcCTTT	circUBE2D2
1753	CAATtccttttgaaATAG	circUBE2D2
1754	ATtccttttgaaataGTTA	circUBE2D2
1755	AGactgcgactttGT	circANKHD1|ANKHD1-EIF4EBP3
1756	AGactgcgactttgTA	circANKHD1|ANKHD1-EIF4EBP3
1757	AGactgcgactttgtAG	circANKHD1|ANKHD1-EIF4EBP3
1758	ACtgcgactttgtagcAA	circANKHD1|ANKHD1-EIF4EBP3
1759	ACtgcgactttgtagcaAG	circANKHD1|ANKHD1-EIF4EBP3
1760	AGATcctctatGAAT	circMAPK9
1761	GTttcagatcctcTAT	circMAPK9
1762	GATcctctatgaaTTAT	circMAPK9
1763	CAgatcctctatgaaTTA	circMAPK9
1764	TTcagatcctctatgaATT	circMAPK9
1765	ATtctgtgttctgCC	circGPBP1
1766	CGgaggatattcTGTG	circGPBP1
1767	GAtattctgtgttctGC	circGPBP1
1768	ATtctgtgttctgcctCA	circGPBP1
1769	GAtattctgtgttctgcCT	circGPBP1
1770	CAgcggagtgaagGT	circCEP72
1771	CTcagcggagtgaaGG	circCEP72
1772	AGctcagcggagtgaAG	circCEP72
1773	GCtcagcggagtgaagGT	circCEP72
1774	AAtgactgaagctcagcGG	circCEP72
1775	AAtcaccatccatGGT	circRP11-98J23.2
1776	GCaatcaccatcctGG	circRP11-98J23.2
1777	GCaatcaccatcctgGT	circRP11-98J23.2
1778	AAtcaccatcctggtgAA	circRP11-98J23.2
1779	CAtcctggtgaagccttAC	circRP11-98J23.2
1780	CCtctgtaggctTAA	circFAM169A
1781	ATcctctgtaggctTA	circFAM169A
1782	CCatcctctgtaggcTT	circFAM169A
1783	AAtgccatcctctgtaGG	circFAM169A
1784	ATcctctgtaggcttaaCT	circFAM169A
1785	CAaataataacTGTT	circWDR41
1786	TGCAaataataaCTGT	circWDR41
1787	CAGcagatgcaaaTAAT	circWDR41
1788	GCAaataataactgtTCT	circWDR41
1789	GCaaataataactgtTCTA	circWDR41
1790	ACtgctggtggacTC	circRASGRF2
1791	GGactgctggtggaCT	circRASGRF2
1792	AGactctaggactgcTG	circRASGRF2
1793	AGgactgctggtggacTC	circRASGRF2
1794	CTaggactgctggtggaCT	circRASGRF2
1795	TTtctttcctggTGT	circRHOBTB3
1796	TTtttctttcctgGTG	circRHOBTB3
1797	TTtttctttcctggtGT	circRHOBTB3
1798	TTtctttcctggtgtttTT	circRHOBTB3
1799	AGttgaatgatCTGC	circCEP85L
1800	TGatctgcaaacTAGC	circCEP85L
1801	GAtctgcaaactagcCA	circCEP85L
1802	GAtctgcaaactagccAC	circCEP85L
1803	GAatgatctgcaaactaGC	circCEP85L
1804	CAagacttcaaCCTG	circARID1B.1
1805	TTcaacctgggaTACT	circARID1B.1
1806	CCaagacttcaacctGG	circARID1B.1
1807	TTcaacctgggatactTG	circARID1B.1
1808	CAagacttcaacctgggAT	circARID1B.1
1809	CAgacagatcctCTT	circARID1B.2
1810	GCcagacagatcctCT	circARID1B.2
1811	AGatcctctttcctgTG	circARID1B.2
1812	GGagccagacagatccTC	circARID1B.2
1813	GAgccagacagatcctcTT	circARID1B.2
1814	CTtacaaatctCGCT	circTULP4|RP11- 732M18.4
1815	GTCttacaaatcTCGC	circTULP4|RP11- 732M18.4
1816	GAgtcttacaaatCTCG	circTULP4|RP11- 732M18.4
1817	AGtcttacaaatctcgCT	circTULP4|RP11- 732M18.4
1818	AGtcttacaaatctcgcTA	circTULP4|RP11- 732M18.4
1819	CAgcacctttcagCC	circTULP4
1820	CCaaacagcaccttTC	circTULP4
1821	AAacagcacctttcaGC	circTULP4
1822	GTgccaaacagcacctTT	circTULP4
1823	TGccaaacagcacctttCA	circTULP4
1824	TAgccctgcacatGT	circTMEM181
1825	CTttagccctgcacAT	circTMEM181
1826	TTtagccctgcacatGT	circTMEM181
1827	GGctttagccctgcacAT	circTMEM181
1828	TTtgaattggctttagcCC	circTMEM181
1829	CTTgggcgatttcTC	circHIST1H3B
1830	CGatttctcgttaGC	circHIST1H3B
1831	CGatttctcgcttagCA	circHIST1H3B
1832	GGgcgatttctcgcttAG	circHIST1H3B
1833	ATttctcgcttagcatgGA	circHIST1H3B
1834	GTGTctctgaaaAGA	circHIST1H3C.2
1835	AAGTgtctctgaaAAG	circHIST1H3C.2
1836	CAcaaaagtgtctCTGA	circHIST1H3C.2
1837	CAcacaaaagtgtctCTG	circHIST1H3C.2
1838	CAcacacaaaagtgtctCT	circHIST1H3C.2
1839	GCcgaccaaagccAA	circUNKNOWN00000008
1840	CCgaccaaagccaaAG	circUNKNOWN00000008
1841	GGccgaccaaagccaAA	circUNKNOWN00000008
1842	CCgaccaaagccaaagGC	circUNKNOWN00000008
1843	AGctaaccggccgaccaAA	circUNKNOWN00000008
1844	CTTgggaagcggTAA	circC6orf136
1845	TTGggaagcggtaATG	circC6orf136
1846	GCttgggaagcggtaAT	circC6orf136
1847	GCttgggaagcggtaaTG	circC6orf136
1848	TGggaagcggtaatgctCG	circC6orf136
1849	GAgacatccagccCA	circHLA-C|HLA-B|XXbac-BPG248L24.10 |WASF5P |XXbac-BPG248L24.13.1
1850	GAgacatccagcccAC	circHLA-C|HLA-B |XXbac-BPG248L24.10 |WASF5P|XXbac-BPG248L24.13.1
1851	GAgacatccagcccaCC	circHLA-C|HLA-B |XXbac-BPG248L24.10 |WASF5P|XXbac-BPG248L24.13.1
1852	CAgcccacctctctggAA	circHLA-C|HLA-B |XXbac-BPG248L24.10|WASF5P|XXbac-BPG248L24.13.1
1853	ATggagacatccagcccAC	circHLA-C|HLA- B|XXbac- BPG248L24.10|WA SF5P|XXbax-BPG248L24.13.1
1854	CTtttccacctgaGC	circHLA-C|HLA- B|XXbac- BPG248L24.10|WA SF5P|XXbax-BPG248L24.13.2
1855	CTccttttccacctGA	circHLA-C|HLA- B|XXbac- BPG248L24.10|WA SF5P|XXbax-BPG248L24.13.2
1856	CTccttttccacctgAG	circHLA-C|HLA- B|XXbac- BPG248L24.10|WA SF5P|XXbax-BPG248L24.13.2
1857	CTccttttccacctgaGC	circHLA-C|HLA- B|XXbac- BPG248L24.10|WA SF5P|XXbax-BPG248L24.13.2
1858	TCcttttccacctgagcTC	circHLA-C|HLA- B|XXbac- BPG248L24.10|WA SF5P|XXbax-BPG248L24.13.2
1859	GTAtccatctcTAAC	circFKBP5
1860	GTatccatctctaaCC	circFKBP5
1861	GTatccatctctaacCA	circFKBP5
1862	GTatccatctctaaccAG	circFKBP5
1863	TCtttggtatccatctcTA	circFKBP5
1864	ACACttggcaaaTCG	circCNPY3
1865	TTtacacacttgGCAA	circCNPY3
1866	ACacacttggcaaATCG	circCNPY3
1867	TAtttacacacttggCAA	circCNPY3
1868	TTacacacttggcaaatCG	circCNPY3
1869	TACCtacgcagggAC	circSRF
1870	ATccctacctacgcAG	circSRF
1871	CTacctacgcagggaCT	circSRF
1872	CCctacctacgcagggAC	circSRF
1873	CTacctacgcagggactGG	circSRF
1874	GTgagggaggaagGG	circRN7SK
1875	CGgtgagggaggaaGG	circRN7SK
1876	CGgtgagggaggaagGG	circRN7SK
1877	AGcggtgagggaggaaGG	circRN7SK
1878	AGcggtgagggaggaagGG	circRN7SK
1879	TAACtgaattgACCA	circFARS2
1880	ACCagcaaataacTGA	circFARS2
1881	AGCAaataactgaATTG	circFARS2
1882	TACcagcaaataacTGAA	circFARS2
1883	TTataccagcaaataACTG	circFARS2
1884	GCAGagacatatTTG	circMLIP
1885	CACcagcagagacaTA	circMLIP
1886	CAgcagagacataTTTG	circMLIP
1887	ACcaccagcagagacaTA	circMLIP
1888	AGacatatttggtttctCG	circMLIP
1889	CTAggagtgtcTTTA	circZNF292
1890	CTaggagtgtctTTAT	circZNF292
1891	CTaggagtgtctttATC	circZNF292
1892	CTaggagtgtctttatCC	circZNF292
1893	AGtgtctttatccttatCC	circZNF292
1894	AAcattgattgTGCC	circPNRC1
1895	AAAAcattgattGTGC	circPNRC1
1896	AAaacattgattgTGCC	circPNRC1
1897	TTAaaacattgattGTGC	circPNRC1
1898	TTGAttttaaaacatTGAT	circPNRC1
1899	GTcacgaggaaTAGT	circUNKNOWN0000 0009
1900	TCACgaggaataGTAAA	circUNKNOWN0000 0009
1901	AGtcacgagaggaataGTA	circUNKNOWN0000 0009
1902	CTtacagtcacgaggAAT	circUNKNOWN0000 0009
1903	AGtcacgaggaatagTAAA	circUNKNOWN0000 0009
1904	ACcaccggcattgTA	circNDUFB2
1905	CGgcattgtacagaGT	circNDUFB2
1906	ACcggcattgtacagAG	circNDUFB2
1907	CCaccggcattgtacaGA	circNDUFB2
1908	ACcggcattgtacagagTG	circNDUFB2
1909	GTTAtaatcagCAAT	circKMT2C
1910	TTGTtataatcaGCAA	circKMT2C
1911	TTCAttgttataaTCAG	circKMT2C
1912	TGTTataatcagcaATAA	circKMT2C
1913	GTTataatcagcaataAGA	circKMT2C
1914	TTAgaacacccgGAA	circESYT2
1915	CCttagaacacccgGA	circESYT2
1916	ATccttagaacacccGG	circESYT2
1917	TCcttagaacacccggAA	circESYT2
1918	TTagaacacccggaaggTT	circESYT2
1919	GTcatggcaccgtAG	circMPP6
1920	TAgtcatggcaccgTA	circMPP6
1921	TTtagtcatggcaccGT	circMPP6
1922	GTcatggcaccgtagtTC	circMPP6
1923	GCaaaatgatttagtCATG	circMPP6
1924	TTcgtcaaccttGCA	circHERPUD2
1925	CCttcgtcaaccttGC	circHERPUD2
1926	ATccttcgtcaacctTG	circHERPUD2
1927	TGatccttcgtcaaccTT	circHERPUD2
1928	CAaccttgcattacataTG	circHERPUD2
1929	TCaaacctcatCAGC	circOGDH
1930	AActcctcaaacCTCA	circOGDH
1931	CCtcaaacctcatcaGC	circOGDH
1932	GGaactcctcaaacctCA	circOGDH
1933	AActcctcaaacctcatCA	circOGDH
1934	TCagtggtccctgGG	circZNF680
1935	TGtcagtggtccctGG	circZNF680
1936	AAtgtcagtggtcccTG	circZNF680
1937	ATgtcagtggtccctgGG	circZNF680
1938	AAatgtcagtggtccctGG	circZNF680
1939	GTctcggactacgCC	circKDELR2|DAGLB
1940	TGgtgatggtctcgGA	circKDELR2|DAGLB
1941	GGtctcggactacgcCG	circKDELR2|DAGLB
1942	GGtgatggtctcggacTA	circKDELR2|DAGLB
1943	TGatggtctcggactacGC	circKDELR2|DAGLB
1944	ACACacctgaaTAAG	circZDHHC4
1945	GTtacacacaccTGAA	circZDHHC4
1946	CAgttacacacacCTGA	circZDHHC4
1947	TAcacacacctgaaTAAG	circZDHHC4
1948	ACAcaccctgaataagAAAG	circZDHHC4
1949	AAGCtcaggttcgAT	circCCZ1B
1950	AAAagctcaggtTCGA	circCCZ1B
1951	AAGCtcaggttcgatGT	circCCZ1B
1952	AAaaagctcaggttCGAT	circCCZ1B
1953	GTaccattaaaaagctCAG	circCCZ1B
1954	GCccctggactatGT	circPOM121
1955	GCccctggactatgTT	circPOM121
1956	ACactggcccctggaCT	circPOM121
1957	TGavavtggcccctggAV	circPOM121
1958	CTggcccctggactatgTT	circPOM121
1959	TCatgcgaggacAGT	circBAZ1B
1960	AGtttcatgcgagGAC	circBAZ1B
1961	GTtccagtttcatgcGA	circBAZ1B
1962	TTtcatgcgaggacagTA	circBAZ1B
1963	TCatgcgaggacagtaaTC	circBAZ1B
1964	ACgaccaccttcGC	circGTF2I
1965	TCacacgaccacctTC	circGTF2I
1966	CAcacgaccaccttcTG	circGTF2I
1967	ACacgaccaccttctgCT	circGTF2I
1968	ACacgaccaccttctgcTG	circGTF2I
1969	GAATgcaatagATGT	circSNORA14A
1970	AATGcaatagatGTTG	circSNORA14A
1971	GCaatagatgttgcaGG	circSNORA14A
1972	AAtagatgttgcagGTAT	circSNORA14A
1973	GTTtaagaatgcaatAGAT	circSNORA14A
1974	CAcatatcgagcTGG	circCDK14
1975	GAcacatatcgagCTG	circCDK14
1976	GTgacacatatcgagCT	circCDK14
1977	TGacacatatcgagcTGG	circCDK14
1978	TGTgacacatatcgagcTG	circCDK14
1979	TGgtgtaacatGCTA	circCCDC132
1980	GTaacatgctatgGTA	circCCDC132
1981	GGtgtaacatgctatGG	circCCDC132
1982	CTggtgtaacatgctaTG	circCCDC132
1983	ATgctatggtaattcttGA	circCCDC132
1984	TTGgcaatcagATCT	circTRRAP |MIR3609
1985	CTTTggcaatcagATC	circTRRAP |MIR3609
1986	CActttggcaatcaGAT	circTRRAP |MIR3609
1987	ACtttggcaatcagatCT	circTRRAP |MIR3609
1988	TTggcaatcagatcttaTC	circTRRAP |MIR3609
1989	ACtatttcaaaatAC	circCYP3A7 |CYP3A7-CYP3A51P
1990	AGGAgaactatttCAA	circCYP3A7 |CYP3A7-CYP3A51P
1991	TTtcaaaatacttGGCA	circCYP3A7 |CYP3A7-CYP3A51P
1992	TTTcaaaatacttgGCAA	circCYP3A7 |CYP3A7-CYP3A51P
1993	GAACtatttcaaaatACTT	circCYP3A7 |CYP3A7-CYP3A51P
1994	TGgcccaacctggTA	circCCAT1.1
1995	GTagtgcctggcccAA	circCCAT1.1
1996	CTggcccaacctggtAA	circCCAT1.1
1997	GGcccaacctggtaagTG	circCCAT1.1
1998	GCctggcccaacctggtAA	circCCAT1.1
1999	TGcctggtaagtGG	circCCAT1.2
2000	CCtggcctggtaagTG	circCCAT1.2
2001	GAgtagtgcctggccTG	circCCAT1.2
2002	AGtgcctggcctggtaAG	circCCAT1.2
2003	GAgtagtgcctggcctgGT	circCCAT1.2
2004	AAtcccaacctgGTA	circCCAT1.3
2005	TAaatcccaacctgGT	circCCAT1.3
2006	TTgccattaaatccCAA	circCCAT1.3
2007	TAaatcccaacctggTAA	circCCAT1.3
2008	ATcttgccattaaatccCA	circCCAT1.3
2009	TGtcaggctcccaAC	circCCAT1.4
2010	CTcccaacctggtaAG	circCCAT1.4
2011	TGatgtcaggctcccAA	circCCAT1.4
2012	GAtgtcaggctcccaaCC	circCCAT1.4
2013	CTcccaacctggtaagtGG	circCCAT1.4
2014	TAATaaccaacCTGG	circCCAT1.5
2015	GCCattaataacCAAC	circCCAT1.5
2016	CCAttaataaccaacCT	circCCAT1.5
2017	CCattaataaccaaccTG	circCCAT1.5
2018	GAgagccattaataacCAA	circCCAT1.5
2019	ATacagtcccaacCT	circCCAT1.6
2020	ACAatacagtccCAAC	circCCAT1.6
2021	CAatacagtcccaacCT	circCCAT1.6
2022	GCagacaatacagtccCA	circCCAT1.6
2023	GCagacaatacagtcccAA	circCCAT1.6
2024	GTctctttccaacCT	circCCAT1.7
2025	CTgtctctttccaaCC	circCCAT1.7
2026	CTgtctctttccaacCT	circCCAT1.7
2027	TTtccaacctggtaagTG	circCCAT1.7
2028	ATtgttctgtctctttcCA	circCCAT1.7
2029	TTTgtatgtggCATG	circASAP1
2030	ATttttgtatgtgGCA	circASAP1
2031	CAatttttgtatgtGGC	circASAP1
2032	ATttttgtatgtggcATG	circASAP1
2033	TTctcaatttttgtaTGTG	circASAP1
2034	TGCtgggcagaaaTC	circPTK2.1
2035	TGGgcagaaatcTTTC	circPTK2.1
2036	GCTgggcagaaatcTTT	circPTK2.1
2037	GCtgggcagaaatcttTC	circPTK2.1
2038	TGggcagaaatctttccTC	circPTK2.1
2039	ATCTgtcatattCTG	circPTK2.2
2040	TCATattctgttGATA	circPTK2.2
2041	TGtcatattctgtTGAT	circPTK2.2
2042	TCtgtcatattctgttGA	circPTK2.2
2043	TAtctgtcatattctgtTG	circPTK2.2
2044	CTGgatgatcaATCT	circSLC45A4
2045	TGATcaatctgcaaCA	circSLC45A4
2046	GATgatcaatctgCAAC	circSLC45A4
2047	ATgatcaatctgcaaCAG	circSLC45A4
2048	ATgatcaatctgcaacaGT	circSLC45A4
2049	AGcacatcactaCCA	circADGRB1
2050	ATAagcacatcaCTAC	circADGRB1
2051	TAagccatcactacCA	circADGRB1
2052	CACtataagcacatcaCT	circADGRB1
2053	ACtataagcacatcacTAC	circADGRB1
2054	TCCGgacattcaaAG	circRBPMS
2055	TAgggtccggacatTC	circRBPMS
2056	CGgacattcaaagCATT	circRBPMS
2057	CGgacattcaaagcaTTC	circRBPMS
2058	CGgacattcaaagcattCT	circRBPMS
2059	TGacccttgttcaGG	circFGFR1
2060	ACtgacccttgttcAG	circFGFR1
2061	TGacccttgttcaggCA	circFGFR1
2062	ACtgacccttgttcagGC	circFGFR1
2063	AAactgacccttgttcaGG	circFGFR1
2064	TTACtcatcagcTGA	circHOOK3
2065	TACtcatcagctGAAT	circHOOK3
2066	TCtttactcatcagcTG	circHOOK3
2067	TCatcagctgaatgtTTC	circHOOK3
2068	CAgctgaatgtttcttcTT	circHOOK3
2069	CAtgctttgtcTCTA	circASPH
2070	TGCtttgtctctaaTA	circASPH
2071	ATGctttgtctctaATA	circASPH
2072	CTccatgctttgtctcTA	circASPH
2073	ATGctttgtctctaaTAAA	circASPH
2074	CCagatcagaaGACT	circTMEM245
2075	AACgtccagatcAGAA	circTMEM245
2076	ACcaacgtccagatcAG	circTMEM245
2077	CGtccagatcagaagaCT	circTMEM245
2078	CCaccaacgtccagatcAG	circTMEM245
2079	CAttactgcctggCG	circUNKNOWN00000010
2080	GAcccaccattactGC	circUNKNOWN00000010
2081	TGgacccaccattacTG	circUNKNOWN00000010
2082	CAccattactgcctggCG	circUNKNOWN00000010
2083	ATggacccaccattactGC	circUNKNOWN00000010
2084	TTCCttgattgTAAC	circHSPAS
2085	TTCCttgattgtaaCA	circHSPAS
2086	ATggttccttgattgTA	circHSPAS
2087	ATggttccttgattgTAA	circHSPAS
2088	CGggatggttccttgatTG	circHSPAS
2089	CAtctgttccttTCA	circGLE1
2090	CAtctgttcctttCAT	circGLE1
2091	AAACatctgttccTTTC	circGLE1
2092	CTaaaacatctgttcCTT	circGLE1
2093	AAacatctgttcctttCAT	circGLE1
2094	TCctccaaagtTGTA	circFOCAD
2095	ATtcctccaaagtTGT	circFOCAD
2096	CCtccaaagttgtatTC	circFOCAD
2097	CCaaagttgtattcaAGA	circFOCAD
2098	CCtccaaagttgtattcAA	circFOCAD
2099	GTtgctccgaaACTT	circNFX1
2100	GTtgctccgaaaCTTT	circNFX1
2101	TGctccgaaactttGAT	circNFX1
2102	TGttgctccgaacttTG	circNFX1
2103	GCtccgaaactttgataAG	circNFX1
2104	GATGacaagatGACT	circUBAP2
2105	CAAggacggatgACAA	circUBAP2
2106	GAcggatgacaagaTGA	circUBAP2
2107	AAggacggatgacaaGAT	circUBAP2
2108	CGgatgacaagatgactGA	circUBAP2
2109	GTATagcatacCAAT	circKDM4C|RP11- 146B14.1
2110	GCataccaatttggCA	circKDM4C|RP11- 146B14.1
2111	TAgcataccaatttgGC	circKDM4C|RP11- 146B14.1
2112	GTatacataccaatTTG	circKDM4C|RP11- 146B14.1
2113	AGcataccaatttggcaAC	circKDM4C|RP11- 146B14.1
2114	AGTCttatagtaACA	circAGTPBP1
2115	AGTCttatagtaACAA	circAGTPBP1
2116	AGTCttatagtaaCAAA	circAGTPBP1
2117	ATTAaatcatagtcTTAT	circAGTPBP1
2118	GTCttatagtaacaaaTGT	circAGTPBP1
2119	CTgtgcaaccttTAG	circFAM120A.1
2120	TGtgcaacctttaGTG	circFAM120A.1
2121	CTgtgcaacctttagTG	circFAM120A.1
2122	GCtctgtgcaacctttAG	circFAM120A.1
2123	CTctgtgcaacctttagTG	circFAM120A.1
2124	AACctgtgaatGCTG	circFAM120A.2
2125	TGcaacctgtgaatGC	circFAM120A.2
2126	CTgtgcaacctgtgaAT	circFAM120A.2
2127	CTctgtgcaacctgtgAA	circFAM120A.2
2128	AAcctgtgaatgctgGAAA	circFAM120A.2
2129	GTagaaccatgggCT	circHIATL1
2130	GAaccatgggctgaTC	circHIATL1
2131	GTttcatgtagaacCAT	circHIATL1
2132	TAgaaccatgggctgaTC	circHIATL1
2133	TGtagaaccatgggctgAT	circHIATL1
2134	AAcaccatcttggCC	circPPP2R3B
2135	AAaacaccatctTGGC	circPPP2R3B
2136	AAaacaccatcttggCC	circPPP2R3B
2137	TTaaaacaccatcttgGC	circPPP2R3B
2138	TTaaaacaccatcttggCC	circPPP2R3B
2139	TCACtctctcaATTT	circATRX
2140	GCtcactctctcaaTT	circATRX
2141	CTgctcactctctcaAT	circATRX
2142	AAtcttcactgctcacTC	circATRX
2143	TCactgctcactctctcAA	circATRX
2144	TAcagcacaccaCAC	circTBL1X
2145	CAtacagcacacCACA	circTBL1X
2146	ATacagcacaccacaCA	circTBL1X
2147	ATacagcacaccacacAC	circTBL1X
2148	CAgacatacagcacaccAC	circTBL1X
2285	AATctgtctcttcACC	circFAT1
2286	CGggaatctgtctcTTC	circFAT1
2287	TGTcgggaatctgtCT	circFAT1
2288	ATAcctgtagtacCGA	circHIPK3
2289	TGaggccatacctgtAG	circHIPK3
2290	ATATttttctggcAATC	circCORO1C
2291	ATTtttctggcaatCTC	circCORO1C
2292	AGgcctcaagcccaGC	circPVT1
2293	GGcctcaagcccagCT	circPVT1
2294	CTTagtctcctcATAA	circFIRRE
2295	GACaccttagtctcCT	circFIRRE
2296	TCTCctcataaaGTAT	circFIRRE
2297	TATCtgcaatagTCAA	circCCT3
2298	TGCAatagtcaaGAAT	circCCT3
2299	CTGcatatttttctgGC	circCORO1C

In the examples and figures, compounds named CRM0167-CRM170 and CRM0172-CRM0174 and CRM0175-CRM0182 corresponds to SEQ ID NO’s: 2285-2288 and SEQ ID NO’s: 2289-2291 and SEQ ID NO’s 2292-2298 respectively. CRM0171 correspond to SEQ ID NO: 374. CRM0175 corresponds to SEQ ID NO 2299.

Each compound listed in Table 2 is to be viewed as single embodiments. In some preferred embodiments, the LNA units in the wings of the antisense oligonucleotide of the invention are Beta-D-Oxy LNA and the antisense oligonucleotide is anyone of SEQ ID NOs: 360 - 2148 or anyone of SEQ ID NO’s: 2285-2299. In some preferred embodiments, the LNA units in the wings of the antisense oligonucleotide of the invention are alpha-L-oxy-LNA and the antisense oligonucleotide is anyone of SEQ ID NOs: 360 - 2148 or anyone of SEQ ID NO’s: 2285-2299. In some preferred embodiments, the LNA units in the wings of the antisense oligonucleotide of the invention are beta-D-amino-LNA and the antisense oligonucleotide is anyone of SEQ ID NOs: 360 - 2148 or anyone of SEQ ID NO’s: 2285-2299. In some preferred embodiments, the LNA units in the wings of the antisense oligonucleotide of the invention are alpha-L-amino-LNA and the antisense oligonucleotide is anyone of SEQ ID NOs: 360 - 2148 or anyone of SEQ ID NO’s: 2285-2299. In some preferred embodiments, the LNA units in the wings of the antisense oligonucleotide of the invention are beta-D-thio-LNA and the antisense oligonucleotide is anyone of SEQ ID NOs: 360 - 2148 or anyone of SEQ ID NO’s: 2285-2299. In some preferred embodiments, the LNA units in the wings of the antisense oligonucleotide of the invention are alpha-L-thio-LNA and the antisense oligonucleotide is anyone of SEQ ID NOs: 360 - 2148 or anyone of SEQ ID NO’s: 2285-2299. In some preferred embodiments, the LNA units in the wings of the antisense oligonucleotide of the invention are 5′-methyl-LNA and the antisense oligonucleotide is anyone of SEQ ID NOs: 360 - 2148 or anyone of SEQ ID NO’s: 2285-2299. In some preferred embodiments, the LNA units in the wings of the antisense oligonucleotide of the invention are beta-D-ENA and the antisense oligonucleotide is anyone of SEQ ID NOs: 360 - 2148 or anyone of SEQ ID NO’s: 2285-2299. In some preferred embodiments, the LNA units in the wings of the antisense oligonucleotide of the invention are alpha-L-ENA and the antisense oligonucleotide is anyone of SEQ ID NOs: 360 - 2148 or anyone of SEQ ID NO’s: 2285-2299. In some embodiments, the nucleoside analogues in the wings are not LNA, but tricyclo-DNA and the antisense oligonucleotide is anyone of SEQ ID NOs: 360 -2148 or anyone of SEQ ID NO’s: 228561-2299. In some embodiments, the nucleoside analogues in the wings are not LNA, but 2′-Fluoro and the antisense oligonucleotide is anyone of SEQ ID NOs: 360 - 2148 or anyone of SEQ ID NO’s: 2285-2299. In some embodiments, the nucleoside analogues in the wings are not LNA, but 2′-O-methyl and the antisense oligonucleotide is anyone of SEQ ID NOs: 360 - 2148 or anyone of SEQ ID NO’s: 2285-2299. In some embodiments, the nucleoside analogues in the wings are not LNA, but 2′-MOE and antisense oligonucleotide is anyone of SEQ ID NOs: 360 - 2148 or anyone of SEQ ID NO’s: 2285-2299. In some embodiments, the nucleoside analogues in the wings are not LNA, but 2′cyclic ethyl (cET) and the antisense oligonucleotide is anyone of SEQ ID NOs: 360 - 2148 or anyone of SEQ ID NO’s: 2285-2299. In some embodiments, the nucleoside analogues in the wings are not LNA, but UNA and the antisense oligonucleotide is anyone of SEQ ID NOs: 360 - 2148 or anyone of SEQ ID NO’s: 2285-2299. In some embodiments, the nucleoside analogues in the wings are not LNA, but CRN and the antisense oligonucleotide is anyone of SEQ ID NOs: 360 - 2148 or anyone of SEQ ID NO’s: 2285-2299. In some embodiments, the nucleoside analogues in the wings are partly LNA, but mixed with another nucleotide analogue selected from the list of tricyclo-DNA, 2′Fluoro, 2′-O-methyl, 2′methoxyethyl (2′-MOE), 2′cyclic ethyl (cET), UNA and Conformationally Restricted Nucleoside (CRN) and the antisense oligonucleotide is anyone of SEQ ID NOs: 360 - 2148 or anyone of SEQ ID NO’s: 2285-2299.

For most pharmaceuticals, efficient delivery is important, in order to ensure cost efficient, effective treatment without adverse effects.

In certain embodiments, the antisense oligonucleotide according to the invention is conjugated with a ligand for targeted delivery, to ensure that the compound is directed to the right target cells for uptake in an efficient manner. In some embodiments, this is achieved by conjugation with folic acid or N-acetylgalactosamine (GalNAc). Folic acid conjugation will ensure uptake in, for example folate receptor-positive cancer cells. Likewise, conjugation with GalNac markedly improves delivery to hepatocytes in the liver.

In some instances, it is preferred to deliver the antisense oligonucleotide in an unconjugated form in a pharmaceutical composition. This approach may be used in order to ensure delivery to the right cellular compartment in the target cell.

In some instances, the antisense oligonucleotide according to the invention is formulated in lipid nanoparticles for delivery. It is well known that lipid nanoparticle formulations of e.g. siRNA may be an effective way of delivery to e.g. hepatocytes in vivo. Further, particle size seems to be important for potency, so that if particle size is above 30 mm, the formulation is more potent than for smaller particle sizes (Chen et al., J Control Release, 2016 May 26, pii: 50168-3659 (16)30349-2).

It is well known that long noncoding RNAs, including circRNAs, may be implicated in disease pathogenesis, why the antisense oligonucleotides according to the invention in preferred embodiments are for use as a medicament.

In particular, the antisense oligonucleotide according to the invention is for use as a medicament in the treatment of cancer, such as hepatocellular carcinoma.

In some embodiments, the antisense oligonucleotides of the invention are formulated in a composition comprising the antisense oligonucleotide and a pharmaceutically acceptable diluent, carrier, salt or adjuvant.

The antisense oligonucleotides of the invention are also useful in compositions for pharmaceutical use or in methods of treatment. In some embodiments, the compositions of the present invention may comprise more than one of the antisense oligonucleotides according to the invention. In one such embodiment, one or more antisense oligonucleotides comprised in the compositions target different circRNAs or different IncRNAs, such as lincRNAs.

When the compositions according to the invention comprise more than one antisense oligonucleotide, such antisense oligonucleotides may be selected from the list of anyone of SEQ ID NOs: 360 - 2148 or anyone of SEQ ID NO’s: 2285-2299.

The invention also provides compositions that comprise the antisense oligonucleotides of the invention, for the treatment of cancer, such as for treatment of hepatocellular carcinoma, breast cancer, CNS tumors, leukemias, melanoma, non-small cell lung cancer, prostate cancer or renal cancer.

In some embodiments, the antisense oligonucleotide according to the invention, or composition, is for treatment of human subjects.

In some embodiments, the antisense oligonucleotide or composition according to the invention is for treatment of a cell ex vivo.

In some embodiments, the invention provides methods of downregulating an endogenous circRNA in a cell, by the administration of a composition comprising an effective amount of an antisense oligonucleotide according to the invention to a cell.

In some embodiments, the invention provides a method for the treatment of cancer, comprising the administration of an effective dosage of an antisense oligonucleotide or a composition according to the invention to a human.

In some embodiments, the invention provides a method of treatment of cancer, wherein the cancer is selected from the list of cancers such as hepatocellular carcinoma or prostate cancer, and wherein the antisense oligonucleotides of the invention are administered to a cancer patient in an effective dosage.

In some embodiments, the invention provides, the antisense oligonucleotides of the invention, or the compositions or methods of treatment according to the invention, wherein the antisense oligonucleotide, or compositions or methods of treatment are for use in combination with another compound, composition or method of treatment, by which combination a synergic or additive effect may be achieved, or treatment of different symptoms of the disease may be achieved.

A method of treating cancer, characterized by the following steps:

• a) Isolate cancer cells from a patient.
• b) Testing the presence of circRNA in the cancer cells.
• c) If the cancer cell is tested positive for a circRNA in step b, for one or more circRNAs, a composition comprising an antisense oligonucleotide according to anyone of claims 1-14 is selected, wherein the antisense oligonucleotide is antisense to the circRNA that is expressed according to the test in step b.

The cancer is treated with the composition of step c, by administering an efficient amount of the composition to the patient having the cancer.

The method according to the previous embodiment, wherein the circRNA level measured in step b is anyone of a circRNA that is expressed in a cancer cell.

The method according to the previous embodiment, wherein the circRNA level measured in step b is anyone selected from the list of ciRS-7, circFAT1, circPVT1, circHIPK3, circSRY, circSLC35E2B, circCDK11A, circUNKNOWN00000001, circARHGAP32, circSLC8A3, circHERC2, circZFAND6, circRP1-168P16.1, circAURKC, circAFTPH, circSCD, circSMC3, circSNORA23|IP07.1, circZNF124.1, circSNX5|OVOL2, circRALY, circTFPI, circAHSG.1, circAHSG.2, circAHSG.3, circUBXN7, circAFP, circHIST1H3A, circHIST1H3C.1, circANAPC2, circRMRP |RMRP, circCENPI, circFIRRE, circMBNL3, circGPC3, circPROSER2, circMALRD1, circFAM208B, circMCU, circKIF20B, circABCC2, circEIF4G2|SNORD97.1, circEIF4G2 |SNORD97.2, circEIF4G2|SNORD97.3, circEIF4G2|SNORD97.4, circEIF4G2|SNORD97.5, circEIF4G2|SNORD97.6, circEIF4G2|SNORD97.7, circEIF4G2|SNORD97.8, circEIF4G2|SNORD97.9, circEIF4G2|SNORD97.10, circIGF2, circQSER1, circUNKNOWN00000002, circCHD1L, circPRUNE, circSLC27A3, circGATAD2B, circKIAA0907, circCCT3, circPLEKHM2, circVWCE, circATF6, circMALAT1.1, circMALAT1.2, circMALAT1.3, circMALAT1.4, circMALAT1.5, circMALAT1.6, circMALAT1.7, circMALAT1.8, circMALAT1.9, circMALAT1.10, circMALAT1.11, circMALAT1.12, circMALAT1.13, circUNKNOWN00000003, circMALAT1.14, circMALAT1.15, circMALAT1.16, circMALAT1.17, circMALAT1.18, circMALAT1.19, circUCK2, circSUCO, circRAB6A, circRPS3 |SNORD15B.1, circRPS3|SNORD15B.2, circRPS3|SNORD15B.3, circRSF1, circABL2, circGNB1, circRPLP2|SNORA52, circPICALM.1, circPICALM.2, circSNORA23|IPO7.2, circSNORA23 |IPO7.3, circCFH, circSLC41A2.1, circSLC41A2.2, circCORO1C, circEIF4G3|RP11-487E1.2, circNAA25, circMED13L, circLPGAT1|RN7SL344P, circAACS, circTP53BP2, circSOX5, circDNAH14, circKDM1A|MIR3115, circTTC13, circEGLN1, circTCEA3, circTOMM20|SNORA14B, circSCCPDH, circZNF124.2, circGLS2, circR3HDM2, circDHDDS, circSNORA73A|RCC1|SNHG3.1, circSNORA73A|RCC1|SNHG3.2, circSNORA61|SNHG12, circCEP831 RBMS2P1, circFGD6, circPUM1, circTMCO3|RP11-230F18.6, circPTP4A2, circZMYM5, circN6AMT2, circRPL21|SNORA27, circGTF2F2, circZMYM4, circLINC00355, circUNKNOWN00000004, circFARP1, circDYNC1H1, circCDC42BPB, circCCNB1IP1|SNORA79AL355075.1, circRPPH1 |RPPH1.1, circRPPH1|RPPH1.2, circRPPH1|RPPH1.3, circRPPH1|RPPH1.4, circSNORD8|CHD8.1, circSNORD8|CHD8.2, circPPP1R3E, circCHMP4A|RP11-468E2.1|AL136419.6, circUNKNOWN00000005, circSEC23A, circSNORD46| RPS8, circSAMD4A, circPCNX, circPSEN1, circFCF1, circSCARNA13|SNHG10.1, circSCARNA13|SNHG10.2, circSCARNA13 |SNHG10.3, circUNKNOWN00000006, circTJP1, circRP11-632K20.7, circTTBK2, circPPIB, circUBE2Q2, circETFA, circSEC11A, circPDE8A, circDAB1|OMA1, circABHD2, circlQGAP1.1, circlQGAP1.2, circCHD2, circlGF1R, circNPRL3, circNDE1, circABCC1, circRPS2 |SNORA64, circPOLR3E, circATXN2L, circMVP, circASPHD1, circITGAL, circRP5-857K21.6.1, circRP5-857K21.6.2, circRP5-857K21.6.3, circRP5-857K21.6.4, circZNF720, circLONP2, circCHD9, circSLC7A6, circCARHSP1, circFANCA, circRAD51D|RAD51L3-RFFL, circHDAC5, circUTP18, circSRSF1, circPPM1D, circBRIP1, circPRKCA.1, circPRKCA.2, circEIF4A1|SNORD10|RP11-186B7.4|SENP3-EIF4A1.1, circEIF4A1|SNORD10|RP11-186B7.4|SENP3-EIF4A1.2, circPGS1, circRPTOR, circRPL26|RP11-849F2.7, circRP11-206L10.8, circPIAS2, circTYMS, circPPP4R1, circZNF91, circWDR62, circADCK4, circARHGAP35, circNUCB1, circSNORD33|RPL13A.1, circSNORD33|RPL13A.2, circSNORD33|RPL13A.3, circMUC16, circLZIC, circSNX5|SNORD17|OVOL2.1, circSNX5 |SNORD17|OVOL2.2, circSNORA71A|SNHG17, circPLTP, circTMEM230, circCYP24A1, circZBTB46, circGART, circRAB3GAP1, circDYRK1A, circUNKNOWN00000007, circCOL18A1.1, circCOL18A1.2, circNBAS, circCH507-513H4.1.1, circCH507-513H4.1.2, circCH507-513H4.1.3, circANKAR, circGLS, circBMPR2, circRHBDD1, circATG16L1|SCARNA5, circDGKD, circPASK, circPPP6R2, circBIRC6, circPRKD3, circKIAA1841|RP11-493E12.3, circRTKN, circELMOD3, circREV1, circZBTB20, circTIMMDC1, circACAD9, circPLXND1, circHDAC11, circCEP70, circRNF13.1, circRNF13.2, circGOLIM4, circEIF4A2|SNORD2.1, circEIF4A2|SNORD2.2, circSDHAP1, circSETD2, circSCAP, circUSP4, circRPL29, circPHF7, circNEK4, circFLNB, circSLC25A26, circNFKB1, circFIP1L1|RP11-231C18.3, circTBC1D14, circALB.1, circALB.2, circALB.3, circNUP54, circAFF1, circSLC12A7| MIR4635, circMAN2A1.1, circMAN2A1.2, circAFF4, circUBE2D2, circANKHD1|ANKHD1-EIF4EBP3, circMAPK9, circGPBP1, circCEP72, circRP11-98J23.2, circFAM169A, circWDR41, circRASGRF2, circRHOBTB3, circCEP85L, circARID1B.1, circARID1B.2, circTULP4|RP11-732M18.4, circTULP4, circTMEM181, circHIST1H3B, circHIST1H3C.2, circUNKNOWN00000008, circC6orf136, circHLA-C|HLA-B|XXbac-BPG248L24.10|WASF5P|XXbac-BPG248L24.13.1, circHLA-C|HLA-B |XXbac-BPG248L24.10|WASF5P|XXbac-BPG248L24.13.2, circFKBP5, circCNPY3, circSRF, circRN7SK, circFARS2, circMLIP, circZNF292, circPNRC1, circUNKNOWN00000009, circNDUFB2, circKMT2C, circESYT2, circMPP6, circHERPUD2, circOGDH, circZNF680, circKDELR2|DAGLB, circZDHHC4, circCCZ1B, circPOM121, circBAZ1B, circGTF2I, circSNORA14A, circCDK14, circCCDC132, circTRRAP|MIR3609, circCYP3A7|CYP3A7-CYP3A51P, circCCAT1.1, circCCAT1.2, circCCAT1.3, circCCAT1.4, circCCAT1.5, circCCAT1.6, circCCAT1.7, circASAP1, circPTK2.1, circPTK2.2, circSLC45A4, circADGRB1, circRBPMS, circFGFR1, circHOOK3, circASPH, circTMEM245, circUNKNOWN00000010, circHSPA5, circGLE1, circFOCAD, circNFX1, circUBAP2, circKDM4C|RP11-146B14.1, circAGTPBP1, circFAM120A.1, circFAM120A.2, circHIATL1, circPPP2R3B, circATRX, or circTBL1X.

In some embodiments, the present invention provides antisense oligonucleotides suitable for the manufacture of a medicament for the treatment of a disease as referred to herein.

In one embodiment, the invention comprises a method for treating a disease as referred to herein, said method comprising administering an antisense oligonucleotide as disclosed herein, and/or a conjugate, and/or a pharmaceutical composition to a patient in need thereof.

One or more embodiment provided herein relates to methods of treating or preventing a cancer disease by modulating the activity of specific targets in cancer patients.

In one embodiment, the invention comprises a method of treating cancer in humans comprising administering to the human a therapeutically effective amount of the compound or composition according to the invention, thereby treating the cancer. In such embodiments, the skilled artisan will know how to determine what an effective dosage for the individual patient will be.

The present invention further provides pharmaceutical compositions, comprising therapeutically active antisense oligonucleotides in accordance with the invention, together with one or more pharmaceutically acceptable excipients. In some preferred embodiments, the invention provides compositions, such as pharmaceutical compositions comprising antisense oligonucleotides according to the invention, which are in single embodiments complementary to anyone of a circRNA selected from the list of ciRS-7, circFAT1, circPVT1, circHIPK3, circSRY, circSLC35E2B, circCDK11A, circUNKNOWN00000001, circARHGAP32, circSLC8A3, circHERC2, circZFAND6, circRP1-168P16.1, circAURKC, circAFTPH, circSCD, circSMC3, circSNORA23|IP07.1, circZNF124.1, circSNX5|OVOL2, circRALY, circTFPI, circAHSG.1, circAHSG.2, circAHSG.3, circUBXN7, circAFP, circHIST1H3A, circHIST1H3C.1, circANAPC2, circRMRP|RMRP, circCENPI, circFIRRE, circMBNL3, circGPC3.

In other preferred embodiments, the invention provides compositions, such as pharmaceutical compositions comprising antisense oligonucleotides according to the invention which are in single embodiments complementary to anyone of the circRNAs selected from the list of ciRS-7, circFAT1, circPVT1, circHIPK3, circSRY, circSLC35E2B, circCDK11A, circUNKNOWN00000001, circARHGAP32, circSLC8A3, circHERC2, circZFAND6, circRP1-168P16.1, circAURKC, circAFTPH, circSCD, circSMC3, circSNORA23|IP07.1, circZNF124.1, circSNX5|OVOL2, circRALY, circTFPI, circAHSG.1, circAHSG.2, circAHSG.3, circUBXN7, circAFP, circHIST1H3A, circHIST1H3C.1, circANAPC2, circRMRP|RMRP, circCENPI, circFIRRE, circMBNL3, circGPC3, circPROSER2, circMALRD1, circFAM208B, circMCU, circKIF20B, circABCC2, circEIF4G2|SNORD97.1, circEIF4G2|SNORD97.2, circEIF4G2|SNORD97.3, circEIF4G2|SNORD97.4, circEIF4G2|SNORD97.5, circEIF4G2|SNORD97.6, circEIF4G2|SNORD97.7, circEIF4G2|SNORD97.8, circEIF4G2|SNORD97.9, circEIF4G2|SNORD97.10, circlGF2, circQSER1, circUNKNOWN00000002, circCHD1L, circPRUNE, circSLC27A3, circGATAD2B, circKIAA0907, circCCT3, circPLEKHM2, circVWCE, circATF6, circMALAT1.1, circMALAT1.2, circMALAT1.3, circMALAT1.4, circMALAT1.5, circMALAT1.6, circMALAT1.7, circMALAT1.8, circMALAT1.9, circMALAT1.10, circMALAT1.11, circMALAT1.12, circMALAT1.13, circUNKNOWN00000003, circMALAT1.14, circMALAT1.15, circMALAT1.16, circMALAT1.17, circMALAT1.18, circMALAT1.19, circUCK2, circSUCO, circRAB6A, circRPS3|SNORD15B.1, circRPS3|SNORD15B.2, circRPS3|SNORD15B.3, circRSF1, circABL2, circGNB1, circRPLP2|SNORA52, circPICALM.1, circPICALM.2, circSNORA23|IPO7.2, circSNORA23|IPO7.3, circCFH, circSLC41A2.1, circSLC41A2.2, circCORO1C, circEIF4G3|RP11-487E1.2, circNAA25, circMED13L, circLPGAT1|RN7SL344P, circAACS, circTP53BP2, circSOX5, circDNAH14, circKDM1A|MIR3115, circTTC13, circEGLN1, circTCEA3, circTOMM20|SNORA14B, circSCCPDH, circZNF124.2, circGLS2, circR3HDM2, circDHDDS, circSNORA73A|RCC1|SNHG3.1, circSNORA73A|RCC1|SNHG3.2, circSNORA61|SNHG12, circCEP83|RBMS2P1, circFGD6, circPUM1, circTMCO3|RP11-230F18.6, circPTP4A2, circZMYM5, circN6AMT2, circRPL21|SNORA27, circGTF2F2, circZMYM4, circLINC00355, circUNKNOWN00000004, circFARP1, circDYNC1H1, circCDC42BPB, circCCNB1IP1|SNORA79|AL355075.1, circRPPH1|RPPH1.1, circRPPH1|RPPH1.2, circRPPH1|RPPH1.3, circRPPH1|RPPH1.4, circSNORD8|CHD8.1, circSNORD8|CHD8.2, circPPP1R3E, circCHMP4A|RP11-468E2.1|AL136419.6, circUNKNOWN00000005, circSEC23A, circSNORD46| RPS8, circSAMD4A, circPCNX, circPSEN1, circFCF1, circSCARNA13|SNHG10.1, circSCARNA13|SNHG10.2, circSCARNA13|SNHG10.3, circUNKNOWN00000006, circTJP1, circRP11-632K20.7, circTTBK2, circPPIB, circUBE2Q2, circETFA, circSEC11A, circPDE8A, circDAB1|OMA1, circABHD2, circlQGAP1.1, circlQGAP1.2, circCHD2, circIGF1R, circNPRL3, circNDE1, circABCC1, circRPS2|SNORA64, circPOLR3E, circATXN2L, circMVP, circASPHD1, circITGAL, circRP5-857K21.6.1, circRP5-857K21.6.2, circRP5-857K21.6.3, circRP5-857K21.6.4, circZNF720, circLONP2, circCHD9, circSLC7A6, circCARHSP1, circFANCA, circRAD51D|RAD51L3-RFFL, circHDAC5, circUTP18, circSRSF1, circPPM1D, circBRIP1, circPRKCA.1, circPRKCA.2, circEIF4A1|SNORD10|RP11-186B7.4|SENP3-EIF4A1.1, circEIF4A1|SNORD10|RP11-186B7.4|SENP3-EIF4A1.2, circPGS1, circRPTOR, circRPL26|RP11-849F2.7, circRP11-206L10.8, circPIAS2, circTYMS, circPPP4R1, circZNF91, circWDR62, circADCK4, circARHGAP35, circNUCB1, circSNORD33|RPL13A.1, circSNORD33|RPL13A.2, circSNORD33|RPL13A.3, circMUC16, circLZIC, circSNX5|SNORD17|OVOL2.1, circSNX5|SNORD17|OVOL2.2, circSNORA71A|SNHG17, circPLTP, circTMEM230, circCYP24A1, circZBTB46, circGART, circRAB3GAP1, circDYRK1A, circUNKNOWN00000007, circCOL18A1.1, circCOL18A1.2, circNBAS, circCH507-513H4.1.1, circCH507-513H4.1.2, circCH507-513H4.1.3, circANKAR, circGLS, circBMPR2, circRHBDD1, circATG16L1|SCARNA5, circDGKD, circPASK, circPPP6R2, circBIRC6, circPRKD3, circKIAA184|RP11-493E12.3, circRTKN, circELMOD3, circREV1, circZBTB20, circTIMMDC1, circACAD9, circPLXND1, circHDAC11, circCEP70, circRNF13.1, circRNF13.2, circGOLIM4, circEIF4A2|SNORD2.1, circEIF4A2|SNORD2.2, circSDHAP1, circSETD2, circSCAP, circUSP4, circRPL29, circPHF7, circNEK4, circFLNB, circSLC25A26, circNFKB1, circFIP1L1|RP11-231C18.3, circTBC1D14, circALB.1, circALB.2, circALB.3, circNUP54, circAFF1, circSLC12A7| MIR4635, circMAN2A1.1, circMAN2A1.2, circAFF4, circUBE2D2, circANKHD1|ANKHD1-EIF4EBP3, circMAPK9, circGPBP1, circCEP72, circRP11-98J23.2, circFAM169A, circWDR41, circRASGRF2, circRHOBTB3, circCEP85L, circARID1B.1, circARID1B.2, circTULP4|RP11-732M18.4, circTULP4, circTMEM181, circHIST1H3B, circHIST1H3C.2, circUNKNOWN00000008, circC6orf136, circHLA-C|HLA-B|XXbac-BPG248L24.10|WASF5P|XXbac-BPG248L24.13.1, circHLA-C|HLA-B|XXbac-BPG248L24.10|WASF5P|XXbac-BPG248L24.13.2, circFKBP5, circCNPY3, circSRF, circRN7SK, circFARS2, circMLIP, circZNF292, circPNRC1, circUNKNOWN00000009, circNDUFB2, circKMT2C, circESYT2, circMPP6, circHERPUD2, circOGDH, circZNF680, circKDELR2|DAGLB, circZDHHC4, circCCZ1B, circPOM121, circBAZ1B, circGTF2I, circSNORA14A, circCDK14, circCCDC132, circTRRAP|MIR3609, circCYP3A7|CYP3A7-CYP3A51P, circCCAT1.1, circCCAT1.2, circCCAT1.3, circCCAT1.4, circCCAT1.5, circCCAT1.6, circCCAT1.7, circASAP1, circPTK2.1, circPTK2.2, circSLC45A4, circADGRB1, circRBPMS, circFGFR1, circHOOK3, circASPH, circTMEM245, circUNKNOWN00000010, circHSPA5, circGLE1, circFOCAD, circNFX1, circUBAP2, circKDM4C|RP11-146B14.1, circAGTPBP1, circFAM120A.1, circFAM120A.2, circHIATL1, circPPP2R3B, circATRX, or circTBL1X.

The diseases to be treated with the compositions or with the antisense oligonucleotides of the invention may in non-limiting example be anyone selected from the list of: hepatocellular carcinoma, ciRS-7 positive cancer, circFAT1 positive cancer, circPVT1 positive cancer, circHIPK3 positive cancer, circSRY positive cancer, circSLC35E2B positive cancer, circCDK11A positive cancer, circUNKNOWN00000001 positive cancer, circARHGAP32 positive cancer, circSLC8A3 positive cancer, circHERC2 positive cancer, circZFAND6 positive cancer, circRP1-168P16.1 positive cancer, circAURKC positive cancer, circAFTPH positive cancer, circSCD positive cancer, circSMC3 positive cancer, circSNORA23|IPO7.1 positive cancer, circZNF124.1 positive cancer, circSNX5|OVOL2 positive cancer, circRALY positive cancer, circTFPI positive cancer, circAHSG.1 positive cancer, circAHSG.2 positive cancer, circAHSG.3 positive cancer, circUBXN7 positive cancer, circAFP positive cancer, circHIST1H3A positive cancer, circHIST1H3C.1 positive cancer, circANAPC2 positive cancer, circRMRP|RMRP positive cancer, circCENPI positive cancer, circFIRRE positive cancer, circMBNL3 positive cancer, circGPC3 positive cancer, circPROSER2 positive cancer, circMALRD1 positive cancer, circFAM208B positive cancer, circMCU positive cancer, circKIF20B positive cancer, circABCC2 positive cancer, circEIF4G2|SNORD97.1 positive cancer, circEIF4G2|SNORD97.2 positive cancer, circEIF4G2|SNORD97.3 positive cancer, circEIF4G2|SNORD97.4 positive cancer, circEIF4G2|SNORD97.5 positive cancer, circEIF4G2|SNORD97.6 positive cancer, circEIF4G2|SNORD97.7 positive cancer, circEIF4G2|SNORD97.8 positive cancer, circEIF4G2|SNORD97.9 positive cancer, circEIF4G2|SNORD97.10 positive cancer, circlGF2 positive cancer, circQSER1 positive cancer, circUNKNOWN00000002 positive cancer, circCHD1L positive cancer, circPRUNE positive cancer, circSLC27A3 positive cancer, circGATAD2B positive cancer, circKIAA0907 positive cancer, circCCT3 positive cancer, circPLEKHM2 positive cancer, circVWCE positive cancer, circATF6 positive cancer, circMALAT1.1 positive cancer, circMALAT1.2 positive cancer, circMALAT1.3 positive cancer, circMALAT1.4 positive cancer, circMALAT1.5 positive cancer, circMALAT1.6 positive cancer, circMALAT1.7 positive cancer, circMALAT1.8 positive cancer, circMALAT1.9 positive cancer, circMALAT1.10 positive cancer, circMALAT1.11 positive cancer, circMALAT1.12 positive cancer, circMALAT1.13 positive cancer, circUNKNOWN00000003 positive cancer, circMALAT1.14 positive cancer, circMALAT1.15 positive cancer, circMALAT1.16 positive cancer, circMALAT1.17 positive cancer, circMALAT1.18 positive cancer, circMALAT1.19 positive cancer, circUCK2 positive cancer, circSUCO positive cancer, circRAB6A positive cancer, circRPS3|SNORD15B.1 positive cancer, circRPS3|SNORD15B.2 positive cancer, circRPS3|SNORD15B.3 positive cancer, circRSF1 positive cancer, circABL2 positive cancer, circGNB1 positive cancer, circRPLP2|SNORA52 positive cancer, circPICALM.1 positive cancer, circPICALM.2 positive cancer, circSNORA23|IPO7.2 positive cancer, circSNORA23|IPO7.3 positive cancer, circCFH positive cancer, circSLC41A2.1 positive cancer, circSLC41A2.2 positive cancer, circCORO1C positive cancer, circEIF4G31 RP11-487E1.2 positive cancer, circNAA25 positive cancer, circMED13L positive cancer, circLPGAT1|RN7SL344P positive cancer, circAACS positive cancer, circTP53BP2 positive cancer, circSOX5 positive cancer, circDNAH14 positive cancer, circKDM1A|MIR3115 positive cancer, circTTC13 positive cancer, circEGLN1 positive cancer, circTCEA3 positive cancer, circTOMM20|SNORA14B positive cancer, circSCCPDH positive cancer, circZNF124.2 positive cancer, circGLS2 positive cancer, circR3HDM2 positive cancer, circDHDDS positive cancer, circSNORA73A|RCC1|SNHG3.1 positive cancer, circSNORA73A|RCC1|SNHG3.2 positive cancer, circSNORA61|SNHG12 positive cancer, circCEP83|RBMS2P1 positive cancer, circFGD6 positive cancer, circPUM1 positive cancer, circTMCO3|RP11-230F18.6 positive cancer, circPTP4A2 positive cancer, circZMYM5 positive cancer, circN6AMT2 positive cancer, circRPL21|SNORA27 positive cancer, circGTF2F2 positive cancer, circZMYM4 positive cancer, circLINC00355 positive cancer, circUNKNOWN00000004 positive cancer, circFARP1 positive cancer, circDYNC1H1 positive cancer, circCDC42BPB positive cancer, circCCNB1IP1|SNORA79|AL355075.1 positive cancer, circRPPH1|RPPH1.1 positive cancer, circRPPH1|RPPH1.2 positive cancer, circRPPH1|RPPH1.3 positive cancer, circRPPH1|RPPH1.4 positive cancer, circSNORD8|CHD8.1 positive cancer, circSNORD8|CHD8.2 positive cancer, circPPP1R3E positive cancer, circCHMP4A|RP11-468E2.1|AL136419.6 positive cancer, circUNKNOWN00000005 positive cancer, circSEC23A positive cancer, circSNORD46|RPS8 positive cancer, circSAMD4A positive cancer, circPCNX positive cancer, circPSEN1 positive cancer, circFCF1 positive cancer, circSCARNA13|SNHG10.1 positive cancer, circSCARNA13|SNHG10.2 positive cancer, circSCARNA13|SNHG10.3 positive cancer, circUNKNOWN00000006 positive cancer, circTJP1 positive cancer, circRP11-632K20.7 positive cancer, circTTBK2 positive cancer, circPPIB positive cancer, circUBE2Q2 positive cancer, circETFA positive cancer, circSEC11A positive cancer, circPDE8A positive cancer, circDAB1|OMA1 positive cancer, circABHD2 positive cancer, circlQGAP1.1 positive cancer, circlQGAP1.2 positive cancer, circCHD2 positive cancer, circlGF1R positive cancer, circNPRL3 positive cancer, circNDE1 positive cancer, circABCC1 positive cancer, circRPS2|SNORA64 positive cancer, circPOLR3E positive cancer, circATXN2L positive cancer, circMVP positive cancer, circASPHD1 positive cancer, circITGAL positive cancer, circRP5-857K21.6.1 positive cancer, circRP5-857K21.6.2 positive cancer, circRP5-857K21.6.3 positive cancer, circRP5-857K21.6.4 positive cancer, circZNF720 positive cancer, circLONP2 positive cancer, circCHD9 positive cancer, circSLC7A6 positive cancer, circCARHSP1 positive cancer, circFANCA positive cancer, circRAD51D|RAD51L3-RFFL positive cancer, circHDAC5 positive cancer, circUTP18 positive cancer, circSRSF1 positive cancer, circPPM1D positive cancer, circBRIP1 positive cancer, circPRKCA.1 positive cancer, circPRKCA.2 positive cancer, circEIF4A1|SNORD10|RP11-186B7.4|SENP3-EIF4A1.1 positive cancer, circEIF4A1|SNORD10|RP11-186B7.4|SENP3-EIF4A1.2 positive cancer, circPGS1 positive cancer, circRPTOR positive cancer, circRPL26|RP11-849F2.7 positive cancer, circRP11-206L10.8 positive cancer, circPIAS2 positive cancer, circTYMS positive cancer, circPPP4R1 positive cancer, circZNF91 positive cancer, circWDR62 positive cancer, circADCK4 positive cancer, circARHGAP35 positive cancer, circNUCB1 positive cancer, circSNORD33 | RPL13A.1 positive cancer, circSNORD33|RPL13A.2 positive cancer, circSNORD33|RPL13A.3 positive cancer, circMUC16 positive cancer, circLZIC positive cancer, circSNX5|SNORD17|OVOL2.1 positive cancer, circSNX5|SNORD17|OVOL2.2 positive cancer, circSNORA71A|SNHG17 positive cancer, circPLTP positive cancer, circTMEM230 positive cancer, circCYP24A1 positive cancer, circZBTB46 positive cancer, circGART positive cancer, circRAB3GAP1 positive cancer, circDYRK1A positive cancer, circUNKNOWN00000007 positive cancer, circCOL18A1.1 positive cancer, circCOL18A1.2 positive cancer, circNBAS positive cancer, circCH507-513H4.1.1 positive cancer, circCH507-513H4.1.2 positive cancer, circCH507-513H4.1.3 positive cancer, circANKAR positive cancer, circGLS positive cancer, circBMPR2 positive cancer, circRHBDD1 positive cancer, circATG16L1|SCARNA5 positive cancer, circDGKD positive cancer, circPASK positive cancer, circPPP6R2 positive cancer, circBIRC6 positive cancer, circPRKD3 positive cancer, circKIAA184|RP11-493E12.3 positive cancer, circRTKN positive cancer, circELMOD3 positive cancer, circREV1 positive cancer, circZBTB20 positive cancer, circTIMMDC1 positive cancer, circACAD9 positive cancer, circPLXND1 positive cancer, circHDAC11 positive cancer, circCEP70 positive cancer, circRNF13.1 positive cancer, circRNF13.2 positive cancer, circGOLIM4 positive cancer, circEIF4A2|SNORD2.1 positive cancer, circEIF4A2|SNORD2.2 positive cancer, circSDHAP1 positive cancer, circSETD2 positive cancer, circSCAP positive cancer, circUSP4 positive cancer, circRPL29 positive cancer, circPHF7 positive cancer, circNEK4 positive cancer, circFLNB positive cancer, circSLC25A26 positive cancer, circNFKB1 positive cancer, circFIP1L1|RP11-231C18.3 positive cancer, circTBC1D14 positive cancer, circALB.1 positive cancer, circALB.2 positive cancer, circALB.3 positive cancer, circNUP54 positive cancer, circAFF1 positive cancer, circSLC12A7| MIR4635 positive cancer, circMAN2A1.1 positive cancer, circMAN2A1.2 positive cancer, circAFF4 positive cancer, circUBE2D2 positive cancer, circANKHD1|ANKHD1-EIF4EBP3 positive cancer, circMAPK9 positive cancer, circGPBP1 positive cancer, circCEP72 positive cancer, circRP11-98J23.2 positive cancer, circFAM169A positive cancer, circWDR41 positive cancer, circRASGRF2 positive cancer, circRHOBTB3 positive cancer, circCEP85L positive cancer, circARID1B.1 positive cancer, circARID1B.2 positive cancer, circTULP41 RP11-732M18.4 positive cancer, circTULP4 positive cancer, circTMEM181 positive cancer, circHIST1H3B positive cancer, circHIST1H3C.2 positive cancer, circUNKNOWN00000008 positive cancer, circC6orf136 positive cancer, circHLA-C|HLA-B |XXbac-BPG248L24.10|WASF5P|XXbac-BPG248L24.13.1 positive cancer, circHLA-C|HLA-B |XXbac-BPG248L24.10|WASF5P|XXbac-BPG248L24.13.2 positive cancer, circFKBP5 positive cancer, circCNPY3 positive cancer, circSRF positive cancer, circRN7SK positive cancer, circFARS2 positive cancer, circMLIP positive cancer, circZNF292 positive cancer, circPNRC1 positive cancer, circUNKNOWN00000009 positive cancer, circNDUFB2 positive cancer, circKMT2C positive cancer, circESYT2 positive cancer, circMPP6 positive cancer, circHERPUD2 positive cancer, circOGDH positive cancer, circZNF680 positive cancer, circKDELR2| DAGLB positive cancer, circZDHHC4 positive cancer, circCCZ1B positive cancer, circPOM121 positive cancer, circBAZ1B positive cancer, circGTF2l positive cancer, circSNORA14A positive cancer, circCDK14 positive cancer, circCCDC132 positive cancer, circTRRAP|MIR3609 positive cancer, circCYP3A7 |CYP3A7-CYP3A51P positive cancer, circCCAT1.1 positive cancer, circCCAT1.2 positive cancer, circCCAT1.3 positive cancer, circCCAT1.4 positive cancer, circCCAT1.5 positive cancer, circCCAT1.6 positive cancer, circCCAT1.7 positive cancer, circASAP1 positive cancer, circPTK2.1 positive cancer, circPTK2.2 positive cancer, circSLC45A4 positive cancer, circADGRB1 positive cancer, circRBPMS positive cancer, circFGFR1 positive cancer, circHOOK3 positive cancer, circASPH positive cancer, circTMEM245 positive cancer, circUNKNOWN00000010 positive cancer, circHSPA5 positive cancer, circGLE1 positive cancer, circFOCAD positive cancer, circNFX1 positive cancer, circUBAP2 positive cancer, circKDM4C|RP11-146B14.1 positive cancer, circAGTPBP1 positive cancer, circFAM120A.1 positive cancer, circFAM120A.2 positive cancer, circHIATL1 positive cancer, circPPP2R3B positive cancer, circATRX positive cancer, or circTBL1X positive cancer. A circ positive cancer is a cancer characterized in that the cancer cells express that particuolar circRNA, or where the cancer cells expresses abnormal amounts of the particular circRNA.

Methods of Treatment

The antisense oligonucleotides of the invention are for use in a method of treatment. The antisense oligonucleotides of the present invention may be used in methods of treatment of many diseases, in example cancer. In some embodiments, the antisense oligonucleotides of the invention are for use in a method of treating cancer, wherein the antisense oligonucleotide is provided in an effective dosage.

ANTISENSE OLIGONUCLEOTIDE-MEDIATED MODULATION OF INCRNAS

One aspect of the invention is to provide antisense oligonucleotides that are effective in modulating IncRNAs, such as large intergenic noncoding RNAs (lincRNAs).

In some embodiments the antisense oligonucleotides of the invention targets a IncRNA selected from the list of DANCR, H19, HOTAIR, HOTTIP, HULC, LINC-ROR, MALAT1, MVIH, NEAT1, PCBP2-OT1, PVT1, TUG1, UCA1, UFC1 and LINC01215 (for review, see Parasramka et al., 2016, Pharmacol. Ther. 161: 67-78). These IncRNAs have all been implicated in the pathogenesis of cancer, such as hepatocellular carcinoma. The expression of some of these have been linked to poor prognosis, increased tumor-driven angiogenesis or metastasis formation, and there are indications that they are important for various cancers, including, but not limited to hepatocellular carcinoma, glioma, osteosarcoma, esophageal squamous cell carcinoma, pancreatic cancer, gastric cancer, breast cancer, non-small cell lung cancer, prostate cancer, ovarian cancer, B-cell lymphoma, colorectal cancer, cutaneous squamous cell carcinoma, multiple myeloma, and tongue squamous cell carcinoma. In some embodiments, the antisense oligonucleotides of the invention having any one of SEQ ID NOs: 2149 - 2259 are for use as medicaments. In some embodiments, the antisense oligonucleotides of the invention having any one of SEQ ID NOs: 2149 - 2259 are for use as medicaments in the treatment of cancer, such as any one of hepatocellular carcinoma, glioma, osteosarcoma, esophageal squamous cell carcinoma, pancreatic cancer, gastric cancer, breast cancer, non-small cell lung cancer, prostate cancer, ovary cancer, B-cell lymphoma, colorectal cancer, cutaneous squamous cell carcinoma, multiple myeloma, and tongue squamous cell carcinoma.

In specific embodiments 1-27 below, the IncRNA-targeting antisense oligonucleotides of the invention, their design, delivery, and uses are described.

1) A compound comprising the modified antisense oligonucleotide consisting of any one of SEQ ID NOs: 2149 - 2259.

2) A compound according to embodiment 1, wherein the nucleotide analogues of the wings are selected from the list of beta-D-oxy LNA, alpha-L-oxy-LNA, beta-D-amino-LNA, alpha-L-amino-LNA, beta-D-thio-LNA, alpha-L-thio-LNA, 5′-methyl-LNA, beta-D-ENA and alpha-L-ENA.

3) A compound according to embodiment 2, wherein the modified antisense oligonucleotide is 100% complementary to the target nucleic acid.

4) A compound according to embodiment 2, wherein the nucleotide analogues of the wings are Beta-D-Oxy LNA.

5) A compound according to embodiment 1, wherein the nucleoside analogues of the wings are not LNA, but anyone of tricyclo-DNA, 2′-Fluoro, 2′-O-methyl, 2′-methoxyethyl (2′-MOE), 2′cyclic ethyl (cET), UNA and Conformationally Restricted Nucleoside (CRN).

6) A compound according to embodiment 1, wherein the nucleoside analogues of the wings are a mixture of LNA and anyone of tricyclo-DNA, 2′Fluoro, 2′-O-methyl, 2′-methoxyethyl (2′-MOE), 2′cyclic ethyl (cET), UNA, and Conformationally Restricted Nucleoside (CRN).

7) A compound according to embodiment 6, wherein the nucleoside analogues of the wings are a mixture of LNA and 2′-Fluoro.

8) The compound according to anyone of embodiments 1-7, wherein the antisense oligonucleotide is conjugated with a ligand for targeted delivery

9) The antisense oligonucleotide according to embodiment 8, wherein the antisense oligonucleotide is conjugated with folic acid or N-acetylgalactosamine (GalNAc).

10) The antisense oligonucleotide according to anyone of embodiments 1-9, wherein the antisense oligonucleotide is unconjugated in a pharmaceutical composition for delivery.

11) The antisense oligonucleotide according to anyone of embodiments 1-9, wherein the antisense oligonucleotide is formulated in lipid nanoparticles for delivery.

12) The antisense oligonucleotide according to any one of the preceding embodiments, for use as a medicament.

13) The antisense oligonucleotide according to embodiment 12, wherein the antisense oligonucleotide is for use as a medicament in the treatment of cancer.

14) The antisense oligonucleotide according to embodiment 13, wherein the cancer is hepatocellular carcinoma.

15) A composition comprising an antisense oligonucleotide according to anyone of the preceding embodiments and a carrier.

16) A composition comprising an antisense oligonucleotide according to any one of embodiments 1-11, for use as a pharmaceutical or in a method of treatment.

17) A composition according to embodiments 15-16, wherein the composition comprises more than one antisense oligonucleotide according to anyone of embodiments 1-14.

18) A composition according to embodiment 17, wherein the two or more antisense oligonucleotides are selected from the list of anyone of SEQ ID NOs: 2149 - 2259.

19) The composition according to anyone of embodiments 15-18, wherein the antisense oligonucleotide or composition is for treatment of cancer.

20) The composition according to embodiment 19, wherein the cancer is selected from the list of cancers such as hepatocellular carcinoma, or prostate cancer.

21) The antisense oligonucleotide according to anyone of embodiments 1-14, or composition according embodiments 15 to 20, wherein the antisense oligonucleotide or composition is for treatment of a human subject.

22) The antisense oligonucleotide or composition according to anyone of the preceding embodiments, wherein the antisense oligonucleotide or composition is for treatment of a cell ex vivo.

23) A method of downregulating an endogenous IncRNA selected from the list of DANCR, H19, HOTAIR, HOTTIP, HULC, LINC-ROR, MALAT1, MVIH, NEAT1, PCBP2-OT1, PVT1, TUG1, UCA1, UFC1 and LINC01215 in a cell, by administration of an effective amount of an antisense oligonucleotide that is complementary to the target and selected from the list according to anyone of embodiments 1-14, or a composition according to anyone of embodiments 15-20 to a cell.

24) The method of embodiment 23, wherein the cell is in a human body.

25) The method of embodiment 24, wherein the cell is a cancer cell in a human body.

26) A method of treatment of cancer, comprising the administration of an effective dosage of an antisense oligonucleotide or a composition according to anyone of embodiments 1-22 to a human subject.

27) The method according to embodiment 26, wherein the cancer is selected from the list of cancers such as hepatocellular carcinoma or prostate cancer.

28) The antisense oligonucleotides, or compositions or methods of treatment according to any one of embodiments 1-27, wherein the antisense oligonucleotide, or compositions or methods of treatment are for use in combination with another compound, composition or method of treatment.

Table 3 shows a list of specific antisense oligonucleotides (SEQ ID NOs: 2149 - 2259) targeting the IncRNAs; DANCR, H19, HOTAIR, HOTTIP, HULC, LINC-ROR, MALAT1, MVIH, NEAT1, PCBP2-OT1, PVT1, TUG1, UCA1, UFC1 and LINC01215. (LNA, such as in non-limiting example Beta-D-Oxy LNA = uppercase, DNA lowercase, complete phosphorothioate backbone, LNA cytosine units are LNA 5-methylcytosines).

Gapmer antisense oligonucleotides for modulation of long noncoding RNAs.
SEQ.ID.NO	Oligonucleotide (5′-3′)	Gene symbol	Ensembl gene id
2149	CAAaccagagaggcgGC	DANCR	ENSG00000226950
2150	CCGcagacgtaagagAC	DANCR	ENSG00000226950
2151	CGAaagccgaagacTGG	DANCR	ENSG00000226950
2152	TGgcgacaaacaGACG	DANCR	ENSG00000226950
2153	TTAgtacgcatattTGG	DANCR	ENSG00000226950
2154	TAcgcatatttggCCT	DANCR	ENSG00000226950
2155	CActcaccgcgcaACT	DANCR	ENSG00000226950
2156	TGtattgcttgttcTAT	DANCR	ENSG00000226950
2157	TTacagggttcactaCTAT	DANCR	ENSG00000226950
2158	CTGcattgagttaGCG	DANCR	ENSG00000226950
2159	CTatagcgcctagataACG	DANCR	ENSG00000226950
2160	ACATagtggcgcgtcAG	DANCR	ENSG00000226950
2161	GAGAccgaaagccgAAG	DANCR	ENSG00000226950
2162	AGAcctgcgccgggAA	DANCR	ENSG00000226950
2163	GTTGtcaacctataGAA	DANCR	ENSG00000226950
2164	ACgtgttggttgtgtGG	H19	ENSG00000130600
2165	CTAgagatagcgacacGT	H19	ENSG00000130600
2166	CTgccacgtcctgtAAC	H19	ENSG00000130600
2167	TACtaaatgaattGCGG	H19	ENSG00000130600
2168	TCacgcacactcgtaCT	H19	ENSG00000130600
2169	GCACaagagatcgagTT	HOTAIR	ENSG00000228630
2170	GCggacagggaaatcaaCT	HOTAIR	ENSG00000228630
2171	GTCtaggaatcagcacgAA	HOTAIR	ENSG00000228630
2172	TCttcgacaacgcCTA	HOTAIR	ENSG00000228630
2173	TGaacaaacgagaGCGT	HOTAIR	ENSG00000228630
2174	GACcgctatgatcctTC	HOTAIR	ENSG00000228630
2175	AGACtaagacggataaCG	HOTAIR	ENSG00000228630
2176	CCactctctcatactaAAT	HOTAIR	ENSG00000228630
2177	GTgaacaaacgagAGCG	HOTAIR	ENSG00000228630
2178	CGGacagggaaatcaaCTA	HOTAIR	ENSG00000228630
2179	CTGggaatgtaagAACG	HOTAIR	ENSG00000228630
2180	AgtgcaaagtcccgtTT	HOTAIR	ENSG00000228630
2181	CCttcaaacgctCGAA	HOTTIP	ENSG00000243766
2182	CCTtctataaacgaccTC	HOTTIP	ENSG00000243766
2183	GACGattctctcataTAAA	HOTTIP	ENSG00000243766
2184	GctacactgtttgacgAT	HOTTIP	ENSG00000243766
2185	GTCagaggcgagaaTTT	HOTTIP	ENSG00000243766
2186	AATTcctttatccgcagAG	HULC	ENSG00000251164
2187	CTTgtaaaggctccaatTC	HULC	ENSG00000251164
2188	GTCgaatataatccTAG	HULC	ENSG00000251164
2189	GTtccagattgttCGAA	HULC	ENSG00000251164
2190	TTgtaagacatctatCATC	HULC	ENSG00000251164
2191	TTATtgattgcgTCTT	LINC01215	ENSG00000271856
2192	AGCGgaagtgagtagtAA	LINC01215	ENSG00000271856
2193	AAggtcaggaagcacGCG	LINC-ROR	ENSG00000258609
2194	CACtacgacacagcaGG	LINC-ROR	ENSG00000258609
2195	CGGgacgattatttatTC	LINC-ROR	ENSG00000258609
2196	GCaacgacgggatGTGA	LINC-ROR	ENSG00000258609
2197	TTcgaggttatcagggTG	LINC-ROR	ENSG00000258609
2198	CACacagcacagcCTC	MALAT1	ENSG00000251562
2199	ATAGacggagaacAACT	MALAT1	ENSG00000251562
2200	CAAAgcaaagacgcCGC	MALAT1	ENSG00000251562
2201	CTGataacgaagagatACC	MALAT1	ENSG00000251562
2202	GAgggacagtaggtataGT	MALAT1	ENSG00000251562
2203	GcttcagacaagattcaTG	MALAT1	ENSG00000251562
2204	CAgcacaactcgtcGC	MALAT1	ENSG00000251562
2205	TTCaccacgaactgcTG	MALAT1	ENSG00000251562
2206	TCACcaccaaatcgtTA	MALAT1	ENSG00000251562
2207	TAGAttccgtaacTTTA	MALAT1	ENSG00000251562
2208	CGttcttccgctcaaaTC	MALAT1	ENSG00000251562
2209	CTCCagtcgtttcacAA	MALAT1	ENSG00000251562
2210	ATTaggttctcgtGTAA	MALAT1	ENSG00000251562
2211	AAatcccactacgcCCA	MVIH	AK094613.1
2212	ATaactccatcgcaACC	MVIH	AK094613.1
2213	CAcctttactccttcGG	MVIH	AK094613.1
2214	CAAtttgaaacgaGCTG	PCBP2-OT1	ENSG00000282977
2215	CAgtgtgggattaagttGA	PCBP2-OT1	ENSG00000282977
2216	GAAagctcgcactgtCG	PCBP2-OT1	ENSG00000282977
2217	ACTtcataggaacggCA	PVT1	ENSG00000249859
2218	AGAAtacaaacggGAGG	PVT1	ENSG00000249859
2219	AGtaacatacagcaCGA	PVT1	ENSG00000249859
2220	GCgagagacaggcTAAC	PVT1	ENSG00000249859
2221	TCGCtaaacaatacTCA	PVT1	ENSG00000249859
2222	AactgtccacgccaaCC	PVT1	ENSG00000249859
2223	CAtttgtcacctaacCC	PVT1	ENSG00000249859
2224	ACTtctcacccattcGT	PVT1	ENSG00000249859
2225	AAgcagacacccgttaGT	PVT1	ENSG00000249859
2226	CTTAaccatcccataTC	PVT1	ENSG00000249859
2227	TAtctccttcgtcctCA	PVT1	ENSG00000249859
2228	TtgttgtttcaccctCG	PVT1	ENSG00000249859
2229	GACaagaattatcCACG	PVT1	ENSG00000249859
2230	CAcgctcatatttAAGG	PVT1	ENSG00000249859
2231	GACGcaataccttatGTA	PVT1	ENSG00000249859
2232	CAACtattatactCACG	PVT1	ENSG00000249859
2233	CGcaacaggattCGGA	PVT1	ENSG00000249859
2234	CATTggagatagataCGC	PVT1	ENSG00000249859
2235	CAGAagcagtagtaattTG	TUG1	ENSG00000253352
2236	CCcatcattcaacatATTG	TUG1	ENSG00000253352
2237	GATAgaggatacataACG	TUG1	ENSG00000253352
2238	GTAatcaagtcgtCATC	TUG1	ENSG00000253352
2239	TAAgaataagtcggtcACA	TUG1	ENSG00000253352
2240	CTGTgttcggaagagTT	TUG1	ENSG00000253352
2241	GAggttccgcagtaGT	TUG1	ENSG00000253352
2242	TTaagggagtctgtcaGTG	TUG1	ENSG00000253352
2243	GATCtaagaataaGTCG	TUG1	ENSG00000253352
2244	CTtgctcagtcgttGTC	TUG1	ENSG00000253352
2245	AACTgtctcgcgaAGC	TUG1	ENSG00000253352
2246	GATCggattcagggtAC	TUG1	ENSG00000253352
2247	TTgtggtgtatgtgggCAA	TUG1	ENSG00000253352
2248	TGccgcatcgtgACAA	TUG1	ENSG00000253352
2249	GTgatgtgtagtttgGAAA	TUG1	ENSG00000253352
2250	ATGggacacgacagcatAA	UCA1	ENSG00000214049
2251	CccacggcagttacGG	UCA1	ENSG00000214049
2252	CGtatagaagacacCCA	UCA1	ENSG00000214049
2253	GAAGtaggataggatagTG	UCA1	ENSG00000214049
2254	GATTggagggtagcGAC	UCA1	ENSG00000214049
2255	AcctagttacccgcttGT	UFC1	ENSG00000143222
2256	CCcttctactaaccttcAT	UFC1	ENSG00000143222
2257	GCggatataaattacCTC	UFC1	ENSG00000143222
2258	TAGAaacacaactaaccCG	UFC1	ENSG00000143222
2259	TgtctacctcagtaagtTC	UFC1	ENSG00000143222

Each compound listed in Table 3 are to be viewed as single embodiments.. In some preferred embodiments, the LNA units in the wings of the antisense oligonucleotide of the invention are Beta-D-Oxy LNA and the antisense oligonucleotide is anyone of SEQ ID NOs: 2149 - 2259. In some preferred embodiments, the LNA units in the wings of the antisense oligonucleotide of the invention are alpha-L-oxy-LNA and the antisense oligonucleotide is anyone of SEQ ID NOs: 2149 - 2259. In some preferred embodiments, the LNA units in the wings of the antisense oligonucleotide of the invention are beta-D-amino-LNA and the antisense oligonucleotide is anyone of SEQ ID NOs: 2149 - 2259. In some preferred embodiments, the LNA units in the wings of the antisense oligonucleotide of the invention are alpha-L-amino-LNA and the antisense oligonucleotide is anyone of SEQ ID NOs: 2149 - 2259. In some preferred embodiments, the LNA units in the wings of the antisense oligonucleotide of the invention are beta-D-thio-LNA and the antisense oligonucleotide is anyone of SEQ ID NOs: 2149 - 2259. In some preferred embodiments, the LNA units in the wings of the antisense oligonucleotide of the invention are alpha-L-thio-LNA and the antisense oligonucleotide is anyone of SEQ ID NOs: 2149 - 2259. In some preferred embodiments, the cytosine LNA units in the wings of the antisense oligonucleotide of the invention are LNA 5′-methylcytosines and the antisense oligonucleotide is anyone of SEQ ID NOs: 2149 - 2259. In some preferred embodiments, the LNA units in the wings of the antisense oligonucleotide of the invention are beta-D-ENA and the antisense oligonucleotide is anyone of SEQ ID NOs: 2149 - 2259. In some preferred embodiments, the LNA units in the wings of the antisense oligonucleotide of the invention are alpha-L-ENA and the antisense oligonucleotide is anyone of SEQ ID NOs: 2149 - 2259. In some embodiments, the nucleoside analogues in the wings are not LNA but tricyclo-DNA and the antisense oligonucleotide is anyone of SEQ ID NOs: 2149 - 2259. In some embodiments, the nucleoside analogues in the wings are not LNA but 2′Fluoro and the antisense oligonucleotide is anyone of SEQ ID NOs: 2149 - 2259. In some embodiments, the nucleoside analogues in the wings are not LNA, but 2′-O-methyl and the antisense oligonucleotide is anyone of SEQ ID NOs: 2149 - 2259. In some embodiments, the nucleoside analogues in the wings are not LNA, but 2′-MOE and antisense oligonucleotide is anyone of SEQ ID NOs: 2149 - 2259. In some embodiments, the nucleoside analogues in the wings are not LNA, but 2′cyclic ethyl (cET) and the antisense oligonucleotide is anyone of SEQ ID NOs: 2149 - 2259. In some embodiments, the nucleoside analogues in the wings are not LNA, but UNA and the antisense oligonucleotide is anyone of SEQ ID NOs: 2149 - 2259. In some embodiments, the nucleoside analogues in the wings are not LNA, but CRN and the antisense oligonucleotide is anyone of SEQ ID NOs: 2149 - 2259. In some embodiments, the nucleoside analogues in the wings are partly LNA, but mixed with another nucleotide analogue selected from the list of tricyclo-DNA, 2′Fluoro, 2′-O-methyl, 2′methoxyethyl (2′MOE), 2′cyclic ethyl (cET), UNA, and Conformationally Restricted Nucleoside (CRN) and the antisense oligonucleotide is anyone of SEQ ID NOs: 2149 - 2259.

In some embodiments, the antisense oligonucleotides of the invention comprising any one of SEQ ID NOs: 2149 - 2259, are for use in combination with another drug or treatment for cancer. In some embodiments, the antisense oligonucleotides of the invention comprising any one of SEQ ID NOs: 2149 - 2259 are for use in combination with another active ingredient. The antisense oligonucleotides of the invention may be formulated together with such other ingredient or drug, or they may be formulated separately.

Dosages and Compositions

The antisense oligonucleotides of the invention may be used in pharmaceutical formulations and compositions, and are for use in treatment of diseases according to the invention. The compounds and compositions will be used in effective dosages, which means in dosages that are sufficient to achieve a desired effect on a disease parameter. The skilled person will without undue burden be able to determine what a reasonably effective dosage is for individual patients.

As explained initially, the antisense oligonucleotides of the invention will constitute suitable drugs with improved properties. The design of a potent and safe drug requires the fine-tuning of various parameters such as affinity/specificity, stability in biological fluids, cellular uptake, mode of action, pharmacokinetic properties and toxicity.

Accordingly, in a further aspect the antisense oligonucleotide may be used in a pharmaceutical composition comprising an oligonucleotide according to the invention and a pharmaceutically acceptable diluent, carrier or adjuvant. Preferably said carrier is saline or buffered saline.

In a still further aspect the present invention relates to an antisense oligonucleotide according to the present invention for use as a medicament.

As will be understood, dosing is dependent on severity and responsiveness of the disease state to be treated, and the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Optimum dosages may vary depending on the relative potency of individual oligonucleotides. Generally it can be estimated based on EC₅₀ values found to be effective in vitro and in vivo animal models. In general, dosage is from 0.01 µg to 1 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 10 years or by continuous infusion for hours up to several months. The repetition rates for dosing can be estimated based on measured residence times and concentrations of the drug in bodily fluids or tissues.

Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state.

As indicated above, the invention also relates to a pharmaceutical composition, which comprises at least one oligonucleotide of the invention as an active ingredient. It should be understood that the pharmaceutical composition according to the invention optionally comprises a pharmaceutical carrier, and that the pharmaceutical composition optionally comprises further active compounds, such as in non-limiting example chemotherapeutic compounds.

The oligonucleotides of the invention can be used “as is” or in form of a variety of pharmaceutically acceptable salts. As used herein, the term “pharmaceutically acceptable salts” refers to salts that retain the desired biological activity of the herein-identified antisense oligonucleotides and exhibit minimal undesired toxicological effects. Non-limiting examples of such salts can be formed with organic amino acid and base addition salts formed with metal cations such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel, cadmium, sodium, potassium, and the like, or with a cation formed from ammonia, N,N-dibenzylethylene-diamine, D-glucosamine, tetraethylammonium, or ethylenediamine.

Delivery

When the antisense oligonucleotides of the present invention are for use in medicine, various means for delivery may be used in order to achieve efficient targeted delivery to cells and tissues.

Targeted delivery of an antisense oligonucleotide is done depending on the target cell or tissue to reach. Such delivery may be modified by conjugation with a ligand in order to facilitate targeted delivery of the antisense oligonucleotide to target cells and tissues. In some embodiments, the antisense oligonucleotides may be formulated in saline for naked delivery.

In some embodiments, the antisense oligonucleotide of the invention is conjugated to anyone of folic acid or N-acetylgalactosamine (GalNAc). In some embodiments, the antisense oligonucleotide according to the invention is made for unconjugated delivery in a pharmaceutical composition. In some embodiments, the circRNA antisense oligonucleotide according to the invention is formulated in lipid nanoparticles for delivery.

There are several approaches for oligonucleotide delivery. One approach is to use a nanoparticle formulation, which determines the tissue distribution and the cellular interactions of the oligonucleotide. Another approach is to use a delivery vehicle to enhance the cellular uptake, in one or more embodiment the vehicle is anyone of folic acid or GalNAc. A third delivery approach is wherein the oligonucleotide is made unconjugated for delivery in a pharmaceutical composition.

The various examples of delivery may be carried out as parenteral administration. By “Parenteral administration” means administration through infusion or injection and comprises intravenous administration, subcutaneous administration, intramuscular administration, intracranial administration, intraperitoneal administration or intra-arterial administration.

The various examples of delivery may be carried out as oral or nasal administration.

The nanoparticle formulation can be a liposomal formulation and in one embodiment the anionic oligonucleotide is complexed with a cationic lipid thereby forming lipid nanoparticles. Such lipid nanoparticles are useful for treating liver diseases. The nanoparticle formulation can also be a polymeric nanoparticle (Juliano et. Al.; Survey and summary, the delivery of therapeutic oligonucleotides, Nucleic Acids Reseach, 2016).

The vehicle used in vehicle-conjugated formulation can be e.g. a lipid vehicle or a polyamine vehicle. One example of a polyamine vehicle is GalNAc - a high-affinity ligand for the hepatocyte-specific asialoglycoprotein receptor (ASGPR). GalNAc-conjugated ASOs show enhanced uptake to hepatocytes instead of non-parenchymal cells since after entry into the cells, the ASO is liberated in the liver (Prakash et. al.; Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice, Nucleic acids research, 2014, vol. 42, no. 13, 8796-8807). GalNAc conjugated ASOs may also show enhance potency and duration of some ASOs targeting human apolipoprotein C-III and human transthyretin (TTR). Folic acid (FA) conjugated ASOs can be used to target the folate receptor that is a cellular surface markers for many solid tumours and myeloid leukemias (Chiu et. al.; Efficient Delivery of an Antisense Oligodeoxyribonucleotide Formulated in Folate Receptor-targeted Liposomes).

In the naked delivery, the oligonucleotide is formulated into a solution comprising saline. This approach is effective in many kinds of cell types among others: primary cells, dividing and non-dividing cells (Soifer et. al.; Silencing of Gene Expression by Gymnotic Delivery of Antisense Oligonucleotides; chapter 25; Michael Kaufmann and claudia Klinger (eds.), Functional Genomics: Methods and Ptotocols).

Formulations of the pharmaceutical compositions described herein may be prepared by methods known in the art of formulation. The preparatory methods may include bringing the antisense oligonucleotide into association with a diluent or another excipient and/or one or more other ingredients, and then if desirable, packaging (e.g. shaping) the product into a desired single- or multi-dose unit. The amount of the antisense oligonucleotide depends on the delivery approach and the specific formulation. The amount of the antisense oligonucleotide will also depend on the subject to be treated (size and condition) and also depend on route of administration. An antisense oligonucleotide, a conjugate or a pharmaceutical composition of the present invention is typically administered in an effective amount.

By way of example, the composition may comprise between 0.1% and 100% (w/w) of the antisense oligonucleotide.

The pharmaceutical formulations according to the present invention may also comprise one or more of the following: a pharmaceutically acceptable excipient, e.g. one or more solvents, dispersion media, diluents, liquid vehicles, dispersion or suspension aids, isotonic agents, surface active agents, preservatives, solid binders, thickening or emulsifying agents, lubricants and the like. It is of cause important that the added excipient are pharmaceutically acceptable and suited to the particular dosage form desired. Remington’s The Science and Practice of Pharmacy, 21″Edition, A. R. Gennaro (Lippincott, Williams 8 Wilkins, Baltimore, MD, 2006; incorporated herein by reference) discloses various excipients used in formulating pharmaceutical compositions and known techniques for the preparation thereof.

The invention will be more fully understood by reference to the following examples. They should not, however, be construed as limiting the scope of the invention. All literature citations are incorporated by reference.

Items Relating to Compounds Targeting circRNAs

1) An antisense oligonucleotide consisting of a sequence of 14-22 nucleobases in length that is a gapmer comprising a central region of 6 to 16 consecutive DNA nucleotides flanked in each end by wing regions each comprising 1 to 5 nucleotide analogues, and wherein the antisense oligonucleotide comprises 1 to 21 phosphorothioate internucleotide linkages, and wherein the oligonucleotide is complementary to an endogenous circRNA.

2) An antisense oligonucleotide consisting of a sequence of 10-22 nucleobases in length that is a mixmer which does not comprise a region of more than anyone of 2, 3, 4 or 5 consecutive DNA nucleotides, and which comprises from 3 to 22 affinity-enhancing nucleotide analogues, and wherein the antisense oligonucleotide comprises 1 to 21 phosphorothioate internucleotide linkages, and wherein the oligonucleotide is complementary to an endogenous circRNA.

3) A siRNA for inhibition of a circRNA, and wherein one strand of the siRNA has a region of 15-21 nucleotides of complementarity to a circRNA backsplice-juncion and wherein the region of complementarity overlaps the circRNA backsplice site with at least 3 nucleotides.

4) The antisense oligonucleotide according to item 1 or 2, wherein the sequence of complementarity of the antisense oligonucleotide to a circRNA, overlaps the circRNA back-splice junction by at least 3 nucleotides.

5) The antisense oligonucleotide according to anyone of items 1 - 4, wherein the circRNA is anyone of a circRNA selected from the list of ciRS-7, circFAT1, circPVT1, circHIPK3, circSRY, circSLC35E2B, circCDK11A, circUNKNOWN00000001, circARHGAP32, circSLC8A3, circHERC2, circZFAND6, circRP1-168P16.1, circAURKC, circAFTPH, circSCD, circSMC3, circSNORA23|lPO7.1, circZNF124.1, circSNX5|OVOL2, circRALY, circTFPI, circAHSG.1, circAHSG.2, circAHSG.3, circUBXN7, circAFP, circHIST1H3A, circHIST1H3C.1, circANAPC2, circRMRP|RMRP, circCENPI, circFIRRE, circMBNL3, circGPC3 and circFAT1.

6) The antisense oligonucleotide according to anyone of items 1 - 5, wherein the circRNA is anyone of a circRNA selected from the list of ciRS-7, circFAT1, circPVT1, circHIPK3, circSRY, circSLC35E2B, circCDK11A, circUNKNOWN00000001, circARHGAP32, circSLC8A3, circHERC2, circZFAND6, circRP1-168P16.1, circAURKC, circAFTPH, circSCD, circSMC3, circSNORA23|lPO7.1, circZNF124.1, circSNX5|OVOL2, circRALY, circTFPI, circAHSG.1, circAHSG.2, circAHSG.3, circUBXN7, circAFP, circHIST1H3A, circHIST1H3C.1, circANAPC2, circRMRP|RMRP, circCENPI, circFIRRE, circMBNL3, circGPC3, circPROSER2, circMALRD1, circFAM208B, circMCU, circKIF20B, circABCC2, circEIF4G2|SNORD97.1, circEIF4G2|SNORD97.2, circEIF4G2|SNORD97.3, circEIF4G2|SNORD97.4, circEIF4G2|SNORD97.5, circEIF4G2|SNORD97.6, circEIF4G2|SNORD97.7, circEIF4G2|SNORD97.8, circEIF4G2|SNORD97.9, circEIF4G2|SNORD97.10, circlGF2, circQSER1, circUNKNOWN00000002, circCHD1L, circPRUNE, circSLC27A3, circGATAD2B, circKIAA0907, circCCT3, circPLEKHM2, circVWCE, circATF6, circMALAT1.1, circMALAT1.2, circMALAT1.3, circMALAT1.4, circMALAT1.5, circMALAT1.6, circMALAT1.7, circMALAT1.8, circMALAT1.9, circMALAT1.10, circMALAT1.11, circMALAT1.12, circMALAT1.13, circUNKNOWN00000003, circMALAT1.14, circMALAT1.15, circMALAT1.16, circMALAT1.17, circMALAT1.18, circMALAT1.19, circUCK2, circSUCO, circRAB6A, circRPS3|SNORD15B.1, circRPS3|SNORD15B.2, circRPS3|SNORD15B.3, circRSF1, circABL2, circGNB1, circRPLP2|SNORA52, circPICALM.1, circPICALM.2, circSNORA23|IPO7.2, circSNORA23|IPO7.3, circCFH, circSLC41A2.1, circSLC41A2.2, circCORO1C, circElF4G3| RP11-487E1.2, circNAA25, circMED13L, circLPGAT1|RN7SL344P, circAACS, circTP53BP2, circSOX5, circDNAH14, circKDM1A| MIR3115, circTTC13, circEGLN1, circTCEA3, circTOMM20|SNORA14B, circSCCPDH, circZNF124.2, circGLS2, circR3HDM2, circDHDDS, circSNORA73A|RCC1|SNHG3.1, circSNORA73A|RCC1|SNHG3.2, circSNORA61|SNHG12, circCEP83|RBMS2P1, circFGD6, circPUM1, circTMCO3|RP11-230F18.6, circPTP4A2, circZMYM5, circN6AMT2, circRPL21|SNORA27, circGTF2F2, circZMYM4, circLINC00355, circUNKNOWN00000004, circFARP1, circDYNC1H1, circCDC42BPB, circCCNB1IP1|SNORA79|AL355075.1, circRPPH1|RPPH1.1, circRPPH1|RPPH1.2, circRPPH1|RPPH1.3, circRPPH1|RPPH1.4, circSNORD8|CHD8.1, circSNORD8|CHD8.2, circPPP1R3E, circCHMP4A|RP11-468E2.1|AL136419.6, circUNKNOWN00000005, circSEC23A, circSNORD46 | RPS8, circSAMD4A, circPCNX, circPSEN1, circFCF1, circSCARNA13|SNHG10.1, circSCARNA13|SNHG10.2, circSCARNA13|SNHG10.3, circUNKNOWN00000006, circTJP1, circRP11-632K20.7, circTTBK2, circPPIB, circUBE2Q2, circETFA, circSEC11A, circPDE8A, circDAB1|OMA1, circABHD2, circlQGAP1.1, circlQGAP1.2, circCHD2, circlGF1R, circNPRL3, circNDE1, circABCC1, circRPS2 |SNORA64, circPOLR3E, circATXN2L, circMVP, circASPHD1, circITGAL, circRP5-857K21.6.1, circRP5-857K21.6.2, circRP5-857K21.6.3, circRP5-857K21.6.4, circZNF720, circLONP2, circCHD9, circSLC7A6, circCARHSP1, circFANCA, circRAD51D|RAD51L3-RFFL, circHDAC5, circUTP18, circSRSF1, circPPM1D, circBRIP1, circPRKCA.1, circPRKCA.2, circElF4A1|SNORD10|RP11-186B7.4|SENP3-EIF4A1.1, circEIF4A1|SNORD10|RP11-186B7.4|SENP3-EIF4A1.2, circPGS1, circRPTOR, circRPL26|RP11-849F2.7, circRP11-206L10.8, circPIAS2, circTYMS, circPPP4R1, circZNF91, circWDR62, circADCK4, circARHGAP35, circNUCB1, circSNORD33|RPL13A.1, circSNORD33|RPL13A.2, circSNORD33 | RPL13A.3, circMUC16, circLZIC, circSNX5|SNORD17|OVOL2.1, circSNX5|SNORD17|OVOL2.2, circSNORA71A|SNHG17, circPLTP, circTMEM230, circCYP24A1, circZBTB46, circGART, circRAB3GAP1, circDYRK1A, circUNKNOWN00000007, circCOL18A1.1, circCOL18A1.2, circNBAS, circCH507-513H4.1.1, circCH507-513H4.1.2, circCH507-513H4.1.3, circANKAR, circGLS, circBMPR2, circRHBDD1, circATG16L1|SCARNA5, circDGKD, circPASK, circPPP6R2, circBIRC6, circPRKD3, circKIAA184|RP11-493E12.3, circRTKN, circELMOD3, circREV1, circZBTB20, circTIMMDC1, circACAD9, circPLXND1, circHDAC11, circCEP70, circRNF13.1, circRNF13.2, circGOLIM4, circElF4A2|SNORD2.1, circEIF4A2|SNORD2.2, circSDHAP1, circSETD2, circSCAP, circUSP4, circRPL29, circPHF7, circNEK4, circFLNB, circSLC25A26, circNFKB1, circFIP1L1|RP11-231C18.3, circTBC1D14, circALB.1, circALB.2, circALB.3, circNUP54, circAFF1, circSLC12A7 | MIR4635, circMAN2A1.1, circMAN2A1.2, circAFF4, circUBE2D2, circANKHD1|ANKHD1-EIF4EBP3, circMAPK9, circGPBP1, circCEP72, circRP11-98J23.2, circFAM169A, circWDR41, circRASGRF2, circRHOBTB3, circCEP85L, circARID1B.1, circARID1B.2, circTULP4|RP11-732M18.4, circTULP4, circTMEM181, circHIST1H3B, circHIST1H3C.2, circUNKNOWN00000008, circC6orf136, circHLA-C|HLA-B |XXbac-BPG248L24.10|WASF5P|XXbac-BPG248L24.13.1, circHLA-C|HLA-B|XXbac-BPG248L24.10|WASF5P|XXbac-BPG248L24.13.2, circFKBP5, circCNPY3, circSRF, circRN7SK, circFARS2, circMLIP, circZNF292, circPNRC1, circUNKNOWN00000009, circNDUFB2, circKMT2C, circESYT2, circMPP6, circHERPUD2, circOGDH, circZNF680, circKDELR2|DAGLB, circZDHHC4, circCCZ1B, circPOM121, circBAZ1B, circGTF2I, circSNORA14A, circCDK14, circCCDC132, circTRRAP|MIR3609, circCYP3A7|CYP3A7-CYP3A51P, circCCAT1.1, circCCAT1.2, circCCAT1.3, circCCAT1.4, circCCAT1.5, circCCAT1.6, circCCAT1.7, circASAP1, circPTK2.1, circPTK2.2, circSLC45A4, circADGRB1, circRBPMS, circFGFR1, circHOOK3, circASPH, circTMEM245, circUNKNOWN00000010, circHSPA5, circGLE1, circFOCAD, circNFX1, circUBAP2, circKDM4C|RP11-146B14.1, circAGTPBP1, circFAM120A.1, circFAM120A.2, circHIATL1, circPPP2R3B, circATRX, circFAT1 or circTBL1X.

7) The antisense oligonucleotide or siRNA or dsRNA according to anyone of items 1 - 6, wherein the antisense oligonucleotide or siRNA or dsRNA is at least 80%, such as at least 85%, such as at least 90 %, such as at least 100% complementary to a sequence of between 14 and 22 nucleotides in length and which is located within anyone of SEQ ID NOs: 1 - 359 and 2260.

8) The antisense oligonucleotide or siRNA or dsRNA of anyone of items 1 - 7, wherein the antisense oligonucleotide comprises in total at least three sugar-modified nucleobases that enhance the binding affinity of the antisense oligonucleotide to the circRNA.

9) The antisense oligonucleotide or siRNA or dsRNA of item 8, wherein the sugar modified nucleobase units are selected from the list of LNA (Locked nucleic acid), tricyclo-DNA, 2′-Fluoro, 2′-O-methyl, 2′methoxyethyl (2′MOE), 2′cyclic ethyl (cET), UNA, and Conformationally Restricted Nucleoside (CRN).

10) A compound according to item 9, wherein the nucleotide analogues are LNA, and selected from the list of beta-D-oxy LNA, alpha-L-oxy-LNA, beta-D-amino-LNA, alpha-L-amino-LNA, beta-D-thio-LNA, alpha-L-thio-LNA, 5′-methyl-LNA, beta-D-ENA and alpha-L-ENA.

11) A compound according to item 10, wherein the nucleosides are Beta-D-Oxy LNA.

12) A compound according to anyone of items 1 - 11, wherein the nucleoside analogues are a mixture of LNA and anyone of tricyclo-DNA, 2′-Fluoro, 2′-O-methyl, 2′-methoxyethyl (2′MOE), 2′cyclic ethyl (cET), UNA, and Conformationally Restricted Nucleoside (CRN).

13) A compound according to items 11 - 12 wherein the nucleoside analogues are a mixture of LNA and 2′-fluoro.

14) The antisense oligonucleotide according to any one of items 1-13, wherein all internucleoside linkages are phosphorothioate linkages.

15) The antisense oligonucleotide according to anyone of the preceding items, wherein the antisense oligonucleotide comprises a gap of at least 7, 8, 9, 10, 11, 12, 13 or 14 DNA units, flanked in each end by wings comprising at least one sugar-modified nucleobase.

16) The antisense oligonucleotide according to item 15, wherein the wings comprises 1, 2, 3, 4, 5, or 6 sugar modified nucleobase units, such as 2 to 5 modified nucleobase units.

17) The antisense oligonucleotide according to anyone of items 1-16, wherein the antisense oligonucleotide is anyone of SEQ ID NO’s: 360 - 2148 or anyone of SEQ ID NO’s 2285-2299.

18) The antisense oligonucleotide or siRNA according to anyone of the preceeding items, wherein the antisense oligonucleotide or siRNA is conjugated with a ligand for targeted delivery.

19) The antisense oligonucleotide or siRNA according to item 18, wherein the antisense oligonucleotide or siRNA is conjugated with folic acid or N-acetylgalactosamine (GalNAc).

20) The antisense oligonucleotide or siRNA according to anyone of items 1-17, wherein the antisense oligonucleotide or siRNA is unconjugated in a pharmaceutical composition for delivery.

21) The antisense oligonucleotide or siRNA according to anyone of items 1-17, wherein the antisense oligonucleotide or siRNA is formulated in lipid nanoparticles for delivery.

22) The antisense oligonucleotide or siRNA according to any one of the preceeding items, for use as a medicament.

23) The antisense oligonucleotide or siRNA according to item 22, wherein the antisense oligonucleotide or siRNA is for use as a medicament in the treatment of cancer.

24) The antisense oligonucleotide or siRNA according to item 23, wherein the antisense oligonucleotide or siRNA is according to items 2 - 5.

25) The antisense oligonucleotide or siRNA according to item 23 or 24, wherein the cancer is hepatocellular carcinoma.

26) A composition comprising an antisense oligonucleotide or siRNA according to anyone of the preceeding items and a carrier.

27) A composition comprising an antisense oligonucleotide or siRNA according to any one of items 1-21, for use as a pharmaceutical or in a method of treatment.

28) A composition according to items 26-27, wherein the composition comprises more than one antisense oligonucleotide or siRNA according to anyone of items 1-25.

29) A composition according to item 28, wherein the two or more antisense oligonucleotides or siRNA are selected from the list of anyone of SEQ ID NOs: 360 - 2148 or anyone of SEQ ID NO’s 2285-2299.

30) The composition according to anyone of items 26-29, wherein the antisense oligonucleotide or siRNA or composition is for treatment of hepatocellular carcinoma.

31) The composition according to item 30, wherein the cancer is selected from the list of cancers, such as hepatocellular carcinoma, breast cancer, CNS tumors, leukemias, melanoma, non-small cell lung cancer, prostate cancer or renal cancer.

32) The antisense oligonucleotide or siRNA according to anyone of items 1-25, or composition according items 26 to 31, wherein the antisense oligonucleotide or composition is for treatment of a human subject.

33) The antisense oligonucleotide or composition according to anyone of the preceding items, wherein the antisense oligonucleotide or siRNA or composition is for treatment of a cell ex vivo.

34) A method of knocking down an endogenous circRNA in a cell, by administration of an effective amount of an antisense oligonucleotide according to anyone of items 1-25, or a composition according to anyone of items 26-31 to a cell.

35) The method of item 34, wherein the cell is in a human body.

36) The method of item 35, wherein the cell is a cancer cell in a human body.

37) A method of treatment of cancer in, comprising the administration of an effective dosage of an antisense oligonucleotide or a composition according to anyone of items 1-36 to a human subject.

38) The method according to item 37, wherein the cancer is selected from the list of cancers such as hepatocellular carcinoma, breast cancer, CNS tumors, leukemias, melanoma, non-small cell lung cancer, prostate cancer or renal cancer.

39) The antisense oligonucleotides or siRNA, or compositions or methods of treatment according to any one of items 1-38, wherein the antisense oligonucleotide, or compositions or methods of treatment are for use in combination with another compound, composition or method of treatment.

40) A method of treating cancer, characterized by the following steps:

• a. Isolate cancer cells from a patient.
• b. Testing the presence of circRNAs in the cancer cells.
• c. If the cancer cell is tested positive for a circRNA in step b, for one or more circRNAs, a composition comprising an antisense oligonucleotide or siRNA according to anyone of items 1-20 is selected, wherein the antisense oligonucleotide or siRNA is antisense to or has a region of complementarity to the circRNA that is expressed according to the test in step b.
• d. The cancer is treated with the composition of step c, by administering an efficient amount of the composition to the patient having the cancer.

41) The method according to item 40, wherein the circRNA level measured in step b is any circRNA. 42) The method according to item 40 or 41, wherein the circRNA level measured in step a is anyone selected from the list of ciRS-7, circFAT1, circPVT1, circHIPK3, circSRY, circSLC35E2B, circCDK11A, circUNKNOWN00000001, circARHGAP32, circSLC8A3, circHERC2, circZFAND6, circRP1-168P16.1, circAURKC, circAFTPH, circSCD, circSMC3, circSNORA23|IP07.1, circZNF124.1, circSNX5|OVOL2, circRALY, circTFPI, circAHSG.1, circAHSG.2, circAHSG.3, circUBXN7, circAFP, circHIST1H3A, circHIST1H3C.1, circANAPC2, circRMRP|RMRP, circCENPI, circFIRRE, circMBNL3, circGPC3, circPROSER2, circMALRD1, circFAM208B, circMCU, circKIF20B, circABCC2, circElF4G2|SNORD97.1, circEIF4G2|SNORD97.2, circEIF4G2|SNORD97.3, circEIF4G2|SNORD97.4, circEIF4G2|SNORD97.5, circEIF4G2|SNORD97.6, circEIF4G2|SNORD97.7, circEIF4G2|SNORD97.8, circEIF4G2|SNORD97.9, circElF4G2|SNORD97.10, circlGF2, circQSER1, circUNKNOWN00000002, circCHD1L, circPRUNE, circSLC27A3, circGATAD2B, circKIAA0907, circCCT3, circPLEKHM2, circVWCE, circATF6, circMALAT1.1, circMALAT1.2, circMALAT1.3, circMALAT1.4, circMALAT1.5, circMALAT1.6, circMALAT1.7, circMALAT1.8, circMALAT1.9, circMALAT1.10, circMALAT1.11, circMALAT1.12, circMALAT1.13, circUNKNOWN00000003, circMALAT1.14, circMALAT1.15, circMALAT1.16, circMALAT1.17, circMALAT1.18, circMALAT1.19, circUCK2, circSUCO, circRAB6A, circRPS3|SNORD15B.1, circRPS3|SNORD15B.2, circRPS3|SNORD15B.3, circRSF1, circABL2, circGNB1, circRPLP2|SNORA52, circPICALM.1, circPICALM.2, circSNORA23|IPO7.2, circSNORA23|IPO7.3, circCFH, circSLC41A2.1, circSLC41A2.2, circCORO1C, circElF4G3|RP11-487E1.2, circNAA25, circMED13L, circLPGAT1| RN7SL344P, circAACS, circTP53BP2, circSOX5, circDNAH14, circKDM1A|MIR3115, circTTC13, circEGLN1, circTCEA3, circTOMM20|SNORA14B, circSCCPDH, circZNF124.2, circGLS2, circR3HDM2, circDHDDS, circSNORA73A|RCC1|SNHG3.1, circSNORA73A|RCC1|SNHG3.2, circSNORA61|SNHG12, circCEP83|RBMS2P1, circFGD6, circPUM1, circTMCO3|RP11-230F18.6, circPTP4A2, circZMYM5, circN6AMT2, circRPL21|SNORA27, circGTF2F2, circZMYM4, circLINC00355, circUNKNOWN00000004, circFARP1, circDYNC1H1, circCDC42BPB, circCCNB1IP1|SNORA79|AL355075.1, circRPPH1|RPPH1.1, circRPPH1|RPPH1.2, circRPPH1|RPPH1.3, circRPPH1|RPPH1.4, circSNORD8|CHD8.1, circSNORD8|CHD8.2, circPPP1R3E, circCHMP4A|RP11-468E2.1|AL136419.6, circUNKNOWN00000005, circSEC23A, circSNORD46 | RPS8, circSAMD4A, circPCNX, circPSEN1, circFCF1, circSCARNA13|SNHG10.1, circSCARNA13|SNHG10.2, circSCARNA13|SNHG10.3, circUNKNOWN00000006, circTJP1, circRP11-632K20.7, circTTBK2, circPPIB, circUBE2Q2, circETFA, circSEC11A, circPDE8A, circDAB1 |OMA1, circABHD2, circlQGAP1.1, circlQGAP1.2, circCHD2, circlGF1R, circNPRL3, circNDE1, circABCC1, circRPS2 |SNORA64, circPOLR3E, circATXN2L, circMVP, circASPHD1, circITGAL, circRP5-857K21.6.1, circRP5-857K21.6.2, circRP5-857K21.6.3, circRP5-857K21.6.4, circZNF720, circLONP2, circCHD9, circSLC7A6, circCARHSP1, circFANCA, circRAD51D|RAD51L3-RFFL, circHDAC5, circUTP18, circSRSF1, circPPM1D, circBRIP1, circPRKCA.1, circPRKCA.2, circEIF4A1|SNORD10|RP11-186B7.4|SENP3-EIF4A1.1, circEIF4A1|SNORD10|RP11-186B7.4|SENP3-EIF4A1.2, circPGS1, circRPTOR, circRPL26|RP11-849F2.7, circRP11-206L10.8, circPIAS2, circTYMS, circPPP4R1, circZNF91, circWDR62, circADCK4, circARHGAP35, circNUCB1, circSNORD33|RPL13A.1, circSNORD33|RPL13A.2, circSNORD33|RPL13A.3, circMUC16, circLZIC, circSNX5|SNORD17|OVOL2.1, circSNX5|SNORD17|OVOL2.2, circSNORA71A|SNHG17, circPLTP, circTMEM230, circCYP24A1, circZBTB46, circGART, circRAB3GAP1, circDYRK1A, circUNKNOWN00000007, circCOL18A1.1, circCOL18A1.2, circNBAS, circCH507-513H4.1.1, circCH507-513H4.1.2, circCH507-513H4.1.3, circANKAR, circGLS, circBMPR2, circRHBDD1, circATG16L1|SCARNA5, circDGKD, circPASK, circPPP6R2, circBIRC6, circPRKD3, circKIAA1841|RP11-493E12.3, circRTKN, circELMOD3, circREV1, circZBTB20, circTIMMDC1, circACAD9, circPLXND1, circHDAC11, circCEP70, circRNF13.1, circRNF13.2, circGOLIM4, circEIF4A2|SNORD2.1, circEIF4A2|SNORD2.2, circSDHAP1, circSETD2, circSCAP, circUSP4, circRPL29, circPHF7, circNEK4, circFLNB, circSLC25A26, circNFKB1, circFIP1L1|RP11-231C18.3, circTBC1D14, circALB.1, circALB.2, circALB.3, circNUP54, circAFF1, circSLC12A7|MIR4635, circMAN2A1.1, circMAN2A1.2, circAFF4, circUBE2D2, circANKHD1|ANKHD1-EIF4EBP3, circMAPK9, circGPBP1, circCEP72, circRP11-98J23.2, circFAM169A, circWDR41, circRASGRF2, circRHOBTB3, circCEP85L, circARID1B.1, circARID1B.2, circTULP4|RP11-732M18.4, circTULP4, circTMEM181, circHIST1H3B, circHIST1H3C.2, circUNKNOWN00000008, circC6orf136, circHLA-C|HLA-B|XXbac-BPG248L24.10|WASF5P|XXbac-BPG248L24.13.1, circHLA-C |HLA-B|XXbac-BPG248L24.10|WASF5P|XXbac-BPG248L24.13.2, circFKBP5, circCNPY3, circSRF, circRN7SK, circFARS2, circMLIP, circZNF292, circPNRC1, circUNKNOWN00000009, circNDUFB2, circKMT2C, circESYT2, circMPP6, circHERPUD2, circOGDH, circZNF680, circKDELR2|DAGLB, circZDHHC4, circCCZ1B, circPOM121, circBAZ1B, circGTF2I, circSNORA14A, circCDK14, circCCDC132, circTRRAP|MIR3609, circCYP3A7|CYP3A7-CYP3A51P, circCCAT1.1, circCCAT1.2, circCCAT1.3, circCCAT1.4, circCCAT1.5, circCCAT1.6, circCCAT1.7, circASAP1, circPTK2.1, circPTK2.2, circSLC45A4, circADGRB1, circRBPMS, circFGFR1, circHOOK3, circASPH, circTMEM245, circUNKNOWN00000010, circHSPA5, circGLE1, circFOCAD, circNFX1, circUBAP2, circKDM4C|RP11-146B14.1, circAGTPBP1, circFAM120A.1, circFAM120A.2, circHIATL1, circPPP2R3B, circATRX, circFAT1 or circTBL1X.

Items Relating to Compounds Targeting IncRNAs

1) A compound comprising a gapmer antisense oligonucleotide consisting of any one of SEQ ID NOs: 2149 - 2259.

2) A compound according to item 1, wherein the nucleotide analogues of the wings are selected from the list of beta-D-oxy LNA, alpha-L-oxy-LNA, beta-D-amino-LNA, alpha-L-amino-LNA, beta-D-thio-LNA, alpha-L-thio-LNA, 5′-methyl-LNA, beta-D-ENA and alpha-L-ENA.

3) A compound according to item 2, wherein the nucleosides of the wings are Beta-D-Oxy LNA.

4) A compound according to item 1, wherein the nucleoside analogues of the wings are not LNA, but anyone of tricyclo-DNA, 2′-Fluoro, 2′-O-methyl, 2′-methoxyethyl (2′-MOE), 2′cyclic ethyl (cET), UNA, and Conformationally Restricted Nucleoside (CRN).

5) A compound according to item 1, wherein the nucleoside analogues of the wings are a mixture of LNA and anyone of tricyclo-DNA, 2′Fluoro, 2′-O-methyl, 2′-methoxyethyl (2′-MOE), 2′cyclic ethyl (cET), UNA, and Conformationally Restricted Nucleoside (CRN).

6) A compound according to item 5, wherein the nucleoside analogues of the wings are a mixture of LNA and 2′-Fluoro.

7) The compound according to anyone of items 1-6, wherein the antisense oligonucleotide is conjugated with a ligand for targeted delivery.

8) The compound according to item 7, wherein the antisense oligonucleotide is conjugated with folic acid or N-acetylgalactosamine (GalNAc).

9) The compound according to anyone of items 1-6, wherein the antisense oligonucleotide is unconjugated in a pharmaceutical composition for delivery.

10) The compound according to anyone of items 1-9, wherein the antisense oligonucleotide is formulated in lipid nanoparticles for delivery.

11) The compound according to any one of the preceding items, for use as a medicament.

12) The compound according to item 11, wherein the antisense oligonucleotide is for use as a medicament in the treatment of cancer.

13) The compound according to item 12, wherein the cancer is hepatocellular carcinoma.

14) A composition comprising a compound or an antisense oligonucleotide according to anyone of the preceding items and a carrier.

15) A composition comprising a compound or an antisense oligonucleotide according to any one of items 1-9, for use as a pharmaceutical or in a method of treatment.

16) A composition according to items 14-15, wherein the composition comprises more than one compound or antisense oligonucleotide according to anyone of items 1-13.

17) A composition according to item 16, wherein the two or more antisense oligonucleotides are selected from the list of anyone of SEQ ID NOs: 2149 - 2259.

18) The composition according to anyone of items 14-17, wherein the composition is for treatment of cancer.

19) The composition according to item 18, wherein the cancer is hepatocellular carcinoma.

20) The compound or antisense oligonucleotide according to anyone of items 1-13, or composition according items 14 to 19, wherein the compound or antisense oligonucleotide or composition is for treatment of a human subject.

21) The compound or antisense oligonucleotide or composition according to anyone of the preceding items, wherein the antisense oligonucleotide or composition is for treatment of a cell ex vivo.

22) A method of downregulating an endogenous IncRNA selected from the list of DANCR, H19, HOTAIR, HOTTIP, HULC, LINC-ROR, MALAT1, MVIH, NEAT1, PCBP2-OT1, PVT1, TUG1, UCA1, UFC1 and LINC01215 in a cell, by administration of an effective amount of a compound or antisense oligonucleotide that is complementary to the target and selected from the list of SEQ ID NOs: 2149 - 2259 and according to anyone of items 1-12, or a composition according to anyone of items 13-18 to a cell.

23) The method of item 22, wherein the cell is in a human body.

24) The method of item 23, wherein the cell is a cancer cell in a human body.

25) A method of treatment of cancer, comprising the administration of an effective dosage of a compound or antisense oligonucleotide or a composition according to anyone of items 1-21 to a human.

26) The method according to item 24, wherein the cancer is hepatocellular carcinoma.

27) The antisense oligonucleotides, or compositions or methods of treatment according to any one of items 1-26, wherein the antisense oligonucleotide, or compositions or methods of treatment are for use in combination with another compound, composition or method of treatment.

EXAMPLES

Example 1. LNA monomer and oligonucleotide synthesis may be performed using the methodology referred to in Examples 1 and 2 of WO2007/11275. Assessment of the stability of LNA oligonucleotides in human or rat plasma may be performed using the methodology referred to in Example 4 of WO2007/112754. Treatment of cultured cells with LNA-modified antisense oligonucleotides may be performed using the methodology referred to in Example 6 of WO2007/11275.

Example 2. RNA isolation and expression analysis from cultured cells and tissues is performed using the methodology referred to in Example 10 of WO2007/112754. RNAseq-based transcriptional profiling from cultured cells and tissues is performed using the methodology referred to in (Jeck et al. 2013, RNA 19: 141-157 or Zheng et al. 2016 Nature Commun. 7: 11215).

Example 3 General Description of the Antisense Oligonucleotide Design Workflow

Antisense oligonucleotides capable of decreasing the expression of target transcript(s) are designed as RNaseH-recruiting gapmer oligonucleotides. Gapmer oligonucleotides are designed by applying various locked nucleid acid (LNA)/DNA patterns (typically the patterns constitute a central region of DNA flanked by short LNA wings, e.g. LLLDDDDDDDDDDLLL, where L denotes LNA and D denotes DNA) to the reverse complement of target site sequences. A comprehensive list of all n-mer target sites in a transcript (n = 14-20 bases, non-limiting example) is generated and oligonucleotides that can bind to the target sites with desired specificity in the transcriptome and have desired thermodynamic and structural properties are synthesized and tested in vitro in cancer cell lines and subsequently in vivo in mouse tumor models. The ASOs of this invention, are listed in Table 2 and 3 (LNA= uppercase, DNA lowercase, complete phosphorothioate backbone), and examples demonstrating their potential in circRNA and IncRNA knockdown are described in examples 4-12 below.

Example 4 Identification of Cancer-Associated circRNAs

RNAseq data was mapped to the human genome (hg38) using the RNAseq aligner STAR (Dobin et al. 2013, Bioinformatics 29: 15-21) with chimeric alignment detection enabled, essentially as described in the manual. Subsequent to read alignment, the chimeric reads were filtered to identify spliced reads where the donor and acceptor are on the same chromosome, same strand, and the donor is positioned downstream of the acceptor (maximum allowed distance between donor and acceptor is 100.000 bases). Donor and acceptor positions were defined as the intronic positions surrounding the bases that are covalently linked by backsplicing, and the chromosomal coordinate system used is 1-based. Each backsplice junction was uniquely identified in the hg38 genome by the chromosome name (chrName), position of the donor and acceptor (posAcceptor and posDonor), and the strand of the chromosome (strand). A unique backsplice ID (bsID) was generated from this info ([chrName]:[posAcceptor]-[posDonor] | [strand], e.g. X:140783175-140784661|+). Back-splice junctions from cancer-associated circRNAs were identified by analyzing RNAseq data from multiple myeloma patients, by searching for hepatocellular carcinoma-associated circRNAs in the circ2Traits database (http://gyanxetbeta.com/circdb/searchdis.php?trait=hepatocellular+carcinoma&but=Search), analysis of HepG2 and liver RNAseq data from the ENCODE project (https://www.encodeproject.org/), and analysis of Gene Expression Omnibus dataset with accession number GSE77661. Multiple myeloma RNAseq data was analyzed to find circRNAs showing up-regulation in sorted malignant plasma cells from multiple myeloma patients compared to plasma cells from healthy donors. The ENCODE data were analyzed to identify back-splice junctions of circRNAs that exhibited higher expression in HepG2 cells than in adolescent/adult liver samples. GSE77661 data was analyzed to find back-splice junctions of circRNAs that were upregulated in hepatocellular carcinoma compared to normal adjacent tissue. Collectively, this resulted in identification of 359 backsplice junctions (Table 1). From the list of 359 backsplice junctions, we generated a shortlist consisting of ciRS-7, circPVT1, circHIPK3, circSRY, the 10 backsplice junctions from circRNAs found to be associated with hepatocellular carcinoma in the circ2Traits database (circSLC35E2B, circCDK11A, circUNKNOWN00000001, circARHGAP32, circSLC8A3, circHERC2, circZFAND6, circRP1-168P16.1, circAURKC, and circAFTPH) and 20 backsplice junctions from circRNAs that also show fetal expression (circSCD, circSMC3, circSNORA23|IPO7.1, circZNF124.1, circSNX5|OVOL2, circRALY, circTFPI, circAHSG.1, circAHSG.2, circAHSG.3, circUBXN7, circAFP, circHIST1H3A, circHIST1H3C.1, circANAPC2, circRMRP|RMRP, circCENPI, circFIRRE, circMBNL3, and circGPC3).

Example 5 Design of LNA-Modified Antisense Oligonucleotides for Knockdown of the ciRS-7 Circular RNA

LNA antisense oligonucleotides that can effectively knock down the ciRS-7 circRNA were designed. In this example, the target region is the sequence that is generated by back-splicing of the CDR1-AS transcript (SEQ ID: 1, see appendix), i.e. linking the end of the transcript to the start of the transcript to form a circular molecule (designated as ciRS-7). Three LNA ASOs were synthesized that cover the ciRS-7 back-splice junction site (Table 3: SEQ ID NOs: 360-362).

Example 6. Design of LNA-Modified Antisense Oligonucleotides for Knockdown of IncRNAs In Hepatocellular Carcinoma.

Several IncRNAs, such as DANCR, H19, HOTAIR, HOTTIP, HULC, LINC-ROR, MALAT1, MVIH, NEAT1, PCBP2-OT1, PVT1, TUG1, UCA1, UFC1 and LINC01215 have been implicated in the pathogenesis of hepatocellular carcinoma (for review, see Parasramka et al., 2016, Pharmacol. Ther. 161: 67-78). LNA antisense oligonucleotides for knockdown of DANCR, H19, HOTAIR, HOTTIP, HULC, LINC-ROR, MALAT1, MVIH, NEAT1, PCBP2-OT1, PVT1, TUG1, UCA1, UFC1 and LINC01215 were designed as described in example 3. In this example, the target regions for DANCR are generated from spliced and unspliced transcripts (SEQ ID NOs 2262 and 2273, respectively), the target regions for H19 are generated from spliced and unspliced transcripts (SEQ ID NOs 2266 and 2278, respectively), the target regions for HOTAIR are generated from spliced and unspliced transcripts (SEQ ID NOs 2267 and 2280, respectively), the target regions for HOTTIP are generated from spliced and unspliced transcripts (SEQ ID NOs 2264 and 2275, respectively), the target regions for HULC are generated from spliced and unspliced transcripts (SEQ ID NOs 2263 and 2274, respectively), the target regions for LINC-ROR are generated from spliced and unspliced transcripts (SEQ ID NOs 2268 and 2281, respectively), the target regions for MALAT1 are generated from unspliced transcript (SEQ ID NO 2277), the target regions for MVIH are generated from unspliced transcript (SEQ ID NO 2284), the target regions for PCBP2-OT1 are generated from unspliced transcript (SEQ ID NO 2279), the target regions for TUG1 are generated from spliced and unspliced transcripts (SEQ ID NOs 2270 and 2283, respectively), the target regions for UCA1 are generated from spliced and unspliced transcripts (SEQ ID NOs 2269 and 2282, respectively), the target regions for UFC1 are generated from spliced and unspliced transcripts (SEQ ID NOs 2260 and 2271, respectively), and the target regions for LINC01215 are generated from spliced and unspliced transcripts (SEQ ID NOs 2261 and 2272, respectively). Two ASOs that target LINC01215 were synthesized (SEQ ID NO: 2191 - 2192).

Example 7 Design of LNA-Modified Antisense Oligonucleotides for Knockdown of the PVT1 LincRNA

LNA antisense oligonucleotides for knockdown PVT1 lincRNA were designed. In this example, the target region is the sequence corresponding to the unspliced PVT1 transcript (SEQ ID NO: 2276) or the spliced transcript (SEQ ID NO: 2265). Two ASOs that target this target region were synthesized (SEQ ID NO: 2233-2234).

Example 8: Cell Culture

Mammalian cancer cell lines are routinely used as models for testing the effect of the antisense oligonucleotides in vitro.

The adherent lung cancer cell line A549 (ECACC cat. no. 86012804) was purchased from Sigma and maintained in Dulbecco’s modified Eagle’s medium (Sigma cat. no. D6546) supplemented with 10% fetal calf serum (Sigma cat. no. F2442), 2 mM L-glutamine (Sigma cat. no. G7513) and penicillin/streptomycin (Sigma cat. no. P4333) in a humidified 5% CO2 incubator at 37° C. and passaged twice a week.

The adherent prostate cancer cell line PC3 (ECACC cat. no. 90112714) was purchased from Sigma and maintained in Ham’s F12K (Kaighn’s) (Life Technologies cat. no. 21127-022) supplemented with 10% fetal calf serum (Sigma cat. no. F2442), and penicillin/streptomycin (Sigma cat. no. P4333) in a humidified 5% CO2 incubator at 37° C. and passaged twice a week.

The semi-adherent multiple myeloma cell line MM.1S was a gift from Prof. K. Dybkjaer at Aalborg University and maintained in RPMI1640 medium (Sigma cat. no. R0883) supplemented with 10% fetal calf serum (Sigma cat. no. F2442), 2 mM L-glutamine (Sigma cat. no. G7513) and penicillin/streptomycin (Sigma ca. no. P4333) in a humidified 5% CO2 incubator at 37° C. and passaged twice a week.

Example 9: Antisense-Mediated Knockdown of the PVT1 lincRNA in Cultured Cancer Cells

The knock down effect mediated by antisense oligonucleotides designed as described in example 3 can be routinely measured in vitro in cultured mammalian cell lines in a number of ways well known to a person skilled in the art. The target transcript must be expressed at a detectable level in the cell lines used, either through endogenous expression or by transient or stable transfection of the target transcript into said cell line. The level of target expression can be measured for example by quantitative PCR or Northern blot. The antisense oligonucleotide can be introduced into the cells using a lipid vehicle or via unassisted uptake.

For lipid-mediated transfection of the PVT1-targeting antisense oligonucleotides listed in Table 3 (SEQ ID NOs: 2233 - 2234) A549 cells were seeded in 12-well cell culture plates the day before transfection and transfected essentially as described in Dean et al. (Journal of Biological Chemistry 1994, 269, 16416-16424) using Lipofectamine 2000 in a final concentration of 5 µl/ml Optimem I (Gibco) and antisense oligonucleotide in a concentration range of 1 nM - 25 nM final concentration. A scrambled sequence oligonucleotide and mock transfection were included as controls. 24 hours after transfection, total RNA was isolated from the cells using the RNeasy mini kit (Qiagen) according to the manufacturer’s instructions and 1 µg total RNA was reverse transcribed into cDNA using the High Capacity cDNA reverse transcription kit (Life Technologies cat. no. 4374967) according to the protocol provided by the manufacturer. PVT1 RNA levels were determined by quantitative RT-PCR using Taqman Gene Expression Master Mix (ABI cat. no. 4369542) and pre-designed PVT1 Taqman assays (IDT Hs.PT.58.24584277), furthermore the expression of GAPDH mRNA was measured (IDT Hs.PT.58.40035104) and used as an endogenous control. Quantitative PCR was carried out on a Quantstudio 6 Flex Real-Time thermocycler (ABI). An example of knockdown of the PVT1 lincRNA in A549 cells, using SEQ ID NOs 2233 and 2234, is shown in FIG. 1.

Example 10: Antisense-Mediated Knockdown of ciRS-7 in Cultured Cancer Cells

For lipid-mediated transfection of the ciRS-7 antisense oligonucleotides listed in Table 2 (SEQ ID NOs: 360 -362), A549 cells were transfected as described in example 9.

For transfection of PC3 cells, cells were seeded in 12-well cell culture plates at a density of 125,000 cells/well the day before transfection and transfected using Lipofectamine 2000 at a final concentration of 2.5 µl/ml using the protocol described in example 9.

Levels of the ciRS-7 RNA were measured using quantitative RT-PCR as described in example 8, briefly, the total amount of ciRS-7 transcript was measured using a Taqman assay designed with convergent PCR primers specific to the RNA, while the circularized form of ciRS-7 was measured using a Taqman assay designed with divergent PCR primers specific to the ciRS-7 RNA, the expression of GAPDH mRNA was measured and used as an endogenous control as described in example 9.

Examples of inhibition of ciRS-7 in A549 cells are shown in FIGS. 2 and 3. Examples of inhibition of ciRS-7 in PC3 cells are shown in FIG. 4.The semi-adherent multiple myeloma cell line MM.1S was a gift from Prof. K. Dybkjaer at Aalborg University and maintained in RPMI1640 medium (Sigma cat. no. R0883) supplemented with 10% fetal calf serum (Sigma cat. no. F2442), 2 mM L-glutamine (Sigma cat. no. G7513) and penicillin/streptomycin (Sigma cat. no. P4333) in a humidified 5% CO2 incubator at 37° C. and passaged twice a week. For unassisted uptake of the ciRS-7 antisense oligonucleotides listed in Table 2, MM.1S cells were seeded in 12-well cell culture plates the day before transfection at a cell density of 125.000 cells/well and transfected essentially as described in Soifer et al. (Methods Mol Biol. 2012; 815: 333-46) using antisense oligonucleotide in a final concentration range of 0.1 µM - 2.5 µM final concentration. Three to six days after transfection, total RNA was isolated from the cells using the RNeasy mini kit (Qiagen) as described in example 9 and levels of ciRS-7 RNA was measured using quantitative PCR as described above. Examples of knockdown of ciRS-7 RNA in MM.1S cells using antisense oligonucleotides CRM0106, CRM0107 and CRM0108 (SEQ ID NOs 360, 361, and 362 respectively) are shown in FIG. 5.

Example 11: Effect of ciRS-7 Knockdown on Cancer Cell Proliferation

For lipid transfection, A549 cells were seeded in clear 96-well plates (NUNC) at a density of 2000 cells pr. well in complete culture medium the day before transfection. Six wells were left without cells for blank control. Lipid transfection was carried out as described in example 9 using 0.25 µl Lipofectamine 2000 in 50 µl OptiMEM pr. well and oligonucleotide concentrations ranging from 1 nM to 25 nM in 6 wells pr. concentration. After 4 hours, the cells were washed with OptiMEM, 100 µl complete culture medium was added to each well and the cells were incubated in a humidified 5% CO2 incubator at 37° C. for 24 - 72 hours. For measurement of cell proliferation, 20 µl of the CellTiter Aqueous One Solution (Promega) was added to each well and the cells were incubated for 1-4 hours in a humidified 5% CO2 incubator at 37° C. The absorbance at 490 nm was read in a Varioskan Lux plate-reader (Thermo Fisher Scientific) and the values from the blank controls were subtracted. The inhibition of proliferation was plotted relative to mock treated controls. Examples on the effect of ciRS-7 knockdown on A549 cell proliferation using antisense oligonucleotides CRM0106, CRM0107 and CRM0108 (SEQ ID NOs 360, 361, and 362 respectively) are shown in FIG. 6.

Example 12: Antisense-Mediated Knockdown of MALAT1 lincRNA in Cultured Cancer Cells

For unassisted uptake of the MALAT1 antisense oligonucleotide listed in Table 3, MM.1S cells were seeded in 12-well cell culture plates transfected essentially as described in Soifer et al. (Methods Mol Biol. 2012; 815: 333-46) and antisense oligonucleotide was added in a concentration range of 0.1 µM -5 µM final concentration. MALAT1 antisense oligonucleotide CRM0058 (SEQ ID NO 2198) was tested against Mock. Three to six days after transfection, total RNA was isolated from the cells using the RNeasy mini kit (Qiagen) as described in example 9. MALAT1 RNA levels were determined by quantitative PCR using Taqman Gene Expression Master Mix (ABI cat. no. 4369542) and pre-designed Taqman assays for MALAT1 (IDT Hs.PT.58.3907580), furthermore the expression of GAPDH mRNA was measured (IDT Hs.PT.58.40035104) and used as an endogenous control. Quantitative PCR was carried out on a Quantstudio 6 Flex Real-Time thermocycler (ABI). Examples of knockdown of MALAT1 in MM.1S cells are shown in FIG. 7.

Example 13: Induction of Apoptosis in Cultured Cancer Cells After MALAT1 Knockdown

The induction of apoptosis in mammalian cells can be measured in various ways using apoptotic markers, such as the translocation of phosphatidylserine to the outer membrane, the activation of caspases, nuclear condensation and DNA fragmentation, which can all be measured by methods well known to a person skilled in the art. For assessment of apoptosis in cultured cancer cells after antisense oligonucleotide-mediated knockdown of MALAT1 (SEQ ID NO 2198), A549 cells were transfected in 12-well plates using Lipofectamine 2000 as described in example 9. Final concentration of the MALAT1 antisense oligonucleotide CRM0058 (SEQ ID NO: 2198) was 25 nM. After 24 hours, cells were harvested by trypsination, washed in cold PBS and stained using the Violet Annexin V/Dead Cell Apoptosis Kit with Pacific Blue annexin V/SYTOX AADvanced (Molecular Probes cat. No. A35136) using the manufacturer’s protocol and cells were subsequently analyzed on an Attune NxT flow cytometer (Life Technologies). Double-negative cells were considered to be live cells, cells positive for annexin V and negative for SYTOX AADvanced were considered as apoptotic cells and cells positive for SYTOX AADvanced were considered to be dead cells. The percentages of live, apoptotic and dead cells in A549 cells treated with CRM0058 (SEQ ID NO: 2198) and mock control as described above are listed in Table 4 and the corresponding dot plots are shown in FIG. 8A and FIG. 8B.

The percentages of live, apoptotic and dead cells in A549 cells treated with CRM0058 (SEQ ID NO: 2198) and mock control
Sample	Live (%)	Apoptotic (%)	Dead (%)
Mock	92,769	0,893	6,339
CRM0058	66,891	22,440	10,670

Example 14: Cell Culture

The adherent liver adenocarcinoma cell line SK-Hep-1 (ECACC cat. no. 91091816) was in EMEM (EBSS) (Sigma cat. no. M2279) supplemented with 10% fetal calf serum (Sigma cat. no. F2442), 2 mM L-glutamine (Sigma cat. no. G7513), 1% NEAA (Sigma cat. no. M7145), 1 mM Sodium Pyruvate (NaP) (Sigma cat. no. S8636) and penicillin/streptomycin (Sigma cat. no. P4333) in a humidified 5% CO2 incubator at 37° C. and passaged twice a week.

The adherent hepatocellular carcinoma cell line Hep3B (ECACC cat. no. 86062703) was maintained in EMEM (EBSS) (Sigma cat. no. M2279) supplemented with 10% fetal calf serum (Sigma cat. no. F2442), 2 mM L-glutamine (Sigma cat. no. G7513), 1% NEAA (Sigma cat. no. M7145) and penicillin/streptomycin (Sigma cat. no. P4333) in a humidified 5% CO2 incubator at 37° C. and passaged twice a week.

The adherent hepatocellular carcinoma cell line HepG2 (ECACC cat. no. 85011430) was maintained in EMEM (EBSS) (Sigma cat. no. M2279) supplemented with 10% fetal calf serum (Sigma cat. no. F2442), 2 mM L-glutamine (Sigma cat. no. G7513), 1% NEAA (Sigma cat. no. M7145) and penicillin/streptomycin (Sigma cat. no. P4333) in a humidified 5% CO2 incubator at 37° C. and passaged twice a week.

The adherent hepatocellular carcinoma cell line Huh-7D12 (ECACC cat. no. 01042712) was maintained in Dulbecco’s modified Eagle’s medium (Sigma cat. no. D6546) supplemented with 10% fetal calf serum (Sigma cat. no. F2442), 2 mM L-glutamine (Sigma cat. no. G7513) and penicillin/streptomycin (Sigma cat. no. P4333) in a humidified 5% CO2 incubator at 37° C. and passaged twice a week.

The adherent glioblastoma cell line U87 (ECACC cat. no. 89081402) was maintained in EMEM (EBSS) (Sigma cat. no. M2279) supplemented with 10% fetal calf serum (Sigma cat. no. F2442), 2 mM L-glutamine (Sigma cat. no. G7513), 1% NEAA (Sigma cat. no. M7145), 1 mM Sodium Pyruvate (NaP) (Sigma cat. no. S8636) and penicillin/streptomycin (Sigma cat. no. P4333) in a humidified 5% CO2 incubator at 37° C. and passaged twice a week.

Example 15: Antisense-Mediated Knockdown of ciRS-7 in Cultured Cancer Cells

For lipid-mediated transfection of the ciRS-7 antisense oligonucleotides listed in Table 2 (SEQ ID NOs: 360 - 362), cells were transfected as described in example 9.

For transfection of SK-Hep-1 cells, cells were seeded in 12-well cell culture plates at a density of 175,000 cells/well the day before transfection and transfected using Lipofectamine 2000 at a final concentration of 5 µl/ml using the protocol described in example 9.

For transfection of Hep3B cells, cells were seeded in 12-well cell culture plates at a density of 200,000 cells/well the day before transfection and transfected using Lipofectamine 2000 at a final concentration of 10 µl/ml using the protocol described in example 9.

Levels of the ciRS-7 RNA were measured using quantitative RT-PCR as described in example 8, briefly, the total amount of ciRS-7 transcript was measured using a Taqman assay designed with convergent PCR primers specific to the RNA, while ciRS-7 was measured using a Taqman assay designed with divergent PCR primers specific to the ciRS-7 RNA, the expression of GAPDH mRNA was measured and used as an endogenous control as described in example 9.

Examples of inhibition of ciRS-7 in SK-Hep-1 cells are shown in FIG. 9A. Examples of inhibition of ciRS-7 in Hep3B cells are shown in FIG. 9B.

Example 16: Antisense-Mediated Knockdown of circRNAs in Cultured Cancercells

Antisense oligonucleotides against circRNAs identified as described in example 4 were designed as described in example 5. The antisense oligonucleotides against circRNAs are listed in Table 2.

For lipid-mediated transfection of the antisense oligonucleotides (CRM0171, CRM0167, CRM0168, CRM0169, CRM0170, CRM0172, CRM0173, CRM0174, CRM0176, CRM0177, CRM0178, CRM0179, CRM0180, CRM0181, CRM0182 and CRM0175) listed in Table 2 (SEQ ID NOs: 374, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298 and 2299 respectively), A549 cells were transfected as described in example9.

For transfection of SK-Hep-1 cells, cells were seeded in 12-well cell culture plates at a density of 125,000 cells/well the day before transfection and transfected using Lipofectamine 2000 at a final concentration of 5 µl/ml using the protocol described in example9.

For transfection of Hep3B cells, cells were seeded in 12-well cell culture plates at a density of 200,000 cells/well the day before transfection and transfected using Lipofectamine 2000 at a final concentration of 10 µl/ml using the protocol described in example9.

Levels of the circRNAs were measured using quantitative RT-PCR as described in example 8, briefly, the amount of linear transcript was measured using a Taqman assay designed with convergent PCR primers specific to the linear RNA, while each circRNA was quantified using a Taqman assay designed with divergent PCR primers specific to the circRNA. The expression of TBP mRNA (IDT cat. no. Hs.PT.58v.39858774) was measured and used as an endogenous control.

Examples of inhibition of circRNAs in A549 cells are shown in FIG. 10. Examples of inhibition of circRNAs in SK-Hep-1 cells are shown in FIG. 11. Examples of inhibition of circRNAs in Hep3B cells are shown in FIG. 12.

Example 17: Effect of circRNA Knockdown by Antisense Oligonucleotides on Cancer Cell Proliferation

For lipid transfection in A549, cells were seeded in clear 96-well plates (NUNC) at a density of 2000 cells per well in complete culture medium the day before transfection. Six wells were left without cells for blank control. Lipid transfection was carried out as described in example 9 using 0.25 µl Lipofectamine 2000 in 50 µl OptiMEM pr. well and oligonucleotide concentrations 5 nM and 25 nM in 6 wells pr. concentration. After 4 hours, the cells were washed with OptiMEM, 100 µl complete culture medium was added to each well and the cells were incubated in a humidified 5% CO₂ incubator at 37° C. for 24 - 72 hours. For measurement of cell proliferation, 20 µl of the CellTiter Aqueous One Solution (Promega) was added to each well and the cells were incubated for 1-4 hours in a humidified 5% CO₂ incubator at 37° C. The absorbance at 490 nm was read in a Varioskan Lux plate-reader (Thermo Fisher Scientific) and the values from the blank controls were subtracted. The inhibition of proliferation was plotted relative to mock treated controls. Examples of the effect of circRNA knockdown on A549 cell proliferation using antisense oligonucleotides CRM0171, CRM0168, CRM0173, CRM0177, CRM0178, CRM0182 (SEQ ID NOs 374, 2286, 2290, 2293, 2294, and 2298 respectively) are shown in FIG. 13A.

Similarly, for lipid transfection in Hep3B cells, cells were seeded in clear 96-well plates (NUNC) at a density of 16000 cells pr. well in complete culture medium the day before transfection. Transfection and analysis was carried out as described for A549 using 0.5 µl Lipofectamine 2000 in 50 µl OptiMEM pr. well.

For lipid transfection in SK-Hep-1 cells, cells were seeded in clear 96-well plates (NUNC) at a density of 16000 cells pr. well in complete culture medium the day before transfection. Transfection and analysis was carried out as described for A549 using 0.25 µl Lipofectamine 2000 in 50 µl OptiMEM p. well.

Examples of the effect of circRNA knockdown on Hep3B cell proliferation using antisense oligonucleotides CRM0171, CRM0168, CRM0173, CRM0177, CRM0178, CRM0182 (SEQ ID NOs 374, 2286, 2290, 2293, 2294, and 2298 respectively) are shown in FIG. 13B.

Examples of the effect of circRNA knockdown on SK-Hep-1 cell proliferation using antisense oligonucleotides CRM0171, CRM0168, CRM0173, CRM0177, CRM0178, CRM0182 (SEQ ID NOs 374, 2286, 2290, 2293, 2294, and 2298 respectively) are shown in FIG. 13C.

Example 18: RNase R Treatment of Total RNA

Circular RNAs are resistant to treatment with the 3′-5′ exoribonuclease RNase R, whereas single-stranded linear RNAs are rapidly degraded. To validate the circular nature of identified putative circRNAs, total RNA extracted from the cell lines used was treated with RNase R and circular and linear transcripts were quantified using qRT-PCR and compared to untreated controls.

Total RNA was isolated from the cells using the RNeasy mini kit (Qiagen) with the addition of a DNase I treatment step according to the manufacturer’s instructions. For the RNase R treatment, 2 µg total DNase treated RNA was incubated with 6 U RNase R (Epicentre cat. no. RNR07250) in a 10 µl reaction at 37° C. for the times indicated. Corresponding samples without enzyme added were included as controls. The reaction was stopped by transfer to ice and addition of 90 µl RNase-free H₂O and 350 µl RLT-lysis buffer and RNA was purified on the RNeasy MinElute columns (Qiagen cat. no. 74204). For the cDNA synthesis, 10 µl RNA was reverse transcribed into cDNA using the High Capacity cDNA reverse transcription kit (Life Technologies cat. no. 4374967) according to the protocol provided by the manufacturer.

Levels of the circRNAs and corresponding linear RNAs were measured using quantitative RT-PCR as described in example 14.

Examples of effect of RNase R on circRNAs and linear RNAs from the cell lines A549, SK-Hep-1 and Hep3B are shown in FIGS. 14 A, B and C, respectively.

Example 19: Array Analysis of Antisense-Mediated Knockdown of ciRS-7 in Cultured Cancercells

The lung cancer cell line A549 was transfected with ciRS-7 antisense oligonucleotides CRM0106 (SEQ ID NO: 360) and CRM0108 (SEQ ID NO: 362) as described in Example 10. Cells were harvested after 48 h and 72 h and total RNA was isolated from the cells using the miRNeasy mini kit (Qiagen cat. no. 217004) according to the manufacturer’s instructions.

RNA was analyzed on the Affymetrix Exon array as described in Bergkvist KS et al. (BMC Immunol. 2014;15: 3. doi: 10.1186/1471-2172-15-3) and data analyses done using R and Bioconductor packages (Genome Biol. 2004; 5: R80. doi: 10.1186/ gb-2004-5-10-r80). Array data was normalized using the RMA algorithm and invariant genes removed. miR-7 target predictions were downloaded from DIANA-microT (http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=microT_CDS/index). Examples of the effect of transfection of the ciRS-7 antisense oligonucleotides in A549 cells on miR-7 targets are shown in FIG. 15.

Example 20: The Effect of Introducing Mismatches Into Gapmer Oligonucleotides on Antisense-Mediated Knockdown of ciRS7 in SK-Hep1 Cells

The knockdown effect mediated by antisense oligonucleotides harboring 2-nucleotide mismatches alongside the perfect match gapmer antisense oligonucleotide CRM0106 (SEQ ID NO: 360) targeting the backsplice site in ciRS-7 (SEQ ID NO: 1) was assessed as described in previous example 11.

The antisense oligonucleotides can be introduced into the cells using a lipid vehicle or via unassisted uptake.

For lipid-mediated transfection of the perfect match gapmer antisense oligonucleotide CRM0106 (SEQ ID NO: 360) targeting the backsplice site in ciRS-7 and the 2-nucleotide mismatched oligonucleotides (SEQ ID NOs: 2285-2293) SK-Hep1 cells were seeded in 12-well cell culture plates the day before transfection and transfected essentially as described in Dean et al. (Journal of Biological Chemistry 1994, 269, 16416-16424) using Lipofectamine 2000 in a final concentration of 5 µl/ml Optimem I (Gibco) and antisense oligonucleotide at a 5 nM final concentration. A scrambled sequence oligonucleotide and mock transfection were included as controls.

24 hours after transfection, total RNA was isolated from the cells using the RNeasy mini kit (Qiagen) according to the manufacturer’s instructions and 1 µg total RNA was reverse transcribed into cDNA using the High Capacity cDNA reverse transcription kit (Life Technologies cat. no. 4374967) according to the protocol provided by the manufacturer. ciRS-7 RNA levels were determined by quantitative RT-PCR using Taqman Gene Expression Master Mix (ABI cat. no. 4369542) and a divergent Taqman probe assay designed to specifically detect ciRS-7 (as described in example 5), furthermore the expression of TBP mRNA was measured (IDT Hs.PT.58v.39858774) and used as an endogenous control.

Quantitative PCR was carried out on a Quantstudio 6 Flex Real-Time thermocycler (ABI) An example of knockdown of ciRS-7 by perfect match gapmer antisense oligonucleotide CRM0106 (SEQ ID NO 360) compared to different mismatched gapmer antisense oligonucleotides CRM0219-227 (SEQ ID NOs 2285-2293) in cultured SK-Hep1 cells, is shown in FIG. 9.

Design of oligonucleotides for assessment of the specificity of the gapmer antisense oligonucleotide targeting the backsplice site in ciRS-7 (SEQ ID NO: 0360, 0361, 0362, 0363, 0364, 0365, 0366, 0367). Uppercase = LNA, lowercase = DNA. Nucleotides written in bold and underlined represent mismatches relative to the perfect match gapmer antisense oligonucleotide.oligoname	seqID	oligoRep
CRM0106	360	GTgccatcggaaaccCT
CRM0219	N/A	CAgccatcggaaaccCT
CRM0220	N/A	GTcgcatcggaaaccCT
CRM0221	N/A	GTgcgttcggaaaccCT
CRM0222	N/A	GTgccaaggaaaccCT
CRM0223	N/A	GTgccatcccaaaccCT
CRM0224	N/A	GTgccatcggttaccCT
CRM0225	N/A	GTgccatcggaatgcCT
CRM0226	N/A	GTgccatcggaaacgGT
CRM0227	N/A	GTgccatcggaaaccGA

Claims

1. A compound comprising a modified antisense oligonucleotide consisting of any one of SEQ ID NOs: 2149 - 2259.

2-13. (canceled)

14. The compound according to claim 1, wherein said modified antisense oligonucleotide comprises wing regions having nucleotide analogues selected from beta-D-oxy LNA, alpha-L-oxy-LNA, beta-D-amino-LNA, alpha-L-amino-LNA, beta-D-thio-LNA, alpha-L-thio-LNA, 5′-methyl-LNA, beta-D-ENA or alpha-L-ENA.

15. The compound according to claim 14, wherein the modified antisense oligonucleotide is 100% complementary to an endogenous lncRNA.

16. The compound according to claim 14, wherein the nucleotide analogues of the wings are Beta-D-Oxy LNA.

17. The compound according to claim 1, wherein said modified antisense oligonucleotide comprises wing regions having nucleoside analogues, which are not LNA, but are selected from tricyclo-DNA, 2′-Fluoro, 2′-O-methyl, 2′-methoxyethyl (2′-MOE), 2′cyclic ethyl (cET), UNA or Conformationally Restricted Nucleoside (CRN).

18. The compound according to claim 1, wherein said modified antisense oligonucleotide comprises wing regions having nucleoside analogues, which are a mixture of LNA and anyone of tricyclo-DNA, 2′Fluoro, 2′-O-methyl, 2′-methoxyethyl (2′-MOE), 2′cyclic ethyl (cET), UNA, or Conformationally Restricted Nucleoside (CRN).

19. The compound according to claim 18, wherein the nucleoside analogues of the wing regions are a mixture of LNA and 2′-Fluoro.

20. The compound according to claim 1, wherein the modified antisense oligonucleotide is conjugated with a ligand.

21. The compound according to claim 20, wherein the modified antisense oligonucleotide is conjugated with folic acid or N-acetylgalactosamine (GalNAc).

22. The compound according to claim 1, wherein the modified antisense oligonucleotide is unconjugated in a pharmaceutical composition.

23. The compound according to claim 1, wherein the modified antisense oligonucleotide is formulated in lipid nanoparticles.

24. A method of therapy, comprising providing a subject the compound of claim 1 and a carrier.

25. The method according to claim 24, wherein the compound comprises more than one modified antisense oligonucleotide consisting of any one of SEQ ID NOs: 2149 - 2259.

26. A method of downregulating an endogenous lncRNA selected from the list of DANCR, H19, HOTAIR, HOTTIP, HULC, LINC-ROR, MALAT1, MVIH, PCBP2-OT1, PVT1, TUG1, UCA1, UFC1 or LINC01215 in a cell, comprising administering to a cell an effective amount of an antisense oligonucleotide that is complementary to DANCR, H19, HOTAIR, HOTTIP, HULC, LINC-ROR, MALAT1, MVIH, PCBP2-OT1, PVT1, TUG1, UCA1, UFC1 or LINC01215.

27. The method of claim 26, wherein the cell is in a human body.

28. The method of claim 26, wherein the cell is a cancer cell in a human body.

29. A method of inhibiting a cancer in a subject, comprising administering an effective dosage of the compound according to claim 1 to a subject in need thereof.

30. The method according to claim 29, wherein the cancer is hepatocellular carcinoma.

31. The method according to claim 30, wherein the subject is a human.

32. The method according to claim 29 further comprising administering an additional cancer therapy to said subject.